Guidelines for ATC classification and DDD assignment 2018. by unknown

  
 
 
 
 
Guidelines for  
ATC classification 
and DDD assignment 
2018 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ISSN 1726-4898 
ISBN 978-82-8082-896-5 
 
 
 
Suggested citation: WHO Collaborating Centre for Drug Statistics Methodology, 
Guidelines for ATC classification and DDD assignment 2018. Oslo, Norway, 
2017.  
 
 
 
© Copyright  
WHO Collaborating Centre for Drug Statistics Methodology, Oslo, Norway. 
Use of all or parts of the material requires reference to the WHO Collaborating 
Centre for Drug Statistics Methodology.  Copying and distribution for commercial 
purposes is not allowed.  Changing or manipulating the material is not allowed. 
  
  
 
 
 
 
 
 
 
Guidelines for  
ATC classification 
and DDD assignment 
 
21st edition 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
WHO Collaborating Centre for Drug Statistics Methodology 
Norwegian Institute of Public Health 
P.O.Box 4404 Nydalen 
N-0403 Oslo  
Norway 
 
Telephone: (47) 21078160 
E-mail: whocc@fhi.no 
Website: www.whocc.no 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
Previous editions: 
1990: Guidelines for ATC classification1) 
1991: Guidelines for DDD1) 
1993: Guidelines for ATC classification 
1993: Guidelines for DDD 
1996: Guidelines for ATC classification and DDD assignment 
1998: Guidelines for ATC classification and DDD assignment 
2000: Guidelines for ATC classification and DDD assignment 
2001: Guidelines for ATC classification and DDD assignment 
2002: Guidelines for ATC classification and DDD assignment 
2003: Guidelines for ATC classification and DDD assignment 
2004: Guidelines for ATC classification and DDD assignment 
2005: Guidelines for ATC classification and DDD assignment 
2006: Guidelines for ATC classification and DDD assignment 
2007: Guidelines for ATC classification and DDD assignment 
2008: Guidelines for ATC classification and DDD assignment 
2009: Guidelines for ATC classification and DDD assignment 
2010: Guidelines for ATC classification and DDD assignment 
2011: Guidelines for ATC classification and DDD assignment 
2012: Guidelines for ATC classification and DDD assignment 
2013: Guidelines for ATC classification and DDD assignment 
2014: Guidelines for ATC classification and DDD assignment 
2015: Guidelines for ATC classification and DDD assignment 
2016: Guidelines for ATC classification and DDD assignment 
2017: Guidelines for ATC classification and DDD assignment 
 
1) A co-publication between the WHO Collaborating Centre for Drug Statistics Methodology and the Nordic 
Council on Medicines 
 PREFACE 
 
The Anatomical Therapeutic Chemical (ATC) classification system and the Defined 
Daily Dose (DDD) as a measuring unit are recommended by the WHO for drug 
utilization monitoring and research .  The system is widely used internationally and 
the number of users is increasing.  The purpose of preparing guidelines is to make 
information about the ATC/DDD system available to the users. 
 
The members of the WHO International Working Group for Drug Statistics 
Methodology have given expert advice and comments on the work with these 
guidelines. 
 
This edition of the Guidelines for ATC classification and DDD assignment is based 
on the ATC classification index with DDDs valid from January 2018.  
 
The guidelines consist of a general part including information about the procedures 
and data requirements for ATC/DDD assignment and alterations.  The second part of 
the publication, the interpretative guidelines, describes the different ATC levels down 
to the 4th level.  These guidelines should be consulted whenever the ATC/DDD 
system is used for drug utilization monitoring and research.  They describe particular 
issues, which have been discussed and resolved by consensus of the Working Group.  
 
The Guidelines and the ATC index with DDDs are updated annually.  Both 
publications can be ordered as electronic or paper copies (English or Spanish 
versions) from the Centre (order form, see website www.whocc.no).  A pdf document 
of the Guidelines and a searchable version of the ATC/DDD index linked to the text 
from the Guidelines are available on the website  (ATC/DDD index). 
 
We hope this book will prove helpful to the users of the ATC/DDD system.  
Suggested improvements can be addressed to the WHO Centre in Oslo. 
 
 
Oslo, December 2017  
Hanne Strøm 
Director 
 
WHO Collaborating Centre for Drug Statistics Methodology 
Norwegian Institute of Public Health 
 Staff of the Centre 
 
Christian Berg, MScPharm/MPH 
Hege Salvesen Blix, MScPharm/PhD 
Irene Litleskare, MScPharm 
Marit Rønning, MScPharm 
Solveig Sakshaug, MScPharm 
Hanne Strøm, MScPharm 
Tove Granum, secretary 
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I. INTRODUCTION 
 
A. History of the ATC/DDD system 
 
The field of Drug Utilization Research (DUR) began attracting attention in the 
1960’s.  This followed the publication of a breakthrough study on drug 
consumption from 1966-1967 (pioneered by the WHO Regional Office for 
Europe) which further exemplified the importance and applicability of DUR (ref: 
Engel A, Siderius P. The consumption of drugs. Report on a study, 1966-1967. 
WHO Regional Office for Europe, Copenhagen 1968 (EURO 3101).  In addition, 
the WHO symposium in 1969 highlighted the need for an internationally accepted 
classification system for drug utilization studies.  As a result the Drug Utilization 
Research Group (DURG) was established and entrusted with the development of 
internationally applicable methods for DUR.  Inspired by this interest, the 
Anatomical Therapeutic Chemical (ATC) classification was developed in Norway 
as a modification and extension of the European Pharmaceutical Market Research 
Association (EphMRA) classification system. 
 
In order to measure drug use, it is important to have both a classification system 
and a unit of measurement.  To deal with the objections against traditional units of 
measurement, a technical unit of measurement called the Defined Daily Dose 
(DDD) was developed for use in drug utilization studies.  
 
Several decades of experience using ATC/DDD methodology has demonstrated its 
suitability in drug utilization monitoring and research.  The increase in number of 
users indicates the usefulness of the system. 
 
 
B. Present Organizational responsibility for the ATC/DDD 
system 
 
1. WHO Collaborating Centre for Drug Statistics Methodology 
 
In 1981, the ATC/DDD system was recommended by WHO as the international 
standard for drug utilization studies, and in 1982 the WHO Collaborating Centre 
for Drug Statistics Methodology was established and given the responsibility for 
coordinating the development and use of the ATC/DDD system.  In 1996, the 
Centre was recognized as a global centre.   This was seen as important to allow 
close integration of international drug utilization studies and WHO’s initiatives to 
achieve universal access to needed drugs and rational use of drugs particularly in 
developing countries.  Access to standardised and validated information on drug 
use is essential to allow audit of patterns of drug utilization, identification of 
problems, educational or other interventions and monitoring of the outcomes of the 
interventions. 
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The Centre is located at the Norwegian Institute of Public Health and funded by 
the Norwegian Government.  The first agreement was drawn up by WHO 
Headquarters with the Government of Norway in 1996.  The latest redesignation of 
the Department of Pharmacoepidemiology, Norwegian Institute of Public Health, 
as a WHO Collaborating Centre for Drug Statistics Methodology, was in May 
2016.  According to this Agreement all activities related to ATC/DDD 
classification have to be conducted in accordance with policies determined by 
WHO.  
 
The main activities of the Centre are development and maintenance of the 
ATC/DDD system, including: 
 
- To classify drugs according to the ATC system. 
 
- To establish DDDs for drugs which have been assigned an ATC code. 
 
- To review and revise as necessary the ATC classification system and DDDs. 
 
- To stimulate and influence the practical use of the ATC system by cooperating 
with researchers in the drug utilization field. To organize training courses in the 
ATC/DDD methodology and to lecture such courses and seminars organized by 
others. 
 
- To provide technical support to countries in setting up their national medicines 
classification systems and build capacity in the use of medicines consumption 
information. 
 
2. WHO International Working Group for Drug Statistics Methodology 
 
In 1996, when the decision on globalizing the ATC/DDD system was taken, the 
WHO Division of Drug Management and Policies established the WHO 
International Working Group for Drug Statistics Methodology.  The International 
Working Group includes 12 expert members selected by WHO Headquarters to 
represent a wide range of geographical and professional backgrounds, including 
clinical pharmacology, clinical medicine, international public health, drug 
utilization and drug regulation.  All six WHO regions are represented in the group. 
The WHO Collaborating Centre for Drug Statistics Methodology receives expert 
advice from the Working Group. 
 
The main terms of reference of the Working Group are: 
 
- To continue the scientific development of the ATC/DDD system. 
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- To discuss and approve all new ATC codes, DDD assignments and alterations to 
existing ATC codes and DDDs. 
 
- To develop further the use of the ATC/DDD system as an international standard 
for drug utilization studies. 
 
- To revise as necessary the guidelines for assignment and change of ATC codes 
and DDDs. 
 
- To revise as necessary the procedures for applications for assignment of and 
changes to ATC codes and DDDs to ensure they are consistent and transparent. 
 
- To assess the sources and availability of statistics on drug use internationally, 
and to encourage the systematic collection of comprehensive drug use statistics 
in all countries and regions using the ATC/DDD system as the international 
standard.   
 
- To develop methods, manuals and guidelines for the practical application and 
appropriate use of the ATC/DDD system in drug utilization studies in a variety 
of settings, particularly those applicable to developing countries. 
 
- To work with groups involved in rational drug use initiatives to integrate 
methods for measurement of drug use in assessing needs and outcomes of 
interventions with the aim of improving drug use. 
 
The International Working Group meets twice annually.  A teleconference may 
replace one of the two annual meetings.  Members are required to complete a 
WHO declaration of interest form before the meeting.  Observers from the WHO 
Collaborating Centre for International Drug Monitoring and the International 
Federation of Pharmaceutical Manufacturers Association are invited to attend the 
meetings of the International Working Group.  An open session is arranged prior to 
one of the annual meetings to which any interested party can register (see further 
information below).  
 
Decisions on ATC classification or DDD assignment from the meetings are 
published on the website of the WHO Collaborating Centre for Drug Statistics 
Methodology and in the publication WHO Drug Information.  Any decision on a 
new or revised ATC classification or DDD assignment is first published as 
temporary.  Any interested party wishing to dispute this decision is invited to 
comment within a specified deadline after its publication.  If there are no 
objections to a temporary decision, it will be published as a final decision and 
implemented in the next issue of the ATC classification index with DDDs.  In case 
of any objection, the decision will be reconsidered at the next meeting of the 
International Working Group.  If a new decision is made at the second meeting, 
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this decision will be published as temporary and will be open to comments similar 
to the first decision.  WHO has the final responsibility for the decisions and any 
dispute arising in the course of this work must be referred to WHO for final 
resolution. 
 
Open Session  
An open session is arranged once a year in connection with the meeting of the 
WHO International Working Group for Drug Statistics Methodology.  It is 
organised in the interest of transparency and consists of a 90 minutes session prior 
to the closed decision-making session of the meeting of the Working Group.  
  
Anyone with a legitimate interest in the Anatomical Therapeutic Chemical (ATC) 
classification system and Defined Daily Dose (DDD) assignment can attend the 
open session.  This includes regulatory authorities, the pharmaceutical industry, 
academia and non-governmental organisations, and it provides an opportunity to 
present additional information to the experts to assist them in their decision 
making. It is also  an opportunity for the international experts of the Working 
Group to exchange ideas and opinions with interested parties. 
 
The open session is not intended to be used as a mechanism to challenge the 
decision of the Working Group.  The procedures for applying for and commenting 
on an ATC classification or a DDD assignment are outlined in these Guidelines 
(see section V). 
 
Interested parties are requested to register for the open session to the WHO 
Headquarter at least 14 days in advance of the meeting and are requested to 
provide a relevant reason for attending.  WHO Headquarter will restrict the time 
allowed for each presentation in order to keep the duration of the open session 
within 90 minutes.  Information on these meetings are made available on the WHO 
website at www.who.int/medicines. 
 
 
C. The purpose of the ATC/DDD system  
 
The purpose of the ATC/DDD system is to serve as a tool for drug utilization 
monitoring and research in order to improve quality of drug use.  One component 
of this is the presentation and comparison of drug consumption statistics at 
international and other levels. 
 
A major aim of the Centre and Working Group is to maintain stable ATC codes 
and DDDs over time to allow trends in drug consumption to be studied without the 
complication of frequent changes to the system.  There is a strong reluctance to 
make changes to classifications or DDDs where such changes are requested for 
reasons not directly related to drug consumption studies.  For this reason the 
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ATC/DDD system by itself is not suitable for guiding decisions about 
reimbursement, pricing and therapeutic substitution.  
 
It is essential that a tool for drug utilization monitoring and research is able to 
cover most medicines available on the market. An important aim of drug 
utilization is to monitor rational as well as irrational drug use as an important step 
in improving the quality of drug use.  The classification of a substance in the 
ATC/DDD system is therefore not a recommendation for use and it does not 
imply any judgements about efficacy or relative efficacy of drugs and groups of 
drugs. 
 
 
II. THE ANATOMICAL THERAPEUTIC CHEMICAL (ATC) 
CLASSIFICATION SYSTEM 
 
A. Structure and nomenclature 
 
Structure 
In the ATC classification system, the active substances are classified in a hierarchy 
with five different levels.  The system has fourteen main 
anatomical/pharmacological groups or 1st levels.  Each ATC main group is 
divided into 2nd levels which could be either pharmacological or therapeutic 
groups.  The 3rd and 4th levels are chemical, pharmacological or therapeutic 
subgroups and the 5th level is the chemical substance.  The 2nd, 3rd and 4th levels 
are often used to identify pharmacological subgroups when that is considered more 
appropriate than therapeutic or chemical subgroups. 
 
The complete classification of metformin illustrates the structure of the code: 
 
A      Alimentary tract and metabolism 
      (1st level, anatomical main group) 
 
A10     Drugs used in diabetes 
      (2nd level, therapeutic subgroup) 
 
A10B    Blood glucose lowering drugs, excl. insulins 
      (3rd level, pharmacological subgroup) 
 
A10BA  Biguanides 
      (4th level, chemical subgroup) 
 
A10BA02 metformin 
      (5th level, chemical substance)  
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Thus, in the ATC system all plain metformin preparations are given the code 
A10BA02. 
 
Nomenclature 
- International nonproprietary names (INN) are preferred.  If INN names are not 
assigned, USAN (United States Adopted Name) or BAN (British Approved 
Name) names are usually chosen.  
 
- A Biological Qualifier (BQ) is not part of the INN and the introduction of a new 
BQ will not have any implication on the ATC code for the specific INN.  Further 
information about the Biological Qualifier can be found here: 
http://www.who.int/medicines/services/inn/WHO_INN_BQ_proposal_2015.pdf?ua=1  
 
 
B. Inclusion and exclusion criteria 
 
The WHO Collaborating Centre in Oslo establishes new entries in the ATC 
classification on requests from the users of the system.  These include 
manufacturers, regulatory agencies and researchers.  The coverage of the system is 
not comprehensive.  A major reason why a substance is not included is that no 
request has been received. 
 
Substances which fulfil one of the following criteria will normally be included in 
the ATC system:  
 
- new chemical entities or biologicals proposed for licensing.  A new chemical 
entity is normally not included in the ATC system before an application for 
marketing authorisation is ready for submission in at least one country. 
 
- existing well defined chemical entities with an approved marketing 
authorization in one or more countries.  An INN should preferably be 
established for the substance.  Alternatively other official names, e.g. USAN or 
BAN names should be available. 
 
- herbal medicinal products assessed and approved by regulatory authorities based 
on dossiers including efficacy, safety, and quality data (e.g. the well-established 
use procedure in EU). 
 
Other medicinal products are considered on a case by case basis.  Complementary, 
homeopathic and herbal traditional medicinal products are in general not included 
in the ATC system. 
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C. Principles for classification 
 
1. Therapeutic use or pharmacological class 
 
Medicinal products are classified according to the main therapeutic use of the main 
active ingredient. The ATC system is, however, not strictly a therapeutic 
classification system.  In many ATC main groups, pharmacological groups have 
been assigned on the 2nd, 3rd and 4th levels allowing drugs with several 
therapeutic uses to be included without specifying the main indication.  For 
example, calcium channel blockers are classified in the pharmacological group 
C08 Calcium channel blockers, which avoids specifying whether the main 
indication is coronary heart disease or hypertension. Subdivision on the 
mechanism of action will, however, often be rather broad (e.g. antidepressants), 
since a too detailed classification according to mode of action often will result in 
having one substance per subgroup which as far as possible is avoided.  Some 
ATC groups are subdivided in both chemical and pharmacological groups (e.g. 
ATC group J05A - Direct acting antivirals).  Preference will be given to 
establishing a new pharmacological 4th level rather than a chemical subgroup. 
 
Many medicines are used and approved for two or more indications, while 
normally only one ATC code will be assigned.  Besides, ATC codes are often 
assigned according to the mechanism of action rather than therapy. An ATC group 
may therefore include medicines with many different indications, and drugs with 
similar therapeutic use may be classified in different groups.  
 
2. Only one ATC code for each route of administration 
 
Medicinal substances are classified according to the main therapeutic use or 
pharmacological class on the basic principle of only one ATC code for each route 
of administration (e.g. oral formulations with similar ingredients and strength will 
have the same ATC code).  This is an important principle for ATC classification as 
it allows aggregation of data in drug utilization monitoring and research without 
counting a pharmaceutical product more than once.  This principle is strictly 
handled by the WHO Centre so that users in different countries shall be able to 
classify a pharmaceutical product (defined by active ingredient/s, route of 
administration and strength) in the same way.  
 
A pharmaceutical product may be approved for two or more equally important 
indications, and the main therapeutic use may differ from one country to another.  
This will often give several classification alternatives.  Such drugs are only given 
one code, the main indication being decided on the basis of the available 
information.  Problems are discussed in the WHO International Working Group for 
Drug Statistics Methodology where the final classification is decided.   
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Cross-references will be given in the guidelines to indicate the various uses of such 
drugs. 
 
3. More than one ATC code for a medicinal substance 
 
A medicinal substance can be given more than one ATC code if it is available in 
two or more strengths or routes of administration with clearly different therapeutic 
uses.  
 
Example of different strengths: 
 
- Finasteride is available in two different strengths.  A low strength tablet for the 
treatment of male pattern baldness is classified under D11AX - Other 
dermatologicals.  A high strength tablet used in the treatment of benign prostatic 
hypertrophy (BPH) is classified under G04C - Drugs used in BPH. 
 
 
Example of different administration forms: 
 
- Prednisolone in single ingredient products is given several ATC codes due to 
different therapeutic use and different formulations. 
 
A07EA01 Intestinal antiinflammatory agents  (enemas and foams) 
C05AA04 Antihemorrhoidals for topical use (suppositories) 
D07AA03 Dermatological preparations  (creams, ointments and lotions) 
H02AB06 Corticosteroids for systemic use (tablets, injections) 
R01AD02 Nasal decongestants   (nasal sprays/drops) 
S01BA04 Ophthalmologicals   (eye drops) 
S02BA03 Otologicals     (ear drops) 
 
4. New ATC groups and “other” groups (X groups) 
 
A new medicinal substance not clearly belonging to any existing ATC 4th level 
will as a main rule be placed in an X group ("other" group) in the relevant 3rd 
level.  To avoid a situation of several 4th levels with only one single substance in 
each, new specific 4th levels are as a general rule only established when at least 
two substances with marketing authorisations fit in the group.  In addition, a new 
4th level should be regarded a benefit for drug utilization research.  New and 
innovative pharmaceutical products will therefore often be classified in an X group 
and such groups could be established for only one single substance. 
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5. Other general principles 
 
Immediate and slow release tablets will normally have the same ATC code. 
 
Different stereoisomeric forms will normally have separate ATC codes.  
Exceptions will be described in the guidelines for the respective ATC groups 
 
Prodrugs are usually assigned separate ATC codes if the dosages used are different 
and/or the nonproprietary name (INN) of the prodrug and the active drugs are 
different.  
 
Example: 
 
J01CA08 pivmecillinam 
J01CA11 mecillinam 
 
Obsolete drugs or drugs withdrawn from the market are kept in the ATC system, 
since exclusion of substances from the ATC system may create difficulties for the 
users of the system when considering historical data.  
 
 
D. Classification of combination products 
 
Pharmaceutical products containing two or more active ingredients are regarded as 
combinations (incl. combination packages) and given different ATC codes from 
plain products containing one active ingredient.  Stereoisomeric mixtures are 
regarded as plain products.  Medicinal products which in addition to one active 
ingredient contain auxiliary substances intended to increase the stability of the 
product (e.g. vaccines containing small amounts of antibacterials), increase the 
duration (e.g. depot formulations) and/or increase the absorption (e.g. different 
solvents in various dermatologicals) are considered as plain products. 
 
The classification of combination products is a challenge in any classification 
system. As for plain products, combinations are in general classified according to 
their main therapeutic use or pharmacological class. A medicinal product 
containing an analgesic and a tranquillizer, and used primarily to ease pain, should 
be classified as an analgesic.  Likewise, combinations of analgesics and 
antispasmodics will be classified in A03 Drugs for functional gastrointestinal 
disorders if the antispasmodic effect of the product is considered most important.  
Similar examples are described in detail in the guidelines for the relevant drug 
groups. 
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In some ATC groups a ranking is introduced to help in the classification of 
combination products (e.g. combinations of different antihypertensives and 
combinations of different analgesics).  This ranking shows which drug takes 
precedence over others when the classification is decided.  This is detailed in the 
guidelines for the relevant drug groups. 
 
A commonly used principle for combinations with active ingredients not belonging 
to the same ATC 4th level, is that the main ingredient in the combination is 
identified and the combination is given a separate 5th level code (50-series) in the 
same 4th level as the main ingredient is classified.  
 
Example: 
 
N02BE01  paracetamol 
N02BE51 paracetamol, combinations excl. psycholeptics  
 
In this example different combination products share the same main active 
ingredient (paracetamol in the example above) and are given the same ATC code.  
Combinations of e.g. paracetamol + acetylsalicylic acid and paracetamol + caffeine 
are thus classified in the same code N02BE51 paracetamol, combinations excl 
psycholeptics. 
 
The names of all active ingredients of a combination are given in some ATC 5th 
levels. This principle has been used more frequently in recent years in order to 
give a better identification of the various combinations.  
 
Example: 
 
M01AE02 naproxen 
M01AE52 naproxen and esomeprazole 
M01AE56 naproxen and misoprostol 
 
Some combination products containing psycholeptic drugs, which are not 
classified under  N05 - Psycholeptics or N06 - Psychoanaleptics, are classified at 
separate 5th levels using the 70-series, e.g. N02BE71 paracetamol, combinations 
with psycholeptics.  
 
Most of the ATC 70-serie codes were established many years ago and the products 
included in these codes may be obsolete today.  
 
Combinations containing two or more active ingredients belonging to the same 4th 
level are in some cases classified using the 5th level code 30 (or 20).  Further 
explanation is given in the relevant chapters of the guidelines.  Only a few new 
codes have been established according to this principle in recent years. 
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Example: 
 
B01AC06 acetylsalicylic acid 
B01AC07 dipyridamole    
B01AC30 combinations (e.g. acetylsalicylic acid and dipyridamole) 
 
An important principle used more frequently in recent years as more rational 
combinations have been marketed, is to assign separate ATC 3rd or 4th levels for 
combinations.  
 
Examples: 
 
C10B Lipid modifying agents, combinations 
J05AR Antivirals for treatment of HIV infections, combinations 
N02AJ Opioids in combination with non-opioid analgesics 
R03AL Adrenergics in combination with anticholinergics incl triple combinations 
with corticosteroids 
 
In these ATC groups for combinations, the ATC 5th level code often specify the 
active ingredients (e.g. C10BX04 simvastatin, acetylsalicylic acid and ramipril).  
How specific and “visible” a combination appears in the ATC classification, will 
to some extent depend on the need for a detailed classification from a drug 
utilization point of view. 
 
There are some exceptions to these main principles and these are explained in the 
guidelines. 
 
 
E. Principles for changing ATC codes 
 
As the selection of drugs and their uses are continually changing and expanding, 
regular revisions of the ATC system will always be necessary. 
 
Changes in the ATC classification should be kept to a minimum.  An important aim 
is to keep a stable classification system over time with as few changes as possible 
and still have a classification where new therapy and new pharmacological 
principles find an appropriate place.  Before alterations are made, any potential 
difficulties for the use of the ATC system in drug utilization monitoring and 
research are considered and related to the benefits that could be achieved by the 
alteration. 
 
Alterations in ATC classification can be made when the main use of a drug has 
clearly changed, and when new groups are required to accommodate new 
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substances or to achieve better specificity in the groupings.  Other reasons for 
changes can be new knowledge about mechanism of action or the need for splitting 
large and complex groups.  
 
When it is decided to make an alteration, the following principles are used: 
 
- When new therapeutic or pharmacological ATC groups are assigned, it should 
always be considered if there are substances in other groups that should be 
included in the new group. 
- When changing ATC codes for plain products, it should always be considered if 
it is necessary to change the ATC code for any combination products with the 
same active ingredient. 
- When an ATC code is changed for a substance, the previous code is not reused 
for new substances. 
 
 
When an ATC code is altered, the DDD is also reviewed.  For example, when the 
classification of chloroquine was changed from ATC group M to P (i.e. classified 
only as an antimalarial), the DDD was changed since the dosages used for 
treatment of malaria are different from the dosages used for rheumatic disorders.  
 
A cumulative overview of all ATC alterations back to 2005 is available on the 
website of the WHO Centre. 
 
 
F. The EphMRA classification system 
 
The ATC classification system was originally based on the same main principles 
as the Anatomical Classification developed by the European Pharmaceutical 
Market Research Association (EphMRA) and the Pharmaceutical Business 
Intelligence and Research Group (PBIRG).  In this classification, drugs are 
classified in a hierarchy of three and sometimes four levels mainly according to 
their indications and use.  Many of these quite similar to the ATC structure, but in 
many groups, less detailed.  There are no specific codes for the active ingredient 
(5th level in the ATC).  Contrary to the ATC classification, EphMRA classifies 
medicinal products.  It is possible to find products with the same active ingredient, 
route of administration and strength in several classes.  Despite a similar structure 
at the higher levels, the ATC classification and the EphMRA classification have 
developed individually for many years.  
 
Since 1991 there has been an annual consultation between the EphMRA 
classification committee and the WHO Collaborating Centre for Drug Statistics 
Methodology to discuss classification problems and to harmonize when possible.  
The purposes of the two systems differ as the primary objective of the EphMRA 
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classification is to satisfy the marketing needs of the pharmaceutical companies.  A 
complete harmonization is therefore neither feasible nor an aim. An important aim 
of the annual meeting is therefore to describe the differences (i.e. show the 
differences by giving bridges) and similarities in groups where harmonization is 
not achieved.  The harmonization process was initiated in order to minimise the 
confusion of having two very similar classification systems. 
 
There are many differences between the EphMRA classification and the ATC 
classification.  This means that data prepared using the ATC classification cannot 
be directly compared with data prepared using the EphMRA system.  Awareness 
of the differences between the two systems is then particularly important.  In some 
settings, and on the EphMRA website, the system is referred to as the ATC 
classification and this has caused confusion among users over the years.   
 
The EphMRA classification system is used worldwide by IMS (Intercontinental 
Medical Statistics) in producing marketing research statistics for the 
pharmaceutical industry. 
 
An annually updated comparison booklet of the two systems is available. 
 
 
III. DDD (DEFINED DAILY DOSE)  
 
A. Definition and general considerations 
 
The basic definition of the unit is: 
 
The DDD is the assumed average maintenance dose per day for a drug used for its 
main indication in adults. 
 
The DDD is a unit of measurement and does not necessarily reflect the 
recommended or Prescribed Daily Dose (see page 30).  Therapeutic doses for 
individual patients and patient groups will often differ from the DDD as they will 
be based on individual characteristics (such as age, weight, ethnic differences, type 
and severity of disease) and pharmacokinetic considerations. 
 
Only one DDD is assigned per ATC code and route of administration (e.g. oral 
formulation).  The DDD is nearly always a compromise based on a review of 
available information including doses used in various countries when this 
information is available.  The DDD is sometimes a “dose” that is rarely if ever 
prescribed, because it might be an average of two or more commonly used doses. 
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Drug utilization data presented in DDDs only give a rough estimate of 
consumption and not an exact picture of actual use.  DDDs provide a fixed unit of 
measurement independent of price, currencies, package size and strength enabling 
the researcher to assess trends in drug consumption and to perform comparisons 
between population groups. 
 
DDDs are not established for topical products, sera, vaccines, antineoplastic 
agents, allergen extracts, general and local anesthetics and contrast media. 
 
 
B. Principles for DDD assignment 
 
1. General principles 
 
DDDs are only assigned to drugs with an ATC code and a DDD will normally not 
be assigned for a substance before a product is approved and marketed in at least 
one country. 
 
The basic principle is to assign only one DDD per route of administration within 
an ATC code. 
 
DDDs for single substances are normally based on monotherapy.  Exceptions to 
this rule are given in the guidelines of the relevant ATC groups. 
 
For substances indicated for rare disorders with highly individual dosing 
schedules, the Working Group could decide not to assign a DDD.  
 
DDDs for herbal medicinal products are not included in the ATC index. They are 
published in an ATC sorted list on the website (www.whocc.no). 
 
When a new DDD is assigned, various sources are used to get the best overview of 
the actual or expected use of a substance.  The assigned DDD is based on the 
following principles:  
 
- The average adult dose recommended for the main indication as reflected by the 
ATC code. When the recommended dose refers to body weight, an adult is 
considered to be a person of 70 kg.  It should be emphasised that even special 
pharmaceutical forms mainly intended for children (e.g. mixtures, suppositories) 
are assigned the DDD used for adults.  Exceptions are made for some products 
only used by children, e.g. growth hormones and fluoride tablets. 
 
- The recommended maintenance dose (long term therapeutic dose) is usually 
preferred when establishing the DDD.  The initial dose may differ from the 
maintenance dose but this is not reflected in the DDD.  If the approved dose 
 24 
recommendation provides limited information about maintenance dose, the 
DDD will usually be the average of the maintenance dose range.  Examples of 
interpretation of approved dose titration recommendations:  
- “Titrate up to a high dose if it is tolerated”: the high dose would normally 
be chosen as the DDD.  
- “Consider to increase the dose only if efficacy is not satisfactory with 
initial dose”: the DDD would normally be based on the initial dose. 
 
-  For some groups of medicinal products specific principles for DDD assignment 
are established (e.g. the DDDs for the selective serotonin agonists in the 
treatment of migraine are based on the approved initial dose).  These principles 
are given in the guidelines for the relevant ATC groups. 
 
- The treatment dose is generally used.  If, however, prophylaxis is the main 
indication, this dose is used, e.g. for fluoride tablets (A01AA01) and some 
antimalarials. 
 
- A DDD is usually established according to the declared content (strength) of the 
product.  Various salts of a substance are usually not given different DDDs.  
Exceptions are described in the guidelines for the relevant ATC groups.  For 
example, the DDDs for antimalarials are expressed as the base. 
 
- Different stereoisomeric forms are normally assigned separate DDDs and ATC 
codes.  The DDDs for stereoisomeric forms are described in the respective ATC 
groups. 
 
- Prodrugs, which have not been given a separate ATC code, are normally not 
given a separate DDD. 
 
- The DDD is often identical for various dosage forms of the same drug.  
Different DDDs can be established when the bioavailability is substantially 
different for various routes of administration (e.g. oral and parenteral 
administration of morphine) or if the dosage forms are used for different 
indications.  When the use of parenteral formulations represents only a minor 
fraction of the total use for a specific indication, these products have normally 
not received a separate DDD even if the bioavailability of the oral form is 
substantially different.  This principle has not been strictly followed in recent 
years.  Parenteral antibacterials are for example mainly used in hospitals and 
often for more severe infections than in primary care. The DDDs are frequently 
used as indicators for antibacterial use in hospitals, and it has been decided that 
assigning different DDDs for oral and parenteral formulations could be 
important in some cases to improve the usefulness of the methodology in drug 
utilization monitoring and research. 
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- Parenteral products with different routes of administration (e.g. i.v. and i.m.) 
have the same DDD. 
 
 
2. Combination products 
 
The DDDs assigned for combination products are based on the main principle of 
counting the combination as one daily dose, regardless of the number of active 
ingredients included in the combination.  If a treatment schedule for a patient 
includes e.g. two single ingredient products, then the consumption will be 
measured by counting the DDDs of each single ingredient product separately.  If, 
however, a treatment schedule includes a combination product containing two 
active ingredients, then the calculated consumption measured in DDDs will 
normally be lower since the DDD for the combination will be counted. 
 
Example I: 
 
Treatment with two products, each containing one active ingredient: 
Product A: Tablets containing 20 mg of substance X (DDD = 20 mg) 
Product B: Tablets containing 25 mg of substance Y (DDD = 25 mg) 
The dosing schedule 1 tablet of A plus 1 tablet of B daily will be calculated as a 
consumption of 2 DDDs. 
 
Example II: 
 
Treatment with a combination product containing two active ingredients: 
Product C: Tablets containing 20 mg of substance X and 12.5 mg of substance Y. 
The DDD of the combination products is assigned as 1 UD = 1 tablet. 
The dosing schedule 1 tablet of C daily will be calculated as 1 DDD (even though 
it will be equivalent to 1.5 DDD of the single active ingredients). 
 
The following principles for assigning DDDs to combination products apply: 
 
1. For combination products (other than the combination products used in 
hypertension, see point 2 below) where the ATC code identifies the main 
ingredient (i.e. for the 50- and 70-series combinations and for some 4th level 
combinations), the DDD for the combination product should be equal to the 
DDD for the main active ingredient. 
 
2. For combination products used for treatment of hypertension (e.g. ATC group 
C02, C03, C07, C08 and C09), DDDs are based on the average number of 
dosing intervals per day. This means that: 1 tablet is the DDD for combinations 
given once daily, whereas 2 tablets is the DDD for combinations given twice 
daily and 3 tablets is the DDD for combinations given three times daily etc. This 
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principle means that the assigned DDDs may differ from the DDD assigned for 
the single active ingredient (according to ATC code). 
 
For all combination products where the DDD assigned deviates from the principles 
given above, a list of DDDs are available from the Centre (published on the 
website www.whocc.no). 
 
 
3. Other factors 
 
a) Fixed doses 
For some groups of products, e.g. cough mixtures in ATC group R05 and 
multivitamins in ATC group A11, the composition of various products may differ, 
but the average recommended dose is usually the same.  Such DDDs are called 
"fixed dose".  
 
In some ATC groups, it has been decided to use fixed DDDs for all combination 
products given in e.g. number of tablets regardless of strength.  These rules are 
clearly stated in the chapters for the respective ATC groups in this publication (e.g. 
ATC group A02AD, A02BD and A02BX). 
 
For eye drops used in glaucoma therapy (S01E), a fixed dose regardless of strength 
has been established in the different subgroups.  This is based on the assumption 
that only one drop is applied in each eye per dose given, regardless of strength.  
 
When fixed doses are assigned, these will be further described in the guidelines for 
the relevant ATC groups. 
 
b) Depot formulations 
Depot formulations (e.g. sustained release formulations) are usually assigned the 
same DDDs as the ordinary dosage forms.  The very few exceptions to this main 
rule are described in the guidelines for the different ATC groups. 
 
c) Intermittent dosing 
In certain therapeutic groups, e.g. hormones, many of the products are 
administered intermittently.  In such cases, the dose administered is divided by the 
number of days in the treatment period to obtain the average daily dose.  This 
means that medicament free periods in between courses are included in the 
treatment period.  This applies to e.g. depot antipsychotics (N05A) and 
contraceptive pills (G03A), which are given intermittently. 
 
d) Duration of treatment 
The duration of treatment is normally not considered when assigning a DDD, even 
if the drugs are used mainly in short periods.  Exceptions from this main rule are 
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explained in the respective ATC groups.  
 
 
4. Selection of units 
For plain products, DDDs are as far as possible given in amount of active 
ingredients, using the following units: g (gram), mg (milligram), mcg (microgram), 
ml (milliliter), mmol (millimole), U (unit), TU (thousand units) and MU (million 
units).  The abbreviation U for unit is used for international as well as other units.   
 
For combination products or products where a DDD for various reasons cannot be 
given in amount of active ingredient, the unit UD (unit dose) is used:  
 
- Tablets, suppositories, pessaries, etc: 
 1 UD equals 1 tablet, 1 suppository, 1 pessary etc. 
 
- Powder for oral use: 
 1 UD equals 1 gram of powder.  If the DDD for an oral powder is given in 
grams, this refers to the content of active ingredient. 
 
- Powder in single dose units for oral use: 
 1 UD equals 1 unit dose powder. 
 
- Powder for injection: 
1 UD equals 1 gram of powder.  If the DDD for powder for injection is given in 
grams, this refers to the content of active ingredient. 
 
- Powder for inhalation: 
 1 UD equals 1 unit dose powder, e.g. 1 capsule. 
 
- Liquid preparations for oral use (mixtures, syrups etc.): 
 1 UD equals 5 ml of the preparation. 
 
- Liquid preparations for parenteral use (injections): 
 1 UD equals 1 ml of the preparation. 
 
- Liquid preparations for rectal use: 
 1 UD equals 1 ml of the preparation. 
 
- Liquid preparations for inhalation: 
 1 UD equals 1 ml of the preparation. 
 
- Liquid preparations for inhalation in single dose units (unit dose): 
 1 UD equals 1 unit dose inhal.sol 
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- Enemas: 
 1 UD equals 1 enema. 
 
- Plaster for transdermal application: 
 1 UD equals 1 plaster. 
 
- Vaginal cream: 
 1 UD equals 1 dose, 1 application. 
 
 
For combination packages consisting of two or more plain products, the UD 
concept is used when assigning DDDs also for these combinations.  1 UD will still 
refer to 1 unit dose in the package, and if a combination package contain e.g. 4 
tablets with different ingredients to be taken once daily, the DDD assigned will be 
4 UD. 
 
 
C. Pediatric DDD 
 
DDDs are normally assigned based on use in adults (see page 22).  
For medicinal products approved for use in children, the dose recommendations 
will differ based on age and body weight.  Many medicinal products used in 
children are not even approved for such use, and documentation regarding dose 
regimens is not available. 
 
Thus the WHO International Working Group for Drug Statistics Methodology has 
concluded that pediatric DDDs are challenging to assign and problems related to 
drug utilization research in children cannot be solved by such means. 
 
Estimating prevalence of drug use in children is not possible by using crude sales 
data presented in DDDs.  Prescribed daily dosages and indications in a pediatric 
population should be used if available and compared with the DDD values.  If the 
pediatric subgroup is difficult to identify, the general DDD should be used as a 
measuring tool for overall comparisons. 
 
 
D. Principles for reviewing and changing DDD 
 
DDDs sometimes need to be reviewed because dosages may change over time, e.g. 
due to the introduction of new main indications or new research.   The 
International Working Group for Drug Statistics Methodology may review a DDD 
whenever the Group finds it appropriate.  
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A major aim of the Collaborating Centre and Working Group is to maintain stable 
ATC codes and DDDs over time. This allows trends in drug utilization to be 
studied without the complication of frequent changes.  Changes in DDDs are to be 
kept to a minimum and avoided as far as possible, as too many alterations are 
disadvantageous for long-term studies on drug utilization.  Before alterations are 
made, difficulties arising for the users are weighed against the benefits achieved by 
the alteration. 
  
- The same principles used to assign new DDDs also apply when DDDs are 
reviewed. 
 
- Changes are generally not made unless they are at least in the order of 50%.  
This rule is not used for the three year revision of DDDs, where smaller 
alterations are allowed.  Further, minor alterations are sometimes accepted for 
important drugs, which are frequently used. 
 
DDD review after three years  
All newly assigned DDDs are reviewed during the third year after inclusion in the 
ATC Index with DDDs.  The DDDs are reviewed at the first semi-annual meeting 
of the International Working Group for Drug Statistics Methodology.  The 
following are considered: 
 
- Recommended dosages as listed in drug catalogues in different countries and/or 
published in peer reviewed scientific journals or major international textbooks. 
 
- Data on prescribed daily doses (PDDs) from a range of countries if available.  
Figures showing the prescribed daily dose (PDD) can be useful when reviewing 
an assigned DDD.  Usually more data concerning PDDs are available after a 
three years period than at the time of marketing.  
 
- Established main indication and therapy profile of the preparation (i.e. has the 
main indication changed?) 
 
- Existing DDDs in the ATC group. 
 
- Written input from users to the DDD. 
 
When reviewing combination products, changes in the DDDs for the different 
active ingredients are an important consideration.   
 
Further reviews of DDDs 
After the first three years period, the DDD normally remains unchanged for at least 
five years unless the WHO Working Group decides to make a total revision of all 
DDDs assigned in an ATC group.  Proposed DDD changes from users of the 
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system, based on new information will always be considered, but only after the 
three years revision has been performed. 
 
 
E. Description of other drug utilization metrics 
 
Cost 
Drug use can be expressed in terms of costs (e.g. national currency).  Cost figures 
are suitable for an overall cost analysis of drug expenditure.  National and 
international comparisons based on cost parameters are often misleading and of 
limited value in the evaluation of drug use.  Price differences between alternative 
preparations and different national cost levels make the evaluation difficult.  Long-
term studies are also difficult due to fluctuations in currency and changes in prices.  
 
When cost data are used, an increase in the use of cheaper drugs may have little 
influence on the total level, while a shift to more expensive drugs is more readily 
noticed. 
 
Volume 
Common physical units (e.g. grams, kilos, litres), numbers of packages or tablets 
and numbers of prescriptions are also used for quantifying drug consumption.  
These units can be applied only when the use of one drug or well defined products 
is evaluated.  Problems arise, however, when the consumption of whole drug 
groups is considered.   
 
If consumption is given in terms of grams of active ingredients, drugs with low 
potency will have a larger fraction of the total than drugs with high potency.  
Combined products may also contain different amounts of active ingredients from 
plain products, which will not be reflected in the figures.   
 
Counting numbers of tablets also has disadvantages, because strengths of tablets 
vary, with the result that low strength preparations contribute relatively more than 
high strength preparations.  Also, short-acting preparations will often contribute 
more than long-acting preparations. 
 
Number of prescriptions do not give a good expression of total use, unless total 
amounts of drugs per prescription are also considered.  Counting prescriptions, 
however, is of great value in measuring the frequency of prescriptions and in 
evaluating the clinical use of drugs (e.g. diagnosis and dosages used). 
 
Prescribed daily dose 
The prescribed daily dose (PDD) is defined as the average dose prescribed 
according to a representative sample of prescriptions. The PDD can be 
determined from prescription studies, medical- or pharmacy records and patient 
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interviews.  It is important to relate the PDD to the diagnosis on which the dosage 
is based.  The PDD will give the average daily amount of a drug that is actually 
prescribed.  When there is a substantial discrepancy between the PDD and the 
defined daily dose (DDD), it is important to take this into consideration when 
evaluating and interpreting drug consumption figures. 
 
For drugs where the recommended dosage differs from one indication to another 
(e.g. the antipsychotics) it is important that diagnosis is linked to the prescribed 
daily dose given.  Pharmacoepidemiological information (e.g. sex, age and 
mono/combined therapy) is also important in order to interpret a PDD.  
The PDD can vary according to both the illness treated and national therapy 
traditions.  For the antiinfectives, for instance, PDDs vary according to the severity 
of the infection.  There can also be substantial differences between PDDs in 
various countries.  PDDs in Asian populations are often lower than in Caucasian 
populations. 
 
The fact that PDDs may differ from one country to another should always be 
considered when making international comparisons. 
 
 
IV. USES OF THE ATC/DDD METHODOLOGY 
 
A Implementation and maintenance of the ATC/DDD methodology 
 
When the decision to introduce and use the ATC/DDD methodology is taken, it is 
essential to realize that its proper use inevitably includes an important and time-
consuming first step:  Each pharmaceutical product has to be linked to the 
appropriate ATC code and DDD.  For monitoring and comparing drug use 
internationally it is important to ensure that the data retrieved are comparable, in 
other words that the ATC groups from different countries, regions or health 
facilities do have the expected content.  In order to achieve this, it is of vital 
importance that the officially correct ATC code is assigned to each pharmaceutical 
product package.  If possible, this work should be done on a national basis to 
secure consistent use of the methodology within a country.  Many countries have 
established systems of unique identifiers for pharmaceutical products at the 
package level.  The number of DDDs per package should be calculated for each 
product package and this information should be added to the pharmaceutical 
products registry.  The national medicines list and ATC/DDDs should be linked at 
the level of the unique product identifier.   
It is recommended to have a common structure of these pharmaceutical products 
registries.  National registries should as a minimum include the following 
variables:  
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• Unique identifier (registration number) 
• Medicinal product name (brand name/trademark) 
• Pharmaceutical form 
• Strength 
• Pack size 
• ATC code 
• Active ingredient(s) 
• DDD 
• Route of administration 
• Number of DDDs in the pack 
 
Good procedures for updating national or other registries with new ATC 
codes/DDDs and alterations should be established.  It is recommended that the 
responsibility for quality assurance and validation of national registries is allocated 
to a national body in each country.  This work should be performed by competent 
persons with good knowledge of the ATC/DDD methodology.  
 
An updated version of the ATC/DDD Index is issued in January each year.  To be 
able to compare drug utilization data from different countries and time periods, it 
is essential to know which ATC codes and DDDs are used.  A minimum number 
of changes in the ATC codes and DDDs are made annually. Thus, it is important to 
give proper references to the ATC/DDD version used when presenting drug 
consumption figures.   
 
 
B. Drug utilization 
 
The main purpose of the ATC/DDD system is as a tool for presenting drug 
utilization statistics with the aim of improving drug use.  This is the purpose for 
which the system was developed and it is with this purpose in mind that all 
decisions about ATC/DDD classification are made.  Consequently, using the 
system for other purposes can be inappropriate.   
 
Use of the ATC/DDD system allows standardisation of drug groups and represents 
a stable drug utilization metric to enable comparisons of drug use between 
countries, regions, and other health care settings, and to examine trends in drug use 
over time and in different settings. 
 
Collecting and publishing drug utilization statistics are critical elements in the 
process of improving the prescribing and dispensing of medicines.  For drug 
utilization statistics to have the best possible impact on drug use, the statistics need 
to be used in a focused and active manner. 
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Examples of ways in which drug utilization statistics based on ATC and DDDs 
have been and can be used to improve drug use include the following: 
 
- National publications, which provide clinicians, pharmacists and others with a 
profile of drug consumption in the country (with or without comparisons 
between countries or between areas within the country). 
 
- Publications providing feedback within health services to individual health 
facilities, groups of health care providers, or individual health providers. 
 
- Use of drug utilization statistics by national health systems, universities, drug 
information centres, and others to identify possible over use, underuse or misuse 
of individual drugs or therapeutic groups.  Depending on the situation, this 
information can then be used to initiate specific studies or specific educational 
interventions.  Educational interventions may include articles in drug bulletins, 
articles in scientific journals, letters to clinicians, etc. 
 
 
1. Data sources 
 
The ATC/DDD system can be used for collection of drug utilization statistics in a 
variety of settings and from a variety of sources:   
 
Examples are: 
- Sales data such as wholesale data at a national, regional or local level. 
 
- Dispensing data either comprehensive or sampled.  Computerised pharmacies 
can easily collect data on drugs dispensed.  Alternatively, sample data can be 
collected manually.  Reimbursement systems, which operate in a number of 
countries at the national level provide comprehensive dispensing data down to 
the individual prescription level, as all prescriptions are submitted and recorded 
for reimbursement.  This is generally called “claims” data.  Similar data are 
often available through health insurance or health maintenance organisations. 
 
- These databases can sometimes allow collection of demographic information on 
the patients, and information on dose, duration of treatment and co-prescribing.  
Linkage to hospital and medical databases can provide information on 
indications, and outcomes such as hospitalisation, use of specific medical 
services, and adverse drug reactions. 
 
- Patient encounter based data.  This is usually collected by specially designed 
sampling studies such as those carried out by market research organisations.  
However, increasing use of information technology at the medical practice level 
are making such data more available.  These methods have the advantage of 
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potentially providing accurate information on Prescribed Daily Doses, patient 
demographics, duration of therapy, co-prescribing, indications, morbidity and 
co-morbidity, and sometimes outcomes. 
 
- Patient survey data.  Collection of data at the patient level can provide 
information about actual drug consumption and takes into account compliance in 
filling prescriptions and taking medications as prescribed.  It can also provide 
qualitative information about perceptions, beliefs, and attitudes to the use of 
medicines. 
 
- Health Facility data.  Data on medication use at all the above levels is often 
available in health care settings such as hospitals and health centres at regional, 
district, or village level. 
 
 
2. DDD indicators and interpretations  
 
Drug utilization figures expressed in DDDs are generally reported in units that 
control for population size differences.  This provides a measure of exposure or 
therapeutic intensity in a defined population, allowing comparisons across various 
time periods and population groups.  
 
Drug Utilization figures should ideally be presented using a relevant denominator 
for the health context such as numbers of DDDs per 1000 inhabitants per day, 
DDD per inhabitant per year, or as DDDs per 100 bed days.  
 
 DDD per 1000 inhabitants per day: Sales or prescription data presented in 
DDDs per 1000 inhabitants per day may provide a rough estimate of the 
proportion of the study population treated daily with a particular drug or 
group of drugs.  The figure 10 DDDs per 1000 inhabitants per day can be 
interpreted as follows: in a representative group of 1000 inhabitants, 10 
DDDs of the drug are utilized on average, on any given day of the year 
analysed.  Alternatively this can be expressed as 10/1000 (1%) of the 
population are receiving this drug each day in that year.  This estimate is 
most useful for drugs used chronically and when there is good agreement 
between the average prescribed daily dose (PDD) and the DDD. 
 
 DDD per 100 bed days: The DDDs per 100 bed days may be applied when 
drug use by inpatients is considered.  The definition of a bed day may differ 
between hospitals or countries.  A common definition is: A bed day is a day 
during which a person is confined to a bed and in which the patient stays 
overnight in a hospital.  Day cases (patients admitted for a medical 
procedure or surgery in the morning and released before the evening) are 
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sometimes included as one bed day and sometimes excluded.  The same 
definition of bed days should always be chosen when performing 
comparative studies.  The figure 70 DDDs per 100 bed days of hypnotics 
provides an estimate of the therapeutic intensity and estimates that 70% of 
the inpatients receive one DDD of a hypnotic every day.  This measure is 
applied in analyses of in-hospital drug use.  This indicator is quite useful for 
benchmarking in and between hospitals. 
 
 DDD/patient: This indicator is often calculated in pharmacoepidemiological 
databases and expresses the treatment intensity/total exposure according to a 
defined study period.  If the actual dose used is equivalent to the DDD, the 
DDD/patient would also express number of treatment days in a specific 
period.   
 
 DDDs per inhabitant per year: This indicator  is often considered useful to 
present the figures for antiinfectives (or other drugs normally used in short 
periods).  It will give an estimate of the number of days for which each 
inhabitant is, on average, treated annually.  For example, 5 
DDDs/inhabitant/year indicates that the consumption is equivalent to 
treatment of every inhabitant with a 5 days course during a certain year.  
Alternatively, if the standard treatment period is known, the total number of 
DDDs can be calculated as the number of treatment courses, and the number 
of treatment courses can then be related to the total population.  
 
Drug utilization data presented in DDDs give a rough estimate of consumption and 
not an exact picture of the actual drug use, and the estimates described above are 
only true if there is good agreement between the actually prescribed dose and the 
DDD. 
 
For some drug groups where DDDs have not been established, alternative ways of 
presenting data are recommended.  For example, consumption of antineoplastic 
agents in ATC group L01 can be presented in grams of active ingredient. 
 
When there is a known discrepancy between the prescribed daily dose (PDD) and 
the DDD, it is important to take this into account when interpreting drug 
consumption figures.  Caution should also be taken in situations where the 
recommended dosage differs from one indication to another (e.g. antipsychotics), 
in severe versus mild disease (e.g. antibiotics) and where PDDs may differ from 
one population to another (e.g., according to sex, age, ethnicity or geographic 
location).  
 
Since alterations of ATC and DDDs do occur it is important to be aware of which 
version of the ATC index is used in drug consumption studies especially when 
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comparing the data over time and when making international comparisons. 
 
When presenting trends in drug consumption over time, the data for the whole 
period (e.g. all years) should always be updated (recalculated) by using the most 
recent version of the ATC index. 
 
 
C. Drug Safety Assessment  
 
The WHO Programme for International Drug Monitoring (PIDM): The WHO 
PIDM aims to enhance patient care and patient safety in relation to the use of 
medicines; and support public health programmes by providing reliable and 
balanced information for the effective assessment of the risk-benefit profile of 
medicines.  
 
One of the main aims of the WHO PIDM is to identify the earliest possible adverse 
drug reaction signals.  The programme has more than 120 countries contributing to 
the WHO global database of Individual Case Safety Reports (ICSRs) called 
VigiBase®.  VigiBase® is maintained and developed on behalf of the WHO by the 
WHO Collaborating Centre for International Drug Monitoring (Uppsala 
Monitoring Centre).  VigiBase® uses the WHO Drug Dictionary which consists of 
the ATC classification and is useful for drug safety assessment.  Please note that 
many unofficial ATC codes are used in the WHO Dictionary, but these are clearly 
marked.  The ATC classification allows aggregation of statistics and analysis in 
reporting of adverse drug reactions. 
 
In pharmacovigilance analyses using VigiBase® or other databases, 
disproportionality analysis is an acknowledged tool to support signal detection.  
Disproportionality metrics, e.g. the proportional reporting ratio (PRR), can be 
calculated based on the ATC classification.  When PRR is applied at the level of 
ATC codes, the reporting rate of one specific event is calculated for a given ATC 
code and compared to the reporting rate of the event in all ICSRs of the database 
except those that contain one or more drugs from the ATC code of interest. 
 
 
D. Drug information  
 
ATC codes are included in the  pharmaceutical product information (e.g. Summary 
of Product Characteristics) approved by EMA, the regulatory medicinal agency in 
EU. 
 
ATC codes are included in some international drug textbooks (e.g. the Martindale) 
and in several national drug catalogues. 
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ATC codes are also included in the WHO Essential Drug List. 
 
 
E. Drug costs, pricing, reimbursement and cost-containment 
 
Basing detailed reimbursement, therapeutic group reference pricing and other 
specific pricing decisions on the ATC and DDD assignments is a misuse of the 
system.  This is because the ATC and DDD assignments are designed solely to 
maintain a stable system of drug consumption measurement, which can be used to 
follow and compare trends in the utilization of drugs within and across therapeutic 
groups.  None the less, drug utilization data have a central role in the quality of 
care cycle and ATC and DDD methodologies can be helpful in following and 
comparing trends in cost, but need to be used with caution. 
 
The DDD is a technical drug use metric.  DDDs do not necessarily reflect 
therapeutically equivalent doses of different drugs and therefore cannot be 
assumed to represent daily doses that produce similar treatment outcomes for all 
products within an ATC category.  Such estimates of therapeutic equivalence are 
very difficult to establish, particularly to the precision usually required for pricing 
decisions.  DDDs, if used with caution can be used to compare, for example, the 
costs of two formulations of the same drug.  However, it is usually not valid to use 
this metric to compare costs of different drugs or drug groups.  The relationships 
between therapeutically equivalent doses, the actual prescribed daily dose (PDD) 
and DDD usually differ between drugs and, for the same drug, between countries.  
Moreover, even though PDDs commonly change over time altering a DDD 
complicates drug utilization research, hence there is a reluctance to alter a DDD. 
Alterations are not made unless there is evidence that changes in PDD are large, or 
there is some particular reason such as a change in the main indication.  For these 
reasons, DDDs are not suitable for comparing drugs for specific, detailed pricing, 
reimbursement and cost-containment decisions. 
 
Similarly, basing reimbursement and pricing comparisons on inclusion of drugs in 
ATC groups is not recommended.  The main indications for drugs (on which ATC 
assignments are based) often differ widely between countries and, like the PDD, 
can change over time.  However, the ATC classifications can be useful when costs 
need to be aggregated into drug groups or therapeutic areas to determine, for 
example, to what extent increased costs can be attributed to increased use of a 
therapeutic group over time. 
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F. Pharmaceutical marketing purposes 
 
It is important to emphasise that the ATC classification does not necessarily reflect 
the recommended therapeutic use in all respects.  Therefore, the ATC system 
should not be used as a tool for promoting medicines concerning efficacy, 
mechanism of action or therapeutic profile in relation to other drugs.  
 
It should be emphasised that assignment to different ATC groups does not mean a 
difference in therapeutic effectiveness and assignment to the same ATC group 
does not indicate therapeutic equivalence. 
 
Concerning use of price comparisons for marketing purposes, see point E above. 
 
 
V. PROCEDURES AND DATA REQUIREMENTS FOR 
ATC/DDD ASSIGNMENT AND ALTERATIONS 
 
A. Requests for ATC classification 
 
1. Procedures and timing 
 
All new entries in the ATC classification system are assigned on request from the 
users.  Requests for ATC classification of a medicinal substance should be 
addressed to the WHO Collaborating Centre for Drug Statistics Methodology.  The 
application form for assignment of new ATC codes and DDDs is available on our 
website www.whocc.no.  Electronic applications are preferred. Application for 
ATC/DDD is free of charge.  The official language of the Centre is English.  
Requests and documentation should accordingly be submitted in English.   
 
If a substance marketed in a country is not included in the latest version of the 
annually updated ATC classification index, a request for an ATC code may in 
principle be sent from any user of the system (e.g. health authorities, 
manufacturers, researchers and other users).  It will usually be the manufacturer 
who has best access to the information required for an application.  The 
manufacturer will usually wish to know about and be involved in an application 
for an ATC classification and/or DDD assignment for one of their products, 
particularly if it is a new drug. 
 
A new chemical entity is normally not included in the ATC system before an 
application for marketing authorisations is ready for submission in at least one 
country.  In some cases, it may be necessary to await a classification until the new 
medicinal product has been approved in at least one country (especially for 
chemical entities where it is considered difficult to establish a new 5th level).  
These conditions are set to avoid including in the ATC system too many chemical 
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entities which never reach the market. 
 
It is left to the national users of the ATC system to classify combination products 
based on the principles given in these guidelines.  The guidelines are prepared in 
order to facilitate this work and to ensure that different users of the ATC system 
classify in a consistent way.  If the content of these guidelines is not sufficient to 
decide a classification of a specific combination, or if it is necessary to establish a 
new ATC entry, such problems should be addressed to the WHO Centre in Oslo.  
The Centre also provides regular training courses to assist those working with the 
system at a national level. 
 
The WHO International Working Group for Drug Statistics Methodology formally 
approves all new ATC codes.  The group has two annual meetings, normally in 
March and October.  
 
The steps in the approval procedure for new ATC codes are normally as follows: 
 
- A standard letter confirming receipt of the request is returned from the Centre to 
the applicant. 
 
- If the new code is easy to assign, a preliminary ATC code assigned by the 
Centre is returned to the applicant within 6-8 weeks, informing them that the 
ATC code still has to be formally approved by the Working Group at the next 
meeting. 
 
- For substances with more than one alternative classification and for substances 
which are difficult to classify into existing classifications, the requests are 
discussed in the Working Group before assignment of a temporary ATC code. 
The applicant receives this information within 6-8 weeks after receipt of the 
request.  After approval of the minutes of the Working Group meetings, the 
decision of the temporary ATC code is sent from the Centre to the applicant. 
 
- After approval of the minutes of the Working Group meeting the new ATC 
codes approved at the meeting are published on the website www.whocc.no and 
in the next issue of the publication WHO Drug Information.  A deadline will 
then be allowed for interested parties to comment or object to the decisions.   
 
- If objections, justified on evidence submitted, are received, the ATC 
classification will be discussed again at the following meeting of the Working 
Group.  If the decision is kept, then the decision is considered final after this 
meeting.  If a new decision is taken by the Working Group, notification of this 
new ATC is published at our website www.whocc.no and in the next issue of 
the publication WHO Drug Information.  A deadline is then allowed for any 
interested part to comment or object to the decision. 
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- If no objections are received, the new ATC code is considered final and 
included in the next issue of the ATC classification index.  A list of new final 
ATC codes is also published semi-annually on the website www.whocc.no and 
in the WHO Drug Information. 
 
In order to include requests for new ATC codes on the agenda for the Working 
Group meetings, they should normally be forwarded to the Centre before 15 
January (March meeting) and before 15 August (October meeting).   
 
ATC codes approved at the March meeting (e.g. March 2018) will be included in 
the ATC index the following year (i.e. January 2019).  ATC codes approved at the 
October meeting of the Working Group (e.g. October 2018) will appear in the 
ATC index the year after the following year (i.e. January 2020).  
 
 
2. Data requirements for submission 
 
The following data should be submitted when requesting an ATC code for a 
substance: 
 
- Chemical structure and relationship to similar drugs 
 
- Pharmacology and mechanism of action and relationships to similar drugs 
 
- Main indication as shown in the product information in major countries where it 
is licensed or submitted for licensing 
 
- Other indications which are licensed or for which licensing is proposed in the 
future 
 
- Proposed ATC classification with justification based on the evidence submitted  
 
- Status concerning marketing authorisation 
 
- Information about therapeutic use, if available 
 
Useful sources of these data would be approved product information documents 
from regulatory authorities or proposed product information documents stating that 
these are not yet approved.  Summaries of submissions to, or evaluations from, 
major regulatory agencies relating to the above are useful, as well as market 
research data showing the percentage use for the main indications.  
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B. Requests for ATC changes 
 
1. Procedures and timing 
 
Any user may in principle propose changes to ATC classifications.  There is no 
application form for ATC alterations. Proposal for changes should be sent to the 
WHO Collaborating Centre for Drug Statistics Methodology, and  all proposals 
will be discussed in the WHO International Working Group for Drug Statistics 
Methodology. 
 
The steps in the evaluation procedure for changes to ATC classifications are as 
follows: 
 
- The Centre will confirm receipt of the proposal for a change and give 
information about the time schedule for discussion at the Working Group 
meeting. 
 
- After approval of the minutes of the Working Group meeting, the decision from 
the meeting concerning the proposed change is distributed from the Centre to 
those requesting the change (the applicant).  Independent of whether it has been 
decided to change or not, a deadline will be allowed for the applicant to 
comment or object to this decision.   
 
- If it is decided to make a change, notification of this change is published at our 
website www.whocc.no and in the next issue of the WHO Drug Information. A 
deadline is then allowed for any interested part to comment or object to the 
change. 
 
- If objections, justified on submitted evidence, are received, the ATC alteration 
will be discussed again at the following meeting of the Working Group, and a 
final decision will then be taken. 
 
- If no objections are received, the altered ATC classification will be implemented 
in the next issue of the ATC classification index. 
 
In order to include proposals for ATC alterations on the agenda for the Working 
Group meetings, they should be forwarded to the Centre before 15 January 
(March meeting) and before 15 August (October meeting).   
 
ATC alterations decided at the March meeting (e.g. March 2018) will be included 
in the ATC index the following year (i.e. January 2019).  ATC alterations decided 
at the October meeting of the Working Group (e.g. October 2018) will be included 
in the ATC index the year after the following year (i.e. January 2020).   
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2. Data requirements for submission 
 
When requesting changes to ATC classifications, the data requirements are similar 
to the data required for new ATC codes.  An important basis for the ATC/DDD 
system is to maintain a stable system for drug consumption studies.  For this 
reason, there need to be compelling reasons for changing ATC codes.  It is 
therefore important to submit data, which justify the proposed change.  
 
If a change in the main therapeutic use is the reason for the proposed change, the 
data submitted should clearly indicate this change (e.g. market research data 
showing the percentage use for the different indications in a range of countries). 
 
If new knowledge of pharmacology or mechanism of action is the reason for the 
proposed change, relevant evidence should be submitted. 
 
If the proposed change is to establish specific ATC groups for one or more 
substances already classified in another group (usually a various group), it is 
necessary to submit data that verify that the change is beneficial and represents an 
improvement of the ATC classification for presenting drug consumption statistics.  
Justifications based on use of the system in reimbursement, for pricing or 
marketing reasons will not be considered. 
 
 
C. Requests for DDD assignment 
 
1. Procedures and timing 
 
New DDDs are assigned on request from the users.  Requests for new DDDs 
should be addressed to the WHO Collaborating Centre for Drug Statistics 
Methodology.  The application form for assignment of new ATC codes and DDDs 
is available on our website (www.whocc.no).  Electronic applications are preferred 
and applications are free of charge. Any user may in principle propose a new DDD 
(e.g. health authorities, manufacturers, researchers and others).  However, as with 
ATC code assignment, it is the manufacturer who will usually have the best access 
to the required information for new drugs.  
 
A DDD will only be assigned for substances which have received an ATC code, or 
where the ATC code can be assigned in connection with the DDD. DDDs are not 
assigned before marketing is approved in at least one country. 
 
All new DDDs are discussed and approved by the WHO International Working 
Group for Drug Statistics Methodology. 
 
The steps in the approval procedure for new DDDs are very similar to the 
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procedure for new ATC codes (see page 38): 
 
- The Centre will confirm receipt of the request for a new DDD and give 
information to those requesting the DDD (the applicant) about the time schedule 
for discussion at the following Working Group meeting. 
 
- After approval of the minutes of the Working Group meeting, the decision from 
the meeting concerning the DDD is distributed from the Centre to the applicant.   
 
- The new DDDs are published on the website www.whocc.no and in the next 
issue of the WHO publication: WHO Drug Information.  A deadline is then 
allowed for interested parties to comment or object to the new DDD. 
 
- If objections, justified on submitted evidence, are received, the DDD will be 
discussed again at the following meeting of the Working Group. If the decision 
is kept, then the decision is considered final after this meeting.  If a new decision 
is taken by the Working Group, notification of this new DDD is published at our 
website www.whocc.no and in the next issue of the publication WHO Drug 
Information.  A deadline is then allowed for any interested part to comment or 
object to the decision. 
 
- If no objections are received, the new DDD is considered final after the deadline, 
and included in the next issue of the ATC classification index.  A list of final 
DDDs is also published semi-annually at our website www.whocc.no and in the 
WHO Drug Information. 
 
In order to include requests for new DDDs on the agenda for the Working Group 
meetings, they should be forwarded to the Centre before 15 January (March 
meeting) and before 15 August (October meeting).   
 
New DDDs decided at the March meeting (e.g. March 2018) will be included in 
the ATC index the following year (i.e. January 2019).  New DDDs decided at the 
October meeting of the Working Group (e.g. October 2018) will be included in the 
ATC index the year after the following year (i.e. January 2020).   
 
 
2. Data requirements for submission 
 
The following information is required when requesting a new DDD: 
 
- Dose ranges and dosing instructions for each indication in the product 
information approved by one or more major regulatory authorities. 
 
- Proposal for a DDD justified by the submitted information. 
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- Status concerning marketing authorisation. 
 
- Doses used in clinical trials to support marketing if available. 
 
- Market research data on doses used in practice in various countries if such data 
are available. 
 
- Where the drug is to fit into an existing ATC classification, comparative dosing 
information should be provided if available.  It is difficult to define 
therapeutically equivalent doses with the degree of precision often asked for, and 
the DDDs within therapeutic groups do not necessarily represent therapeutically 
equivalent doses.   
 
 
D. Requests for DDD changes 
 
1. Procedures and timing 
 
Any user may in principle propose changes in DDDs. There is no application form 
for DDD changes. Proposal for changes should be sent to the WHO Collaborating 
Centre for Drug Statistics Methodology.  All proposals will be discussed by the 
WHO International Working Group for Drug Statistics Methodology. 
 
The steps in the evaluation procedure for changes to DDDs are the same as the 
procedures for changes to ATC classifications (see page 41). 
 
2. Data requirements for submission 
 
When requesting changes of DDDs, the data requirements are similar to the data 
required for new DDDs.  An important basis for the ATC/DDD system is to 
maintain a stable system for drug consumption studies.  Because of this, there need 
to be compelling reasons to change DDDs. Arguments for DDD changes might be: 
 
- a change in the main indication so that the dose recommendation has been 
altered. 
 
- a large change (in the order of 50%) in the average dose used (see also page 29). 
This would need to be supported by market research data in a range of countries.  
However, for the three year revision a smaller change can be accepted (see page 
29). 
 
Minor changes in DDD for use in reimbursement, for pricing or marketing 
purposes will not be considered. 
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VI. DESCRIPTION OF ATC INDEX WITH DDDs 
 
The WHO Collaborating Centre for Drug Statistics Methodology publishes an 
updated version of the complete ATC index with DDDs annually.  The ATC 
index is available in paper copy and includes one list sorted according to ATC 
codes, with all the established ATC codes and DDDs for plain substances, and one 
list alphabetically sorted according to nonproprietary drug names, including all 
ATC 5th levels. The ATC index is also available in electronic format (Excel or 
XML)  Order form  is  available on the website www.whocc.no. 
 
The DDDs which are to be reviewed during the year, are listed in Annex I  in the 
ATC index. 
 
A searchable version of the index is available on the website www.whocc.no.  The 
search options enable the user to find ATC codes and DDDs based on substance 
name or ATC levels.  Text from the Guidelines for ATC classification and DDD 
assignment linked to the ATC level is also available.  The text will give 
information related to the background for the ATC and DDD assignment.   
 
A pdf document of the Guidelines is available on our website. 
 
Lists of the annual ATC/DDD alterations and new ATC/DDDs are available in 
December each year on our website www.whocc.no.  The lists are distributed free 
of charge by email to the users of the ATC/DDD system included on the Centre’s 
mailing list.   
 
Cumulative lists of ATC/DDD alterations performed since 2005 are available on 
our website www.whocc.no. 
 
List of DDDs for combined products where the assigned DDD deviates from the 
general principles is available on our website www.whocc.no.  
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VII. OTHER ATC CLASSIFICATION SYSTEMS 
 
A. ATCvet classification 
 
The Anatomical Therapeutic Chemical classification for veterinary medicinal 
products, ATCvet, is based on the same main principles as the ATC system for 
medicines for human use.  The ATCvet classification is kept as close to the human 
system as possible, but with special adaptations in order to make it suitable for 
veterinary medicines.  The ATCvet classification was developed by the Nordic 
Council on Medicines, and was taken over by the WHO Collaborating Centre for 
Drug Statistics Methodology in January 2001.  Further information on the ATCvet 
classification can be found on our website www.whocc.no.   
 
 
B. ATC herbal classification 
 
The Herbal ATC (HATC) system provides a framework for the nomenclature and 
therapeutic classification of herbal substances and their combinations.  The 
classification is structurally similar to the official ATC system.  Herbal remedies in 
the Herbal ATC system are divided into groups according to their therapeutic use, 
and additional categories are introduced to the HATC for herbal-specific groups.  
 
The herbal classification is not adopted by WHO.  The Uppsala Monitoring Centre 
is responsible for the ATC herbal classification, and it is used in their WHO Drug 
Global Dictionary to facilitate capture, grouping and aggregation of herbal 
remedies data at different levels of specificity. 
 
Further information about the Herbal ATC classification can be obtained from the 
Uppsala Monitoring Centre (WHO Collaborating Centre for International Drug 
Monitoring), http://www.who-umc.org/. 
 
 
VIII. ATC/DDD INTERPRETATIVE GUIDELINES 
 
This book includes all ATC headings down to the 4th level. 
 
The comments included vary from one ATC group to another.  No comments are 
given if the establishment of ATC codes and DDDs is considered to cause no 
special problems.  
 
Comments related to the assignment of DDDs are given in shadowed boxes. 
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The interpretative guidelines that follow should be consulted whenever the 
ATC/DDD system is used for drug utilization research.  They describe particular 
issues that were discussed and resolved by consensus of the Working Group while 
establishing ATC/DDDs.  If no special problems or issues arose during that 
process, no comments are given. 
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ATC SYSTEM MAIN GROUPS  
The main groups of the ATC classification system are listed below.  A survey of 
each main group is given in the beginning of each of the following chapters. 
 
 
A Alimentary tract and metabolism 
 
B Blood and blood forming organs 
 
C Cardiovascular system 
 
D Dermatologicals 
 
G Genito urinary system and sex hormones 
 
H Systemic hormonal preparations, excl. sex hormones and insulins 
 
J Antiinfectives for systemic use 
 
L Antineoplastic and immunomodulating agents 
 
M Musculo-skeletal system 
 
N Nervous system 
 
P Antiparasitic products, insecticides and repellents 
 
R Respiratory system 
 
S Sensory organs 
 
V Various 
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A ALIMENTARY TRACT AND METABOLISM 
 
A01  STOMATOLOGICAL PREPARATIONS 
A Stomatological preparations 
 
A02 DRUGS FOR ACID RELATED DISORDERS  
A Antacids 
B Drugs for peptic ulcer and gastro-oesophageal reflux disease 
(GORD) 
X Other drugs for acid related disorders 
 
A03  DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS 
A Drugs for functional gastrointestinal disorders 
B Belladonna and derivatives, plain 
C Antispasmodics in combination with psycholeptics 
D Antispasmodics in combination with analgesics 
E Antispasmodics and anticholinergics in combination with other 
drugs  
F Propulsives 
 
A04  ANTIEMETICS AND ANTINAUSEANTS 
A Antiemetics and antinauseants 
 
A05 BILE AND LIVER THERAPY 
A Bile therapy 
B Liver therapy, lipotropics 
C Drugs for bile therapy and lipotropics in combination 
 
A06  DRUGS FOR CONSTIPATION 
A Drugs for constipation 
 
A07 ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ 
ANTIINFECTIVE AGENTS  
A Intestinal antiinfectives 
B Intestinal adsorbents 
C Electrolytes with carbohydrates 
D Antipropulsives 
E Intestinal antiinflammatory agents 
F Antidiarrheal microorganisms 
X Other antidiarrheals 
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A08  ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS 
A Antiobesity preparations, excl. diet products 
 
A09 DIGESTIVES, INCL. ENZYMES 
A Digestives, incl. enzymes 
 
A10  DRUGS USED IN DIABETES 
A Insulins and analogues 
B Blood glucose lowering drugs, excl. insulins 
X Other drugs used in diabetes 
 
A11  VITAMINS 
A Multivitamins, combinations 
B Multivitamins, plain 
C Vitamin A and D, incl. combinations of the two 
D Vitamin B1, plain and in combination with vitamin B6 and B12 
E Vitamin B-complex, incl. combinations 
G Ascorbic acid (vitamin C), incl. combinations 
H Other plain vitamin preparations 
J Other vitamin products, combinations 
 
A12  MINERAL SUPPLEMENTS 
A Calcium 
B Potassium 
C Other mineral supplements 
 
A13  TONICS 
A Tonics 
 
A14  ANABOLIC AGENTS FOR SYSTEMIC USE 
A Anabolic steroids 
B Other anabolic agents 
 
A15  APPETITE STIMULANTS 
 
A16  OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS 
A Other alimentary tract and metabolism products 
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A  ALIMENTARY TRACT AND METABOLISM 
 
A01  STOMATOLOGICAL PREPARATIONS 
 
A01A  STOMATOLOGICAL PREPARATIONS 
 
This group comprises agents for treatment of conditions of mouth and 
teeth.  Preparations mainly used in gingivitis, stomatitis etc. should be 
classified in this group.   
 
Preparations for the treatment of throat infections, (lozenges for 
common cold conditions) or treatment of symptoms both in mouth and 
throat are classified in R02 - Throat preparations.  
 
Preparations containing local anesthetics, see N01B - Anesthetics, local, 
and R02AD - Anesthetics, local.   
 
A01AA  Caries prophylactic agents 
 
This group comprises all types of fluoride preparations (tablets, gargles, 
toothpastes, chewing-gum etc.).   
 
Combinations of olaflur and dectaflur are classified at the 5th level of 
olaflur - A01AA03.  Combinations of sodium fluoride and sodium 
monofluorophosphate are classified in A01AA30. 
 
Combinations of colecalciferol and sodium fluoride indicated for 
prophylaxis of rickets and caries are classified in A11CC. 
 
For caries prophylactic agents in A01AA, the DDDs are based on use in 
children.  DDDs are only established for tablets. 
 
A01AB  Antiinfectives and antiseptics for local oral treatment 
 
This group comprises all antiinfective and antiseptic agents for the 
treatment of stomatitis, gingivitis etc.  Products used in common minor 
infections of mouth and throat are classified in R02, e.g. cetylpyridinium. 
 
Other antibiotics for local use, see D - Dermatologicals. 
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The DDD for amphotericin in this group refers to lozenges. 
 
The DDD for minocycline is based on the amount of active substance 
used in one periodontal pocket in local treatment of periodontitis. 
 
A01AC Corticosteroids for local oral treatment 
 
This group comprises corticosteroid preparations for the treatment of 
gingivitis, stomatitis etc., i.e. corticosteroid preparations for use in the 
oral cavity.   
 
Combinations of corticosteroids and local anesthetics are classified 
here. 
 
Other corticosteroids for local use, see D - Dermatologicals.   
 
No DDDs have been established in this group.  The dosage forms are 
mainly ointments and pastes. 
 
A01AD  Other agents for local oral treatment 
 
This group comprises e.g. various gargles and hemostatic agents used in 
dentistry. 
 
Becaplermin in a kit for implantation indicated to treat periodontally 
related defects is classified here.  
 
Other hemostatic agents, see B02BC - Local hemostatics.   
E.g. combinations with local anesthetics for oral treatment are classified 
at the various level A01AD11.   
 
See also N01B - Anesthetics, local.   
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A02 DRUGS FOR ACID RELATED DISORDERS  
 
A02A  ANTACIDS 
 
This group comprises plain antacid drugs, antacids in combination with 
antiflatulents and antacids in combination with other drugs.   
 
Antacids in combination with liquorice root or linseed are classified in 
this group.   
 
Plain antiflatulents, see A03AX - Other drugs for functional 
gastrointestinal disorders. 
 
The DDDs for antacids are based on treatment of hyperacidity and 
dyspepsia, not ulcus.  One exception, however, is antacids in 
combination with antispasmodics in A02AG, where the DDDs are based 
on treatment of ulcus. 
 
For ordinary salt combinations in A02AD, fixed doses are used instead of 
individual doses for every single preparation (10 tablets = 10 UD; 50 ml 
mixture = 10 UD). 
 
A02AA  Magnesium compounds 
 
Magnesium carbonate used for treatment of mineral deficiency is 
classified here. 
 
Combinations of different magnesium compounds are classified in 
A02AA10 - combinations.   
 
A02AB  Aluminium compounds 
 
Combinations of different aluminium compounds are classified in 
A02AB10 - combinations.   
 
A02AC  Calcium compounds 
 
Combinations of different calcium compounds are classified in  
A02AC10 - combinations.   
 
A02AD  Combinations and complexes of aluminium, calcium and magnesium 
compounds  
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Antacids with two or more of the substances in combination are 
classified here.   
 
Ordinary salt combinations are classified at the same 5th level 
A02AD01 e.g. combinations of aluminium hydroxide, magnesium 
carbonate gel and attapulgite, while the various complexes with a layer 
structure are classified at separate 5th levels e.g. magaldrate and 
almagate.  
 
A02AF  Antacids with antiflatulents 
 
A02AG  Antacids with antispasmodics 
 
Preparations containing a combination of antacids and antispasmodics 
are classified in this group if the main use is as an antacid.  See also 
A03 - Drugs for functional gastrointestinal disorders. 
 
A02AH  Antacids with sodium bicarbonate 
 
No ATC 5th levels are assigned in this group.   
 
All oral formulations containing sodium bicarbonate including products 
indicated for metabolic acidosis are classified in this group.  
 
Parenteral formulations, see B05BB. 
 
Preparations containing sodium bicarbonate to be used only in 
connection with double-contrast radiography are classified in V07AY. 
 
A02AX  Antacids, other combinations 
 
 
A02B  DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL 
REFLUX DISEASE (GORD) 
 
Peptic ulcer includes ulcers in the oesophagus, stomach or duodenum. 
 
Combinations with H2-receptor antagonists are classified in A02B. 
 
See also A03 - Drugs for functional gastrointestinal disorders.  
Antacids in combination with liquorice root or linseed are classified in 
A02A - Antacids.   
 
Combinations with NSAIDs are classified in M01A. 
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A02BA H2-receptor antagonists 
 
Ranitidine bismuth citrate is classified here, whereas other bismuth salts 
are classified in A02BX. 
 
The DDDs are based on treatment of peptic ulcers. 
 
A02BB  Prostaglandins 
 
A02BC  Proton pump inhibitors 
 
The DDDs are based on treatment of gastro-oesophageal reflux 
disease. 
 
A02BD Combinations for eradication of Helicobacter pylori 
 
 This group comprises fixed combination packages. 
 
The DDDs for combination packages in this group are given a fixed 
dose DDD, e.g. 6 tablets per day gives a DDD = 6 UD. 
 
A02BX  Other drugs for peptic ulcer and gastro-oesophageal reflux disease 
(GORD) 
 
Ranitidine bismuth citrate is classified in A02BA. 
 
Alginic acid in combination with antacids (e.g. aluminium hydroxide, 
calcium carbonate) is given the code A02BX13. 
 
The DDD for alginic acid in combination with antacids (A02BX13) 
is given in a fixed doses (10 tablets = 10 UD; 50 ml mixture = 10 
UD). 
 
 
A02X OTHER DRUGS FOR ACID RELATED DISORDERS  
 
This group comprises preparations, which cannot be classified in the 
preceding groups.   
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A03  DRUGS FOR FUNCTIONAL GASTROINTESTINAL 
DISORDERS 
 
A major part of the preparations in this group are combined prepara-
tions.  Preparations containing e.g. analgesics and antispasmodics could 
be classified either in this group or in N02 - Analgesics.  Combinations 
of psycholeptics and antispasmodics could be classified in A03 or in 
N05 - Psycholeptics etc.  The main indication for the use of the 
combination will, together with the relative effect of the active 
components, decide the classification.  In the treatment of pain caused 
by spasms, the spasmolytic component must be judged as more 
important than the analgesic component.  Accordingly, 
analgesic/antispasmodic combinations should be classified in A03 if the 
main effect of the preparation is the antispasmodic action.   
Combined preparations are classified in: 
 
A03C - Antispasmodics in combination with psycholeptics   
A03D - Antispasmodics in combination with analgesics  
A03E - Antispasmodics and anticholinergics in combination with other 
drugs  
 
Antispasmodics, which are used specifically in the urogenital tractus, 
are classified in G04BD - Drugs for urinary frequency and 
incontinence.   
 
The DDD for the substances is usually equal for different routes of 
administration (oral, parenteral or rectal) of the same compound 
and is based on the oral dose.  
 
 
A03A DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS 
 
Drugs for constipation are classified in A06. 
 
Semisynthetic derivatives such as butylscopolamine, are classified in 
A03B - Belladonna and derivatives, plain.   
 
A03AA  Synthetic anticholinergics, esters with tertiary amino group  
 
A03AB Synthetic anticholinergics, quaternary ammonium compounds  
 
Plain preparations for systemic use containing glycopyrronium bromide 
are classified in this group.  Preparations containing glycopyrronium in 
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combination with neostigmine are classified in N07AA51.  Trospium 
see G04BD and A03DA. 
 
Pipenzolate in combination with silicones is classified in A03AB14. 
 
The parenteral DDD for glycopyrronium bromide is based on the 
use as premedication for anesthetic procedures. 
 
A03AC  Synthetic antispasmodics, amides with tertiary amines  
 
A03AD  Papaverine and derivatives 
 
Combinations with sterculia are classified here.  Systemic combinations 
containing papaverine are classified at the plain level for papaverine. 
Papaverine used for treatment of erectil dysfunction, see G04BE. 
 
A03AE Serotonin receptor antagonists 
 
A03AX  Other drugs for functional gastrointestinal disorders 
 
This group comprises drugs for functional gastrointestinal disorders, 
which cannot be classified in the preceding groups.  
 
Combinations of silicones and antispasmodics are classified in 
A03AX13 if the main indication is flatulence.   
Combinations of silicones and antacids are classified in A02AF. 
 
Combinations of silicones and antipropulsives are classified in A07DA. 
 
Trimethylphloroglucinol and combinations with 
trimethylphloroglucinol are allowed at the 5th level A03AX12 - 
phloroglucinol. 
 
Dimeticone is classified in A03AX13 - silicones 
 
 
A03B  BELLADONNA AND DERIVATIVES, PLAIN 
 
A03BA  Belladonna alkaloids, tertiary amines 
 
A03BB Belladonna alkaloids, semisynthetic, quaternary ammonium compounds  
 
 Combinations with codeine are classified in N02AA.  
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A03C ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS 
 
Antispasmodics in combination with psycholeptics and other drugs 
(excl. analgesics) are classified in this group. 
 
Antispasmodics in combination with both psycholeptics and analgesics 
are classified in A03EA. 
 
 The classification at the 5th levels is based on the antispasmodic 
component.  At each 5th level several psycholeptics may occur.  When 
classifying such combined products, it is necessary to look at the main 
indication and the composition, to see if the preparation should be 
classified in A03 or in N05 - Psycholeptics (see comments under A03).  
 
A03CA Synthetic anticholinergic agents in combination with psycholeptics  
 
General comments, see A03C. 
 
Combinations with more than one antispasmodic substance are 
classified in a ranking according to the ATC code.  A substance 
classified in A03CA01 takes precedence over a substance classified in 
A03CA02 etc.  
 
A03CB  Belladonna and derivatives in combination with psycholeptics  
 
General comments, see A03C. 
 
Combinations with more than one antispasmodic are classified in a 
ranking according to the ATC code.  A substance classified in 
A03CB01 takes precedence over a substance classified in A03CB02 
etc.   
 
A03CC  Other antispasmodics in combination with psycholeptics  
 
This group comprises combined preparations with psycholeptics, which 
are not covered by A03CA and A03CB. 
 
 
A03D ANTISPASMODICS IN COMBINATION WITH ANALGESICS 
 
This group is completely parallel to A03C. 
 
The classification at the 5th levels is based on the antispasmodic 
component.  At each 5th level several analgesics may occur.  
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Antispasmodics in combination with analgesics and other drugs (excl. 
psycholeptics) are classified in this group. 
 
When classifying these combination products, it is necessary to look at 
the indications and the composition to see if the preparation should be 
classified in A03 or in N02 - Analgesics.  
 
Opioid analgesics in combination with antispasmodics, see N02AG - 
Opioids in combination with antispasmodics.  Ethylmorphine is not 
regarded as a narcotic in this context.   
 
 Antispasmodics in combination with psycholeptics and analgesics are 
classified in A03EA. 
 
A03DA  Synthetic anticholinergic agents in combination with analgesics  
 
General comments, see A03D. 
 
Combinations with more than one antispasmodic are classified in a 
ranking according to the ATC code.  A substance classified in 
A03DA01 takes precedence over a substance classified in A03DA02 
etc. 
 
Combinations containing codeine are classified here, provided the 
codeine content is less than 20 mg.  See also N02AA. 
 
Combinations of trospium and analgesics are classified here. 
 
A03DB  Belladonna and derivatives in combination with analgesics  
 
General comments, see A03D. 
 
Combinations with more than one antispasmodic are classified in a 
ranking according to the ATC code.  A substance classified in 
A03DB01 takes precedence over a substance classified in A03DB02 
etc.   
 
A03DC  Other antispasmodics in combination with analgesics 
 
This group comprises combined preparations with analgesics, which are 
not covered by A03DA and A03DB. 
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A03E  ANTISPASMODICS AND ANTICHOLINERGICS IN COMBI-
NATION WITH OTHER DRUGS  
 
General comments, see A03. 
 
This group comprises all combined preparations with antispasmodics 
and anticholinergics, which are not covered by A03C or A03D.   
 
A03EA  Antispasmodics, psycholeptics and analgesics in combination  
 
Antispasmodics in combination with psycholeptics, analgesics and 
other agents are classified in this group.  
 
A03ED  Antispasmodics in combination with other drugs  
 
 
A03F PROPULSIVES 
 
A03FA Propulsives 
 
Agents stimulating gastro-intestinal motility are classified here, e.g. 
substituted benzamides.  
 
Trimebutine is classified in A03AA. 
 
Levosulpiride is classified in N05AL07. 
 
 
A04  ANTIEMETICS AND ANTINAUSEANTS 
 
A04A  ANTIEMETICS AND ANTINAUSEANTS 
 
Antihistamines, which are often used as antiemetics, are classified in 
R06 - Antihistamines for systemic use.   
 
Metoclopramide is classified in A03FA. 
 
Combinations with analgesics are classified in N02 - Analgesics. 
 
Antivertigo preparations, see N07C. 
 
Antipsychotics, see N05A. 
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A04AA Serotonin (5HT3) antagonists 
 
The DDDs are based on antiemetic treatment. The DDD for 
palonosetron is based on single dose treatment. 
 
A04AD  Other antiemetics 
 
Fosaprepitant, a prodrug of aprepitant, is classified together with the 
parent drug in A04AD12.  
 
Droperidol used for prevention of nausea and vomiting is classified in 
N05AD.  
 
The DDD for scopolamine plaster is one plaster (i.e. 1 UD).  This 
DDD is based on prophylaxis of motion sickness. 
 
DDDs for other substances classified in this group are based on 
antiemetic treatment. 
 
The parenteral DDD for aprepitant (expressed as fosaprepitant) is 
based on the average daily dose in a three days combined 
parenteral/oral course. 
 
 
A05  BILE AND LIVER THERAPY 
 
A05A  BILE THERAPY 
 
A05AA  Bile acids and derivatives 
 
Preparations classified in this group are primarily bile acid preparations, 
but various combinations, e.g. with spasmolytics, can also be included 
in each 5th level. 
 
A05AB  Preparations for biliary tract therapy 
 
A05AX  Other drugs for bile therapy 
 
This group comprises other drugs for bile therapy, which cannot be 
classified in the preceding groups.   
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A05B  LIVER THERAPY, LIPOTROPICS 
 
A05BA  Liver therapy 
 
Thioctic acid is classified in A16AX. 
 
Preparations containing silibinin are classified at the same ATC 5th 
level as silymarin. 
 
 
A05C DRUGS FOR BILE THERAPY AND LIPOTROPICS IN 
COMBINATION 
 
 
A06  DRUGS FOR CONSTIPATION 
 
A06A  DRUGS FOR CONSTIPATION 
 
All agents used for treatment of constipation (regardless of indication) 
are classified here. 
 
The agents are mainly subdivided according to mode of action.  All 
enemas are classified in A06AG, regardless of mode of action.   
 
Some combination products are classified at separate levels.  These are 
mentioned in the respective ATC group. 
 
Otherwise combination products are classified at separate 5th levels 
using the corresponding 50-series.   
 
Laxatives in combination with centrally acting antiobesity agents are 
classified in A08A - Antiobesity preparations, excl. diet products.   
 
A06AA Softeners, emollients 
 
This group comprises preparations containing liquid paraffin, docusate 
sodium etc.  Docusate potassium is classified at the same 5th level as 
docusate sodium. 
 
Combinations with contact laxatives are classified in A06AB, except all 
liquid paraffin combinations, which are classified in A06AA.   
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DDDs for e.g. liquid paraffin and castor oil are given using the 
following unit: g (gram), (1 g = 1 ml for all practical purposes). 
Preparations classified in A06AA51 - liquid paraffin, combinations, 
are all given the same DDD = 3 UD (15 ml), independent of liquid 
paraffin concentration. 
 
A06AB  Contact laxatives 
 
This group comprises agents, which mainly inhibit the absorption of 
electrolytes and water through a specific pharmacological mechanism.   
 
Combinations with osmotically acting laxatives are classified here. 
 
Combinations with bulk producing laxatives are classified in  
A06AC - Bulk-forming laxatives.   
Gas producing rectal preparations and glycerol suppositories, see 
A06AX - Other drugs for constipation.   
 
Phenolphthalein in combination with liquid paraffin, see A06AA.   
Combined packages with tablets and enemas are classified in A06AG.   
 
A major part of the products classified in this group are various 
combinations of two or more contact laxatives.  These are classified at 
separate 5th levels:  
 
A06AB20 -  contact laxatives in combination 
A06AB30 -  contact laxatives in combination with belladonna alkaloids  
 
Otherwise combination products are classified at separate 5th levels 
using the corresponding 50-series.   
 
Preparations containing bark (cortex) of Rhamnus pursiana and 
Rhamnus frangula are classified in A06AB07 cascara. 
 
A06AC  Bulk-forming laxatives 
 
This group comprises linseed and psylla seed products, methyl cellulose 
etc.   
 
Lactulose, see A06AD. 
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Products containing linseed in combination with antacids are classified 
in A02A. 
 
Products containing sterculia in combination with alverine are 
classified in A03AX. 
 
A06AD  Osmotically acting laxatives 
 
This group comprises various saline purgatives and e.g. lactulose, 
which is primarily considered as an osmotically acting substance.   
 
Combinations with contact laxatives are classified in A06AB.   
Mineral salts in combinations are classified in A06AD10. 
Combinations of lactulose with liquid paraffin should be classified in 
A06AD61. 
 
Macrogol in combination with electrolytes is classified in A06AD65. 
 
Magnesium hydroxide is classified as an antacid in A02AA.   
 
Magnesium in combination with albumin tannate are classified in 
A07XA. 
 
The DDD for macrogol refers to macrogol 4000. 
 
A06AG  Enemas 
 
All enemas and laxative rectal solutions are classified in this group, 
regardless of mode of action.   
 
Combined packages containing tablets and enemas are classified in this 
group.   
 
Some 5th levels for plain substances also include combinations, e.g.: 
 
A06AG10 - docusate sodium- and e.g. sorbitol or glycerol  
A06AG11 - sodium lauryl sulfoacetate and e.g. sodium citrate  
 
Sodium  laurilsulfate is also classified in A06AG11. 
 
The DDDs for enemas classified in this group are 1 enema. 
 
A06AH Peripheral opioid receptor antagonists  
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A06AX  Other drugs for constipation 
 
This group comprises all agents, which cannot be classified in the 
preceding groups, e.g. lubiprostone, linaclotide and prucalopride.  
 
The DDD for linaclotide is based on treatment of irritable bowel 
syndrome with constipation. 
 
 
A07  ANTIDIARRHEALS, INTESTINAL 
ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS  
 
A07A  INTESTINAL ANTIINFECTIVES 
 
This group comprises locally acting antiinfectives.  Antiinfectives for 
systemic use, see J - Antiinfectives for systemic use.   
 
See also P - Antiparasitic products, insecticides and repellents.   
 
A07AA  Antibiotics 
 
Vancomycin and colistin for oral therapy are classified in this group as 
they are used in enterocolitis.  Vancomycin injection/infusion is classified 
in J01XA - Glycopeptide antibacterials, and colistin injection/infusion in 
J01XB - Polymyxins. 
 
Most of the combined products containing more than one antibiotic, 
contain neomycin.  Neomycin is given classification priority, thus all 
combined products containing neomycin and other antibiotics should be 
classified in A07AA51 - neomycin, combinations.   
 
Paromomycin injection used in the treatment of leishmaniasis is classified 
here. 
 
The DDDs are based on treatment of intestinal infections. 
 
A07AB  Sulfonamides 
 
The DDDs are based on preoperative prophylaxis of intestinal 
infections. 
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A07AC  Imidazole derivatives 
 
The DDDs are based on treatment of gastrointestinal mycosis. 
 
A07AX  Other intestinal antiinfectives 
 
This group comprises antiinfectives, which cannot be classified in 
A07AA-C.   
 
 
A07B  INTESTINAL ADSORBENTS 
 
Combinations with intestinal antiinfectives are classified in A07A.   
 
A07BA  Charcoal preparations 
 
The DDD for charcoal preparations is based on treatment of common 
diarrhea. 
 
A07BB  Bismuth preparations 
 
See also A02BX - Other drugs for peptic ulcer and gastro-oesophageal 
reflux disease (GORD).   
 
No ATC 5th levels are assigned in this group. 
 
A07BC  Other intestinal adsorbents 
 
This group comprises all other intestinal adsorbents.   
 
Combinations with albumin tannate are classified in A07XA. 
 
 
A07C  ELECTROLYTES WITH CARBOHYDRATES 
 
A07CA  Oral rehydration salt formulations 
 
The DDDs are mainly based on use in children. 
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A07D  ANTIPROPULSIVES 
 
A07DA  Antipropulsives 
 
This group comprises agents which reduce gastrointestinal motility, e.g. 
diphenoxylate and loperamide.  Loperamide and loperamide oxide are 
classified at the two separate 5th levels. 
A07DA01 - diphenoxylate - includes combinations with atropine 
A07DA02 -  opium - includes also combinations with belladonna and/or 
bismuth subgallate, albumin etc.   
 
Combinations with antiflatulents are classified here. 
 
The DDDs are based on treatment of acute diarrhea. 
 
 
A07E  INTESTINAL ANTIINFLAMMATORY AGENTS 
 
A07EA  Corticosteroids acting locally 
 
Enemas and rectal foams for treatment of e.g. ulcerative colitis are 
classified here.  Oral budesonide for treatment of morbus Crohn is also 
classified here. 
 
The DDDs are given as 1 enema.  The DDD for hydrocortisone rectal 
foam is given in amount of active substance. 
 
The DDD for oral budesonide is based on the treatment of morbus 
Crohn. 
 
A07EB  Antiallergic agents, excl. corticosteroids 
 
Cromoglicic acid for oral use in food allergy is classified in this group. 
 
The DDD is based on treatment of food allergy. 
 
A07EC  Aminosalicylic acid and similar agents 
 
Some preparations classified in this group are also used for treatment of 
rheumatoid arthritis.   
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The DDDs are based on treatment of colitis ulcerosa and morbus 
Crohn. 
 
 
A07F  ANTIDIARRHEAL MICROORGANISMS 
 
A07FA  Antidiarrheal microorganisms 
 
Preparations with e.g. lactic acid producing organisms are classified in 
this group.   
 
The DDDs are given in UDs (e.g. numbers of tablets). 
 
 
A07X  OTHER ANTIDIARRHEALS 
 
A07XA  Other antidiarrheals 
 
Combinations with pectin and magnesium peroxide are classified here. 
 
 
A08  ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS 
 
A08A  ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS 
 
Low-energy diets, see V06AA. 
 
A08AA  Centrally acting antiobesity products 
 
Centrally acting drugs mainly used to produce anorexia are classified in 
this group.  Amfetamine, which is commonly used in psychiatry, is 
classified in N06B - Psychostimulants, agents used for ADHD and 
nootropics. 
 
A08AB Peripherally acting antiobesity products 
 
A08AX Other antiobesity drugs 
 
Liraglutide used as an antiobesity drug is classified as a blood glucose 
lowering drug in A10BJ. 
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A09  DIGESTIVES, INCL. ENZYMES 
 
A09A  DIGESTIVES, INCL. ENZYMES 
 
A09AA  Enzyme preparations 
 
Only enzymes used in digestion disorders are classified in this group. 
Other enzymes, see B06AA - Enzymes, and D03BA - Proteolytic 
enzymes.   
 
Enzyme preparations, which are indicated to treat inflammatory 
conditions, are classified in M09AB - Enzymes. 
 
Combinations of digestive enzymes and other agents (e.g. silicone 
compounds and spasmolytics) are classified in this group if the main 
indication is digestion disorders.   
Cholagogues are classified in A05 - Bile and liver therapy.   
 
DDDs can be difficult to establish because of great variations in 
enzyme content.  The DDDs are based on average recommended doses 
given in different drug catalogues.  Most of the preparations are 
combinations of different enzymes, and the DDDs are therefore given 
in UDs.  Some specific products have been given a DDD, see list of 
DDDs for combination products, www.whocc.no. 
 
A09AB  Acid preparations 
 
A09AC  Enzyme and acid preparations, combinations 
 
 
A10  DRUGS USED IN DIABETES 
 
A10A  INSULINS AND ANALOGUES 
 
This group comprises both human - and animal insulins.   
 
Insulin preparations are classified at 4 different 4th levels, according to 
onset and duration of action.  Each 4th level is differentiated in 5th 
levels according to origin of insulin. 
 
Products consisting of, e.g. beef and pork insulin, are classified as 
combinations (30-levels) at each 4th level according to onset and 
duration of action. 
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The DDD for insulins is 40 units. 
 
A10AB  Insulins and analogues for injection, fast-acting 
 
A10AC Insulins and analogues for injection, intermediate-acting 
 
A10AD Insulins and analogues for injection, intermediate- or long-acting 
combined with fast-acting 
 
A10AE Insulins and analogues for injection, long-acting 
 
A10AF Insulins and analogues for inhalation 
 
 
A10B  BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS 
 
A10BA  Biguanides 
 
A10BB  Sulfonylureas 
 
The DDD for micronized glibenclamide is lower compared to non-
micronized formulations, due to higher bioavailability. 
 
The DDD for gliclazide is based on the modified release formulation. 
 
A10BC Sulfonamides (heterocyclic) 
 
A10BD Combinations of oral blood glucose lowering drugs 
 
Combinations with thioctic acid are allowed in A10BD05. 
 
It has been considered most appropriate to assign fixed DDDs based on 
the average use of the different combinations without considering and 
comparing the strengths of the various components.  One UD is the 
fixed DDD for products dosed as 1 tablet daily whereas two UD is the 
fixed DDD for products dosed as 2 tablets daily.  The assigned DDDs 
cannot always be compared with the DDDs assigned for plain 
preparations. 
 
See list of DDDs for combined products, www.whocc.no 
 
A10BF Alpha glucosidase inhibitors 
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A10BG Thiazolidinediones 
 
The DDD for troglitazone is based on combination therapy.  The DDDs 
for rosiglitazone and pioglitazone are based on monotherapy. 
 
A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors 
 
A10BJ Glucagon-like peptide-1 (GLP-1) analogues 
 
A10BK Sodium-glucose co-transporter 2 (SGLT2) inhibitors 
 
A10BX Other blood glucose lowering drugs, excl. insulins 
 
Low strength tablets (e.g. 0.8 mg) of bromocriptine are classified in 
G02CB01. 
 
Nateglinide in combination with thioctic acid is classified in A10BX03. 
 
 
A10X OTHER DRUGS USED IN DIABETES 
 
A10XA Aldose reductase inhibitors 
 
 
A11  VITAMINS 
 
Vitamins constitute a comprehensive group of therapeutic and 
prophylactic preparations.  Before classifying any product it is 
important to be familiar with the main subdivision of the group.   
 
It may be necessary to consider whether a product is a vitamin 
preparation with iron or an iron preparation with vitamins, a mineral 
preparation with vitamins or a vitamin preparation with minerals, or if 
the product should be regarded as a tonic etc.  As an aid to such 
considerations, guidelines are given at each sublevel.   
Vitamin B12 is classified in B03 - Antianemic preparations.  
Vitamin K is classified in B02 - Antihemorrhagics. 
 
Vitamins administered as i.v. solution additives, see B05XC.   
 
Some definitions: 
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Multivitamins: Products containing minimum vitamins A, B, C and 
D.  One B-vitamin is sufficient.   
 
B-complex:  Products containing minimum thiamine, riboflavine, 
pyridoxine, nicotinamide.  The products may contain 
other B-vitamins.   
 
 
A11A  MULTIVITAMINS, COMBINATIONS 
 
The DDDs are based on prophylaxis.  For simplicity, the DDDs for oral 
formulations are given as fixed doses (1 tablet = 1 UD; 30 ml mixture = 
6 UD). 
 
A11AA  Multivitamins with minerals 
 
The group is subdivided: 
 
A11AA01 - multivitamins and iron 
A11AA02 -  multivitamins and calcium 
A11AA03 -  multivitamins and other minerals, incl. combinations 
A11AA04 - multivitamins and trace elements 
 
In A11AA01, 02 and 03, combinations with trace elements are allowed.  
 
In A11AA04 only trace elements are allowed in addition to 
multivitamins.   
 
Combinations with other substances, e.g. caffeine, are classified in 
A11AB.   
 
Cholin, biotin, inositol and para-amino benzoic acid are regarded as 
vitamins and are allowed in preparations classified in A11AA.   
 
A11AA01  multivitamins and iron 
 
Preparations containing multivitamins and sub-therapeutic doses of iron 
are classified in this group.   
Sub-therapeutic doses of iron are defined as 5-30 mg of Fe2+ per 
defined daily dose, with corresponding limits for the various Fe3+ salts, 
if the main indication is not "iron deficiency".  Preparations containing 
more than 30 mg Fe2+ (or corresponding doses of Fe3+) are classified as 
iron preparations (B03A) regardless of therapeutic use.   
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See also A11AA. 
 
A11AA02  multivitamins and calcium 
 
Preparations containing multivitamins and sub-therapeutic doses of 
calcium are classified in this group, e.g. a calcium content of up to 
500  mg calcium carbonate per tablet have been allowed.  
See also A11AA. 
 
Calcium preparations, see A12A. 
 
 A11AA03 multivitamins and other minerals, incl. combinations  
 
Preparations containing multivitamins and sub-therapeutic doses of one 
or more mineral are classified in this group.  Definitions of sub-
therapeutic doses of iron and calcium, see A11AA01 and A11AA02. 
See also A11AA.   
 
Mineral supplements, see A12. 
 
A11AA04  multivitamins and trace elements 
 
Preparations containing multivitamins and trace elements are classified 
in this group.  No other combinations should occur in this group.   
 
A11AB  Multivitamins, other combinations 
 
This group comprises all combined preparations with multivitamins, 
which are not classified in A11AA.   
 
Preparations containing caffeine, strychnine etc. are classified in this 
group.   
Preparations containing cholin, biotin, inositol, para-amino benzoic acid 
etc. should be classified in A11AA.   
 
 
A11B  MULTIVITAMINS, PLAIN 
 
A11BA  Multivitamins, plain 
 
Only plain multivitamin preparations are allowed.   
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The DDDs are based on prophylaxis.  For simplicity, the DDDs are 
given as fixed doses (1 tablet = 1 UD; 30 ml mixture = 6 UD). 
 
 
A11C VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO 
 
Combinations with trace elements are allowed.  Other combinations, 
see A11J - Other vitamin products, combinations.   
 
See also A12 - Mineral supplements. 
 
A11CA  Vitamin A, plain 
 
The DDD is based on treatment of vitamin A deficiency. 
 
A11CB  Vitamin A and D in combination 
 
Cod-liver oil products are classified in this group.   
 
A11CC  Vitamin D and analogues 
 
Vitamin D and analogues may be regarded as hormones, but are 
classified in this group.  Calcium homeostasis, see H05.   
 
Paricalcitol and doxercalciferol indicated for the prevention and 
treatment of secondary hyperparathyroidism are classified in H05BX - 
Other anti-parathyroid agents. 
 
Colecalciferol in combination with sodium fluoride indicated for 
prophylaxis of rickets and caries is classified in A11CC55.   
 
Modified-release oral formulations of calcifediol indicated for the 
treatment of  hyperparathyroidism are classified in this group. 
 
The DDDs are based on therapeutic use.  No DDD is established for 
ergocalciferol due to great differences between doses used for various 
indications. The DDD of 20 mcg colecalciferol corresponds to 800 IU. 
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A11D  VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 
AND B12  
 
Combinations with trace elements are allowed.  Other combinations see 
A11J - Other vitamin products, combinations.   
 
A11DA  Vitamin B1, plain 
 
The DDDs are based on treatment of vitamin B1 deficiency. 
 
A11DB  Vitamin B1 in combination with vitamin B6 and/or vitamin B12  
 
Combinations with vitamin B2 are also allowed in this group. 
 
For vitamin B1 in combination with vitamin B6 and/or vitamin B12, 
DDDs are only established for parenteral preparations, based on the 
volume of one ampoule.  The DDDs are given in UDs (1 UD = 1 ml). 
 
 
A11E  VITAMIN B-COMPLEX, INCL. COMBINATIONS 
 
Definition of vitamin B-complex, see A11 - Vitamins.   
The group is subdivided:  
 
A11EA -   Vitamin B-complex, plain 
A11EB -   Vitamin B-complex with vitamin C 
A11EC -   Vitamin B-complex with minerals 
A11ED -   Vitamin B-complex with anabolic steroids 
A11EX -   Vitamin B-complex, other combinations 
 
Combinations with trace elements are allowed.  Vitamin B-complex in 
combination with other vitamins than vitamin C, see A11J - Other 
vitamin products, combinations.   
 
DDDs are based on prophylaxis.  DDDs are given as fixed doses  
(1 tablet = 1 UD; 30 ml mixture = 6 UD).  DDDs for parenteral 
preparations are based on the volume of one ampoule.  The DDDs for 
these preparations are given in UDs (1 UD = 1 ml). 
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A11EA  Vitamin B-complex, plain 
 
This group comprises plain vitamin B-complex preparations, also in 
combination with liver extract.  Liver extract preparations, see also 
B03BA - Vitamin B12 (cyanocobalamin and derivatives).  See also 
A11E.   
 
A11EB  Vitamin B-complex with vitamin C 
 
This group comprises all combinations of vitamin B-complex and 
vitamin C.  Combinations with anabolic steroids, see A11ED.   
 
See also A11E, A11ED and A11EX.   
 
A11EC  Vitamin B-complex with minerals 
 
Preparations containing vitamin B-complex and sub-therapeutic doses 
of one or more mineral are classified in this group.   
 
See also A11E. 
 
Mineral supplements, see A12. 
 
A11ED  Vitamin B-complex with anabolic steroids 
 
Preparations containing vitamin B-complex and anabolic steroids are 
classified in this group.  Even combinations containing vitamin C, 
minerals or other substances, e.g. caffeine are classified in this group. 
 
A11EX  Vitamin B-complex, other combinations 
 
This group comprises preparations with vitamin B-complex (plain or in 
combination with vitamin C or minerals) and other substances, e.g. 
caffeine, strychnine.   
 
 
A11G  ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS 
 
Other preparations with vitamin C, see A11EB - Vitamin B-complex 
with vitamin C, and A11J - Other vitamin products, combinations.   
 
Combinations with analgesics are classified in N02B. 
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The DDD refers to the assumed daily requirement. 
For combination products, the DDDs are given as fixed doses for all 
tablets (1 tablet = 1 UD). 
 
A11GA  Ascorbic acid (vitamin C), plain 
 
Combinations with trace elements only, are allowed.   
 
A11GB  Ascorbic acid (vitamin C), combinations 
 
This group comprises combinations with e.g. minerals. 
 
Preparations containing ascorbic acid and calcium should be classified in 
A12AX - Calcium, combinations with vitamin D and/or other drugs - if 
they are used in calcium deficiency or osteoporosis.   
 
 
A11H  OTHER PLAIN VITAMIN PREPARATIONS 
 
A11HA  Other plain vitamin preparations 
 
Vitamin B12, see B03BA. 
 
Vitamin K, see B02 - Antihemorrhagics. 
 
Combinations with trace elements are allowed.  Other combinations, see 
A11DB and A11J.   
 
DDDs are established only for tocopherol, pyridoxine and nicotinamide, 
and refer to assumed daily requirement in vitamin deficiency. 
 
 
A11J  OTHER VITAMIN PRODUCTS, COMBINATIONS 
 
The group is subdivided: 
 
A11JA -   Combinations of vitamins 
A11JB -   Vitamins with minerals 
A11JC -   Vitamins, other combinations 
 
Combinations with trace elements are allowed. 
  
 78 
 
The DDDs are given as fixed doses (1 tablet = 1 UD; 30 ml mixture = 
6 UD), except for concentrated ACD vitamin drops. 
 
A11JA  Combinations of vitamins 
 
This group comprises all combinations of vitamins with no addition of 
other substances, not covered by the preceding groups.   
 
A11JB  Vitamins with minerals 
 
This group comprises all combinations of vitamins with minerals in 
sub-therapeutic doses, not covered by the preceding groups.   
 
See also A12 - Mineral supplements. 
 
A11JC Vitamins, other combinations 
 
This group comprises all products, which contain vitamins (with or 
without minerals) and in addition other substances, e.g. caffeine and 
strychnine.  Combinations with folic acid are classified in B03BB if 
"folic acid deficiency" is the main indication.   
 
This group contains products, which may also be regarded as tonics. No 
sharp line has been drawn between these two groups.   
Tonics are classified in A13.  The vitamin content of tonics should be 
rather low.   
 
 
A12  MINERAL SUPPLEMENTS 
 
This group contains mineral supplements used for treatment of mineral 
deficiency.  Magnesium carbonate used for treatment of mineral 
deficiency is classified in A02AA01. 
 
 
A12A  CALCIUM 
 
A12AA  Calcium 
 
Plain calcium preparations, incl. bone extracts are classified in this 
group.  Calcium acetate mainly used  for the treatment of 
hyperphosphatemia, is classified in V03AE07.   
 79 
See also B05X - I.v. solution additives.   
 
Combinations of different calcium salts are given the following ATC 
code: A12AA20.  Small amounts of calcium carbonate (i.e. 300 mg per 
tablet) are, however, allowed at each 5th level for plain calcium 
preparations.   
 
Combinations of calcium and vitamine D are classified in A12AX. 
 
The combination of calcium acetate and magnesium carbonate is 
classified in V03AE. 
 
Antacids with calcium carbonate are classified in A02AC. 
 
See also: 
 
A11AA02 -  multivitamins and calcium 
A11EC -  Vitamin B-complex with minerals 
A11GB01 -  ascorbic acid (vit C) and calcium 
A11JB -  Vitamins with minerals 
 
The DDDs are based on treatment of calcium deficiency and 
osteoporosis. 
 
A12AX  Calcium, combinations with vitamin D and/or other drugs 
 
This group comprises all combined calcium preparations used in the 
treatment of calcium deficiency conditions and osteoporosis.  Many of 
these are combinations with vitamins, especially vitamin A and D. 
 
Combination packages of calcium and bisphosphonates are classified in 
M05BB. 
 
Combinations with fluoride are classified in A12CD. 
 
 
A12B  POTASSIUM 
 
A12BA  Potassium 
 
This group comprises preparations used as potassium supplements. 
 
This group comprises also all combined potassium preparations used in 
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the treatment of potassium deficiency conditions.   
 
Small non-therapeutic amounts of potassium hydrogencarbonate are 
allowed at each level of plain potassium salts. 
Potassium, combinations with other drugs, are classified at separate 5th 
levels using the corresponding 50-series.   
Diuretics and potassium in combination, see C03 - Diuretics.   
 
See also B05 - Blood substitutes and perfusion solutions.   
 
The DDDs are based on treatment of potassium deficiency and 
correspond to a potassium content of about 40 mmol potassium. 
 
 
A12C  OTHER MINERAL SUPPLEMENTS 
 
This group comprises other minerals.   
 
See also B05 - Blood substitutes and perfusion solutions.   
 
A12CA  Sodium 
 
The DDD has been set to 1 g NaCl. 
 
A12CB  Zinc 
 
The DDD is based on treatment of zinc deficiency. 
 
A12CC  Magnesium 
 
The DDDs for the various magnesium salts are equivalent to an 
assumed daily requirement of 300 mg Mg (oral dose).  The DDD for 
some of the oral formulations are higher than the parenteral 
formulations due to lower bioavailability. 
 
A12CD  Fluoride 
 
This group comprises preparations used e.g. in the treatment of 
osteoporosis.  Fluoride used in caries prophylaxis, see A01AA - Caries 
prophylatic agents.  
 
Bisphosphonates are classified in M05B. 
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Calcitonin is classified in H05BA. 
Calcium preparations are classified in A12A. 
Combinations with calcium are classified here. 
 
The DDD is based on treatment of osteoporosis. 
 
A12CE  Selenium 
 
The DDDs are based on treatment of selenium deficiency and is 
expressed as amount of selenium (Se). 
 
A12CX  Other mineral products 
 
 
A13  TONICS 
 
A13A  TONICS 
 
This group comprises preparations used as tonics etc., if preparations do 
not fill the requirements to be classified as iron preparations, vitamin 
preparations etc.   
 
All mixtures classified in this group are given a fixed DDD 
(30 ml = 6 UD). 
 
 
A14  ANABOLIC AGENTS FOR SYSTEMIC USE 
 
A14A  ANABOLIC STEROIDS 
 
Anabolic steroids are subdivided in different 4th levels according to 
chemical structure.   
 
Anabolic steroids used exclusively in cancer therapy, see  
L - Antineoplastic and immunomodulating agents.   
 
The DDDs are based on e.g. treatment of anemia. 
 
A14AA  Androstan derivatives 
 
A14AB  Estren derivatives 
 
 82 
A14B  OTHER ANABOLIC AGENTS 
 
This group comprises all other anabolic agents which cannot be 
classified in the preceding groups.   
 
 
A15  APPETITE STIMULANTS 
 
This group comprises preparations only used as appetite stimulants.   
A number of drugs with other main actions may have appetite 
stimulating properties.   
 
Cyproheptadine, also used as an appetite stimulant in children, is 
classified in R06AX.  Pizotifen is classified in N02CX. 
 
No DDDs are established in this group. 
 
 
A16  OTHER ALIMENTARY TRACT AND METABOLISM 
PRODUCTS 
 
A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS 
 
This group comprises all products acting on the alimentary tract and 
metabolism which cannot be classified in the preceding groups. V03 - 
All other therapeutic products, should also be considered.   
 
Nutrients are classified in V06 - General nutrients. 
 
A16AA Amino acids and derivatives 
 
Agents used in various metabolic deficiency states are classified here, 
when this is considered to be the main indication e.g. levocarnitine.  
Tryptophan and oxitriptan are classified in N06A. 
 
Metreleptin used for treatment of  complications of leptin deficiency in 
patients with generalised lipodystrophy is classified in this group. 
 
The DDD of levocarnitine is based on treatment of primary carnitine 
deficiency. 
 
A16AB Enzymes 
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A16AX Various alimentary tract and metabolism products 
 
Thioctic acid is classified in this group. 
 
The DDD for zinc acetate is expressed as the amount of zinc (Zn). 
The DDD for nitisinone is based on the treatment of children with a 
bodyweight of 20 kg. 
The DDD for thioctic acid is based on the treatment of patients with 
peripheral diabetic polyneuropathy. 
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B  BLOOD AND BLOOD FORMING ORGANS 
 
B01  ANTITHROMBOTIC AGENTS 
A Antithrombotic agents 
 
B02  ANTIHEMORRHAGICS 
A Antifibrinolytics 
B Vitamin K and other hemostatics 
 
B03  ANTIANEMIC PREPARATIONS 
A Iron preparations 
B Vitamin B12 and folic acid 
X Other antianemic preparations 
 
B05  BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS 
A Blood and related products 
B I.v. solutions 
C Irrigating solutions 
D Peritoneal dialytics 
X I.v. solution additives 
Z Hemodialytics and hemofiltrates 
 
B06  OTHER HEMATOLOGICAL AGENTS 
A Other hematological agents 
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B  BLOOD AND BLOOD FORMING ORGANS 
 
B01  ANTITHROMBOTIC AGENTS 
 
B01A  ANTITHROMBOTIC AGENTS 
 
B01AA  Vitamin K antagonists 
 
This group comprises vitamin K antagonists such as dicoumarol, 
warfarin etc.  
 
The DDDs are based on prophylaxis of thrombosis. 
 
B01AB  Heparin group 
 
This group comprises heparin preparations, including products for non-
therapeutic use, e.g. for rinsing of indwelling vein cannulas. Heparin 
sodium and heparin calcium are classified at the same 5th level, i.e. 
B01AB01.  The low molecular weight heparins are classified at 
separate 5th levels. 
 
The DDDs of nonfractionated heparin and antithrombin are based on 
prophylaxis of thrombosis and pulmonary emboli, and given in 
international units (U).  The DDDs for the different low molecular 
weight heparins are assigned according to their recommended dose in 
prophylaxis of deep vein thrombosis in moderate risk patients.  Since 
the anti Xa activity is a major determinant of the anticoagulant activity 
of low molecular weight heparins the DDDs are given in international 
units based on anti Xa activity. 
 
The DDD for sulodexide is expressed in lipoprotein lipase releasing 
units (LSU). 
 
B01AC  Platelet aggregation inhibitors excl. heparin 
 
Acetylsalicylic acid preparations specifically intended for use as 
antithrombotic agents are classified in this group.  This exception from 
the basic principle of only one code for each route of administration is 
made because of the extensive use of acetylsalicylic acid both as an 
antithrombotic agent and as an analgesic.  Whether an acetylsalicylic 
acid product should be classified in this group or in N02BA, should be 
decided at the national level based on the main indication of the 
product. 
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Lysine acetylsalicylate is classified at the same 5th level as 
acetylsalicylic acid. 
 
Sulfinpyrazone is classified in M04AB.  Alprostadil is classified in 
C01EA and G04BE. 
 
Combinations of acetylsalicylic acid and statins are classified in 
C10BX. 
 
Combinations of acetylsalicylic acid, ACE inhibitors and statins are 
classified in C10BX. 
 
Combinations of acetylsalicylic acid and beta blocking agents are 
classified in C07FX. 
 
 
Prostaglandines are classified in this group while other agents used for 
pulmonary arterial hypertension are classified in C02KX or in G04BE. 
 
The DDDs are based on prophylaxis of thrombosis.  The DDDs of 
acetylsalicylic acid and carbasalate calcium are given as 1 tablet 
independent of tablet strength.  This is due to the great variations 
between different countries in the dosages/strengths recommended for 
prophylaxis of thrombosis.   
 
The DDD of iloprost is based on treatment of peripheral vascular 
disease.   
 
The DDD of vorapaxar is based on the content of one tablet (2.08 mg). 
 
The DDD of selexipag is based on treatment of pulmonary arterial 
hypertension. 
 
For combinations products, see list of DDDs for combinations, 
www.whocc.no.  
 
B01AD Enzymes 
 
The DDDs of streptokinase, alteplase, anistreplase and reteplase are 
based on thrombolytic treatment in connection with acute myocardial 
infarction.  The DDD of urokinase is based on treatment of acute lung 
emboli.  The DDDs are either expressed in international units or gram. 
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B01AE Direct thrombin inhibitors 
 
The DDD for dabigatran etexilate is based on  treatment of patients 
with NVAF (nonvalvular atrial fibrillation). 
 
B01AF Direct factor Xa inhibitors 
 
The DDDs are based on the  treatment of patients with NVAF 
(nonvalvular atrial fibrillation). 
 
B01AX Other antithrombotic agents 
 
 
B02  ANTIHEMORRHAGICS 
 
B02A  ANTIFIBRINOLYTICS 
 
This group comprises agents, which inhibit fibrinolytic activity.  
 
Combinations with vitamin K, see B02B - Vitamin K and other 
hemostatics.  
 
The DDDs are based on treatment of hemorrhage associated with 
fibrinolysis. 
 
B02AA  Amino acids 
 
B02AB  Proteinase inhibitors 
 
Combinations with aprotinin used as local hemostatics are classified in 
B02BC30. 
 
 
B02B  VITAMIN K AND OTHER HEMOSTATICS 
 
The DDDs are based on treatment of hemorrhage associated with 
different deficiency states (e.g. vitamin K deficiency, deficiency of 
different blood coagulation factors etc.). 
 
B02BA  Vitamin K 
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B02BB  Fibrinogen 
 
 Preparations containing human fibrinogen for systemic use are 
classified here.  B02BB01 is reserved for systemic formulations only. 
 
B02BC  Local hemostatics 
 
This group comprises gauze, tampons etc. impregnated with hemostatic 
agents.  Local hemostatics used in dentistry, see A01AD - Other agents 
for local oral treatment.  Epinephrine injection, see C01C - Cardiac 
stimulants excl. cardiac glycosides.  Tissue adhesives, e.g. 
cyanoacrylate based adhesives, are classified in V03AK.  Combinations 
of e.g. human fibrinogen, aprotinin, thrombin and collagen are 
classified in B02BC30. 
 
No DDDs are established for local hemostatics classified in this group. 
 
B02BD Blood coagulation factors 
 
This group comprises all blood coagulation factors, thrombin etc., incl. 
preparations for local use, and their combinations.  Fibrinogen (factor 
I), see - B02BB - Fibrinogen. 
 
Both human derived and recombinant factor VIII and factor IX products 
will be classified in B02BD02 - coagulation factor VIII and 
B02BD04 - coagulation factor IX, respectively. 
 
No DDDs are established for blood coagulation factors. The use of 
blood coagulation factors could be measured in blood factor units (IU). 
 
B02BX  Other systemic hemostatics 
 
This group comprises systemic hemostatics, which cannot be classified 
elsewhere.  
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B03  ANTIANEMIC PREPARATIONS 
 
B03A  IRON PREPARATIONS 
 
This group comprises all plain iron preparations and all combination 
products containing more than 30 mg Fe2+ (or corresponding amounts 
of Fe3+ salts) per defined daily dose (DDD) of the product, regardless of 
therapeutic use.  
 
Combined preparations with 30 mg or less Fe2+ per DDD should be 
classified as vitamin preparations in group A11 or as tonics in group 
A13.  All iron preparations with "iron deficiency" as the main 
indication are classified in B03A, regardless of the amount of iron salts.  
 
Only plain preparations should be classified in the groups B03AA, 
B03AB and B03AC.  Combinations with stabilizing agents (e.g. 
ascorbic acid) are allowed at each 5th level.  Combinations with e.g. 
laxatives are classified at separate 5th levels by using the 50-series. 
 
Other combinations, see B03AD and B03AE.  
 
B03AA  Iron bivalent, oral preparations 
 
The DDDs are based on treatment of iron deficiency anemia.  The 
DDDs are established according to amount of Fe2+ and are equal for all 
compounds regardless of iron salt (i.e. the DDD corresponds to 0.2 g 
Fe2+). 
 
B03AB  Iron trivalent, oral preparations 
 
Ferric citrate mainly used  for the treatment of hyperphosphatemia, is 
classified in V03AE08. 
 
The DDDs are based on treatment of iron deficiency anemia.  Separate 
DDDs are established for the different trivalent iron salts. The DDDs 
are expressed in grams of Fe3+. 
 
B03AC  Iron, parenteral preparations 
 
The DDDs are based on treatment of iron deficiency anemia.  The 
DDDs are established according to amount of Fe and are equal for all 
compounds (i.e. the DDD corresponds to 0.1 g Fe). 
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B03AD  Iron in combination with folic acid 
 
This group comprises iron in combination with folic acid.  Preparations 
containing additional substances, see B03AE.   
 
Historically: 
The DDDs have been based on prophylaxis of iron deficiency anemia 
and folic acid deficiency during pregnancy (i.e. about half the iron 
dose for treatment of anemia). 
 
B03AE  Iron in other combinations 
 
This group comprises preparations, which in addition to iron or iron and 
folic acid contain other substances. 
 
The group is subdivided: 
 
B03AE01 - iron, vitamin B12 and folic acid 
Intrinsic factor and/or liver extract are also allowed in this 
group 
B03AE02 - iron, multivitamins and folic acid 
B03AE03 - iron and multivitamins 
B03AE04 - iron, multivitamins and minerals 
B03AE10 - various combinations 
This group comprises some "borderline" combined iron 
preparations i.e. preparations with an iron content of 
approximately 30 mg Fe2+ per defined daily dose (DDD).  
 
Historically: 
For combinations of iron, vitamin B12 and folic acid (B03AE01), the 
DDDs have been based on prophylaxis of iron deficiency anemia and 
folic acid deficiency during pregnancy. 
 
Various combinations, classified in B03AE10, contain very small 
amounts of iron.  The DDDs for these combinations have been based 
on dose recommendations, and can be as low as corresponding to 30 
mg Fe2+. 
 
The DDDs for iron in other combinations have been based on 
treatment of iron deficiency anemia, and correspond to a DDD of 0.2 g 
Fe2+. 
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B03B  VITAMIN B12 AND FOLIC ACID 
 
B03BA  Vitamin B12 (cyanocobalamin and analogues) 
 
Hydroxocobalamin for treatment of neuralgia is classified here. 
Combinations with liver extract are classified at separate 5th levels 
using the corresponding 50-series.  Combinations with folic acid are 
classified in this group by using the 50-series.  
 
Vitamin B12, see also: 
 
A11D - Vitamin B1, plain and in combination with vitamin B6 and 
B12  
A11EA - Vitamin B-complex, plain 
B03A - Iron preparations 
 
The DDDs are based on maintenance treatment of pernicious anemia.  
Different DDDs are assigned for oral and parenteral formulations of 
cyanocobalamin due to great differences in bioavailability.   
 
The DDD for mecobalamin is based on the treatment of peripheral 
neuropathies. 
 
B03BB  Folic acid and derivatives 
 
Folic acid and derivatives in combination with other substances are 
classified in this group at separate 5th levels using the corresponding 
50-series, if folic acid deficiency is the main indication.  Folinates, used 
as antidotes, are classified in V03A.  Combinations with iron, see 
B03AD and B03AE.   
 
Combinations with vitamin B12 are classified in B03BA. 
 
The DDD for oral folic acid is based on prophylactic use and the 
parenteral DDD is based on treatment. 
 
 
B03X  OTHER ANTIANEMIC PREPARATIONS 
 
This group comprises antianemic preparations other than iron, vitamin 
B12 and folic acid.  
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B03XA  Other antianemic preparations 
 
The DDDs are based on treatment of renal anemia in patients 
maintained by hemodialysis. 
 
 
B05  BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS 
 
See also: 
 
V07AB - Solvents and diluting agents, incl. irrigating solutions 
 V07AC - Blood transfusion, auxiliary products 
 
No DDDs are established in this group.  It is considered difficult to 
establish DDDs, because of the great variations in dosages given. 
 
 
B05A  BLOOD AND RELATED PRODUCTS 
 
B05AA  Blood substitutes and plasma protein fractions 
 
Polygeline is classified in B05AA06 gelatin agents. 
 
ATC level B05AA07 hydroxyethylstarch includes starches that have 
been etherified to varying extent e.g. hepta-, hexa-, penta,- and 
tetrastarches. 
 
B05AX Other blood products 
 
 
B05B  I.V. SOLUTIONS 
 
This group comprises i.v. solutions used in parenteral administration of 
fluids, electrolytes and nutrients.  Agents administered as i.v. solutions 
or additives, see the respective therapeutic groups.  I.v. solution 
additives, see B05X.  
 
B05BA  Solutions for parenteral nutrition 
 
This group comprises amino acids, carbohydrates, fat emulsions etc. for 
parenteral nutrition.  Combinations with electrolytes are allowed. 
Combinations of electrolytes and glucose are classified in B05BB - 
Solutions affecting the electrolyte balance.  These and similar 
combinations are not primarily used as nutrients.  
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B05BB  Solutions affecting the electrolyte balance 
 
This group comprises electrolyte solutions, incl. combinations with e.g. 
carbohydrates.  Combinations with amino acids, fat etc. should be 
classified in B05BA.  
B05BC  Solutions producing osmotic diuresis 
 
 
B05C  IRRIGATING SOLUTIONS 
 
In this group products used for bladder irrigation, surgical irrigation, 
incl. instruments etc. are classified.  See also V07AB - Solvents and 
diluting agents, incl. irrigating solutions.  
 
Combined preparations are classified by using 5th level - 10.  Only 
plain preparations are classified at the other 5th levels.  
 
B05CA  Antiinfectives 
 
B05CB Salt solutions 
 
B05CX  Other irrigating solutions 
 
 
B05D  PERITONEAL DIALYTICS 
 
B05DA  Isotonic solutions 
 
B05DB  Hypertonic solutions 
 
 
B05X  I.V. SOLUTION ADDITIVES 
 
I.v. solution additives are concentrated preparations containing 
substances used for correcting fluid and electrolyte balance and 
nutritional status.  Drugs administered as i.v. solutions or additives, see 
the respective groups.  
 
B05XA  Electrolyte solutions 
 
This group comprises plain electrolyte solutions, combinations of 
electrolytes, and combinations of electrolytes and other substances (e.g. 
trace elements).  Products containing trace elements only are classified 
in B05XA31. 
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See also A12 - Mineral supplements.  
 
B05XB  Amino acids 
 
B05XC  Vitamins 
 
See also A11 - Vitamins 
 
B05XX  Other i.v. solution additives 
 
This group comprises all i.v. additives, which cannot be classified in the 
preceding groups.  
 
 
B05Z  HEMODIALYTICS AND HEMOFILTRATES 
 
B05ZA  Hemodialytics, concentrates 
 
B05ZB  Hemofiltrates 
 
 
B06 OTHER HEMATOLOGICAL AGENTS 
 
No DDDs are established in this group. 
 
 
B06A  OTHER HEMATOLOGICAL AGENTS 
 
This group includes preparations for local and systemic use, and also 
some preparations used for dissolving clots in catheters, hemodialysis 
clots etc.  
 
See also: 
 
V07A -  All other non-therapeutic products 
B01AB -  Heparin group 
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B06AA  Enzymes 
 
This group comprises enzymes with fibrinolytic properties.  Enzymes 
with other well defined therapeutic use should be classified in the 
respective groups, see e.g.:  
 
A09A -  Digestives, incl. enzymes 
B01AD - Enzymes 
D03BA -  Proteolytic enzymes 
S01KX -  Other surgical aids  
 
B06AB  Other hem products 
 
B06AC Drugs used in hereditary angioedema
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C  CARDIOVASCULAR SYSTEM 
 
C01  CARDIAC THERAPY 
A Cardiac glycosides 
B Antiarrhythmics, class I and III 
C Cardiac stimulants excl. cardiac glycosides  
D Vasodilators used in cardiac diseases 
E Other cardiac preparations 
 
C02  ANTIHYPERTENSIVES 
A Antiadrenergic agents, centrally acting 
B Antiadrenergic agents, ganglion-blocking 
C Antiadrenergic agents, peripherally acting 
D Arteriolar smooth muscle, agents acting on 
K Other antihypertensives 
L Antihypertensives and diuretics in combination 
N Combinations of antihypertensives in ATC-gr. C02 
 
C03  DIURETICS 
A Low-ceiling diuretics, thiazides 
B Low-ceiling diuretics, excl. thiazides 
C High-ceiling diuretics 
D Potassium-sparing agents 
E Diuretics and potassium-sparing agents in combination 
X Other diuretics  
 
C04  PERIPHERAL VASODILATORS 
A Peripheral vasodilators 
 
C05  VASOPROTECTIVES 
A Agents for treatment of hemorrhoids and anal fissures for topical use 
B Antivaricose therapy 
C Capillary stabilizing agents 
 
C07  BETA BLOCKING AGENTS 
A Beta blocking agents 
B Beta blocking agents and thiazides 
C Beta blocking agents and other diuretics 
D Beta blocking agents, thiazides and other diuretics  
E Beta blocking agents and vasodilators 
F Beta blocking agents and other antihypertensives 
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C08 CALCIUM CHANNEL BLOCKERS 
C Selective calcium channel blockers with mainly vascular effects 
D Selective calcium channel blockers with direct cardiac effects 
E Non-selective calcium channel blockers 
G Calcium channel blockers and diuretics 
 
C09 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM 
A ACE inhibitors, plain 
B ACE inhibitors, combinations 
C Angiotensin II antagonists, plain 
D Angiotensin II antagonists, combinations 
X Other agents acting on the renin-angiotensin system 
 
C10 LIPID MODIFYING AGENTS 
 A Lipid modifying agents, plain 
 B Lipid modifying agents, combinations  
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C  CARDIOVASCULAR SYSTEM 
 
C01  CARDIAC THERAPY 
 
C01A  CARDIAC GLYCOSIDES 
 
This group comprises plain and combined preparations containing 
cardiac glycosides, incl. standardized herbal extracts.  Cardiac 
glycosides in combination with substances in group C01D and C01E 
are classified in this group.  Combinations with antihypertensives, beta 
blocking agents, calcium channel blockers and ACE inhibitors, see 
group C02, C07, C08 and C09 respectively. 
 
The DDDs are based on the average maintenance dose for the 
treatment of cardiac failure.  Exception: the DDD for deslanoside is for 
acute treatment. 
 
C01AA  Digitalis glycosides  
 
Combinations with diuretics are classified here. 
 
C01AB  Scilla glycosides 
 
C01AC  Strophanthus glycosides 
 
C01AX  Other cardiac glycosides 
 
 
C01B  ANTIARRHYTHMICS, CLASS I AND III 
 
This group comprises preparations used in the treatment of arrhythmias. 
 
The agents are listed according to the Vaughan Williams classification 
of antiarrhythmics.  The division of class I antiarrhythmics may vary, 
depending on the literature used.  The 3rd ed. of Avery's "Drug 
Treatment" (1987) and "Drugs" 31, 93 - 95, 1986 are used as a basis for 
the ATC classification.  Class II antiarrhythmics see C07 and class IV, 
see C08 (e.g. verapamil). 
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Adenosine, which is also used as an antiarrhythmic, is classified in 
C01EB.  
 
Combined preparations are classified at separate 5th levels using the 
corresponding 50-series.  Combinations with psycholeptics are 
classified at separate 5th levels using the corresponding 70-series.  
Combinations with an antihypertensive e.g. reserpine are classified in 
C02AA. 
 
The DDDs are based on the prophylaxis and treatment of 
supraventricular and ventricular arrhythmias.  The DDDs are based on 
the maintenance dose.  Preparations for parenteral administration are 
only used initially and are therefore given the same DDD as oral 
preparations. 
 
C01BA  Antiarrhythmics, class Ia 
 
Combinations containing quinidine and verapamil are classified in 
C08DA. 
 
C01BB  Antiarrhythmics, class Ib  
 
Lidocaine used as a local anaesthetic is classified in N01BB.  
Phenytoin, a class Ib antiarrhythmic, is classified as an antiepileptic in 
N03. 
 
C01BC  Antiarrhythmics, class Ic 
 
C01BD  Antiarrhythmics, class III 
 
Sotalol, which has class III antiarrhythmic properties, is classified in 
C07AA. 
 
The DDD for ibutilide refer to ibutilide fumarate. 
 
C01BG Other antiarrhythmics, class I and III 
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C01C CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES  
 
This group comprises agents for the treatment of hypotension.  
Respiratory stimulants are classified in R07AB. 
 
Dihydroergotamine, which is used in the treatment of migraine as well 
as hypotension, is classified in N02CA - Ergot alkaloids. 
 
Combinations with peripheral vasodilators, see C04 - Peripheral 
vasodilators. 
 
This group includes various drugs used on different indications.  The 
DDDs are therefore established individually for each substance (i.e. 
each ATC 5th level). 
 
C01CA   Adrenergic and dopaminergic agents 
 
This group comprises sympathomimetics used in the treatment of 
hypotension.  Etilefrin in combination with dihydroergotamine is 
classified in this group.  Oral products of ephedrine are classified in 
R03CA. 
 
C01CE  Phosphodiesterase inhibitors 
 
Phosphodiesterase inhibitors such as theophylline, which are used in 
asthma therapy, are classified in R03D. 
 
C01CX  Other cardiac stimulants 
 
This group includes agents, which cannot be classified in the preceding 
groups. 
 
 
C01D  VASODILATORS USED IN CARDIAC DISEASES 
 
This group comprises preparations used in ischemic heart diseases. See 
also C02 - Antihypertensives, C03 - Diuretics, C04 - Peripheral 
vasodilators, C07 - Beta blocking agents, C08 - Calcium channel 
blockers and C09 - Agents acting on the renin-angiotensin system. 
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Combinations with cardiac glycosides, see C01A. 
 
Combinations with rauwolfia alkaloids, see C02AA. 
 
Combinations with beta blocking agents, see C07. 
 
Combinations with calcium channel blockers, see C08. 
 
C01DA  Organic nitrates 
 
This group comprises nitrates used on the indication angina pectoris, 
including transdermal preparations.  Amyl nitrite is classified in 
V03AB - Antidotes. 
 
Combinations of isosorbide dinitrate and hydralazine are classified in 
C01DA58. 
 
All nitrate preparations in combination with psycholeptics are classified 
in C01DA70.  Nitrates in combination with psycholeptics and other 
agents are also given the code C01DA70. 
 
The DDDs for the nitrates are mainly based on the treatment of angina 
pectoris attacks (3-4 times daily).  The DDDs of preparations for oral 
and transdermal administration are higher than the DDDs for other 
routes of administration (e.g. sublingual) due to a lower 
bioavailability. 
 
The DDDs for some preparations are mainly based on prophylaxis, for 
instance the DDDs of isosorbide dinitrate and glyceryl trinitrate 
plaster. 
 
No DDDs are established for parenteral preparations due to great 
differences in the dosages used. 
 
C01DB Quinolone vasodilators 
 
C01DX Other vasodilators used in cardiac diseases 
 
This group comprises vasodilators used in cardiac diseases, which 
cannot be classified in the preceding groups. 
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C01E  OTHER CARDIAC PREPARATIONS 
 
This group comprises various preparations used in the treatment of 
ischemic heart diseases, which cannot be classified in any of the 
preceding groups. 
 
C01EA  Prostaglandins 
 
This group comprises e.g. alprostadil.  Specific formulations of 
alprostadil for treatment of erectile dysfunction are classified in  
G04BE01. 
 
The DDD for alprostadil equals the content of active substance in one 
ampoule. 
 
C01EB  Other cardiac preparations 
 
This group comprises plain products used in the treatment of ischemic 
heart diseases, which cannot be classified in the preceding groups.   
 
Adenosine, which is also used as an antiarrhythmic, is classified here. 
Antiarrhythmics, see C01B. 
 
Combinations of ivabradine and beta blocking agents are classified in 
C07FX. 
 
Other cardiovascular agents which cannot be classified in ATC group 
C02-C09 are also classified here. 
 
Products containing indometacin or ibuprofen, which are only used for 
closing the ductus arteriosus in premature infants, are classified here. 
Indometacin used as an antiinflammatory agent is classified in 
M01AB01 or S01BC01. 
 
The DDD for ibuprofen is based on the course dose. 
 
C01EX  Other cardiac combination products 
 
This group comprises combined preparations, which cannot be 
classified in the preceding groups. 
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C02  ANTIHYPERTENSIVES 
 
See also C03 - Diuretics, C07 - Beta blocking agents, C08 - Calcium 
channel blockers and C09 - Agents acting on the renin-angiotensin 
system. 
 
Antihypertensives are mainly classified at 3rd levels according to the 
mechanism of action.  Most headings are self-explanatory:  
 
C02A Antiadrenergic agents, centrally acting 
C02B Antiadrenergic agents, ganglion-blocking 
C02C Antiadrenergic agents, peripherally acting 
C02D Arteriolar smooth muscle, agents acting on 
C02K Other antihypertensives 
C02L Antihypertensives and diuretics in combination 
C02N Combinations of antihypertensives in ATC gr. C02 
 
The oral DDDs are based on the average doses needed to reduce the 
blood pressure to a normal level in patients with mild-moderate 
hypertension. 
 
Parenteral DDDs are based on dosages used for the treatment of 
hypertensive crises and are based on the content of the active 
ingredient pr. vial (ampoule). 
 
 
C02A  ANTIADRENERGIC AGENTS, CENTRALLY ACTING 
 
C02AA  Rauwolfia alkaloids 
 
This group comprises plain and combined rauwolfia preparations used 
in hypertension. 
 
There are separate 5th levels for combinations of rauwolfia alkaloids 
(C02AA03) and for rauwolfia, whole root (C02AA04). 
 
Combinations with beta blocking agents, see C07F - Beta blocking 
agents, other combinations. 
 
Combinations with diuretics, see C02LA - Rauwolfia alkaloids and 
diuretics in combination. 
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Combinations with other antihypertensives, see C02N - Combinations 
of antihypertensives. 
 
Combined products are otherwise classified at separate 5th levels using 
the corresponding 50-series. 
 
C02AB  Methyldopa 
 
Combinations with diuretics, see C02LB - Methyldopa and diuretics in 
combination. 
 
Combinations with Rauwolfia alkaloids and diuretics, see C02LA - 
Rauwolfia alkaloids and diuretics in combination. 
 
Different DDDs have been established for the various stereoiso-meric 
forms of methyldopa, because of different potency. 
 
C02AC  Imidazoline receptor agonists 
 
Clonidine and guanfacine also used in ADHD are classified in this 
group.  
 
Low strength clonidine preparations used in the treatment of migraine 
are classified in N02C - Antimigraine preparations. 
 
Combinations with diuretics, see C02LC - Imidazoline receptor 
agonists in combination with diuretics. 
 
 
C02B  ANTIADRENERGIC AGENTS, GANGLION-BLOCKING 
 
C02BA  Sulfonium derivatives 
 
C02BB  Secondary and tertiary amines 
 
C02BC  Bisquaternary ammonium compounds 
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C02C  ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING 
 
Alpha- and beta-blocking agents, see C07AG. 
 
C02CA  Alpha-adrenoreceptor antagonists 
 
Combinations with diuretics, see C02LE - Alpha-adrenoreceptor 
antagonists and diuretics. 
 
Alfuzosin and terazosin are classified in G04CA. 
 
C02CC  Guanidine derivatives 
 
Combinations with diuretics, see C02LF - Guanidine derivatives and 
diuretics. 
 
 
C02D  ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON 
 
See also C08 - Calcium channel blockers. 
 
C02DA  Thiazide derivatives 
 
Parenteral preparations of diazoxide are classified here. 
Oral preparations containing diazoxide for treatment of hypoglycemia 
are classified in V03AH. 
 
C02DB  Hydrazinophthalazine derivatives 
 
Combinations with diuretics, see C02LG - Hydrazinophthalazine 
derivatives and diuretics. 
 
Combinations of isosorbide dinitrate and hydralazine are classified in 
C01DA - Organic nitrates. 
 
The oral DDD of dihydralazine is higher than the parenteral DDD. The 
parenteral DDD is given as the chloride salt while the oral DDD is 
given as the mesylate salt. 
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C02DC  Pyrimidine derivatives 
 
Minoxidil for systemic use is classified here. 
Dermatological preparations containing minoxidil are classified in 
D11AX. 
 
C02DD  Nitroferricyanide derivatives 
 
C02DG  Guanidine derivatives 
 
 
C02K  OTHER ANTIHYPERTENSIVES 
 
This group comprises all antihypertensives which cannot be classified 
in groups C02A-D, C02L, C02N, C03 - Diuretics, C07 - Beta blocking 
agents, C08 - Calcium channel blockers or C09 - Agents acting on the 
renin-angiotensin system. 
 
C02KA  Alkaloids, excl. rauwolfia 
 
C02KB  Tyrosine hydroxylase inhibitors 
 
C02KC  MAO inhibitors 
 
C02KD  Serotonin antagonists 
 
C02KX Antihypertensives for pulmonary arterial hypertension 
 
All agents classified in this group are for treatment of pulmonary 
arterial hypertension (PAH).  
Other agents used for treatment of PAH such as phosphodiesterase 
inhibitors (e.g. sildenafil) or prostaglandins (e.g. epoprostenol) are 
classified in G04BE and in B01AC respectively.  
 
The DDDs are based on treatment of pulmonary arterial hypertension. 
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C02L  ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION 
 
All substances classified in groups C02A-K, in combination with 
diuretics are classified in this group.  At each 5th level, various 
combinations containing e.g. different diuretics, other antihypertensives 
or potassium may occur. 
 
Combinations with beta blocking agents, see comments under C07. 
 
Diuretics in combination with calcium channel blockers are classified in 
C08. 
 
Diuretics in combination with ACE inhibitors, are classified in  
C09BA. 
 
Diuretics in combination with angiotensin II antagonists are classified 
in C09DA. 
 
The need for a systematic approach to classify combinations of different 
antihypertensives has resulted in a ranking according to the ATC codes. 
Substances classified in ATC group C02AA take precedence over 
C02AB and substances in C02A take precedence over C02B etc. 
 
Example: A combined preparation containing bietaserpine, hydralazine 
and hydrochlorothiazide will be given the code C02LA07 according to 
the above mentioned ranking.  
 
Combinations with psycholeptics are classified at separate 5th levels 
using the corresponding 70-series. 
 
It has been considered most appropriate to assign fixed DDDs based 
on the average use of the different combinations without considering 
and comparing the strengths of the various components.  1 tablet is the 
fixed DDD for products given once daily whereas the fixed DDD for 
products given twice daily and three times daily is respectively 2 
tablets and 3 tablets.  The assigned DDDs cannot always be compared 
with the DDDs assigned for plain preparations.  
 
C02LA  Rauwolfia alkaloids and diuretics in combination 
 
C02LB  Methyldopa and diuretics in combination 
 
C02LC  Imidazoline receptor agonists in combination with diuretics 
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C02LE  Alpha-adrenoreceptor antagonists and diuretics 
 
C02LF  Guanidine derivatives and diuretics 
 
C02LG  Hydrazinophthalazine derivatives and diuretics 
 
C02LK  Alkaloids, excl. rauwolfia, in combination with diuretics  
 
C02LL  MAO inhibitors and diuretics 
 
C02LN  Serotonin antagonists and diuretics 
 
C02LX Other antihypertensives and diuretics 
 
 
C02N  COMBINATIONS OF ANTIHYPERTENSIVES IN ATC-GR. C02 
 
Comprises combinations of different antihypertensives classified in 
ATC-gr. C02. 
 
Antihypertensives in combination with diuretics are classified in C02L - 
Antihypertensives and diuretics in combination. 
 
Combinations with beta blocking agents, see C07F - Beta blocking 
agents, other combinations. 
 
The DDDs for fixed combinations are commented in C02L. 
 
 
C03  DIURETICS 
 
This group comprises diuretics, plain and in combination with 
potassium or other agents.  Vasopressin antagonists are also included in 
this group. Potassium-sparing agents are classified in C03D and C03E. 
 
Combinations with digitalis glycosides, see C01AA. 
 
Combinations with antihypertensives, see C02L - Antihypertensives and 
diuretics in combination. 
 
Combinations with beta blocking agents, see C07B - C07D. 
 
Combinations with calcium channel blockers, see C08. 
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Combinations with agents acting on the renin angiotensin system, see 
C09B and C09D. 
 
The DDDs for diuretics are based on monotherapy.  Most diuretics are 
used both for the treatment of edema and hypertension in similar doses 
and the DDDs are therefore based on both indications. 
 
The DDDs for combinations correspond to the DDD for the diuretic 
component, except for ATC group C03E, see comments under this 
level. 
 
 
C03A  LOW-CEILING DIURETICS, THIAZIDES 
 
Combinations with potassium-sparing agents, see C03EA. 
 
The different lipid solubility of the thiazides should be considered 
when assigning DDDs. 
 
C03AA  Thiazides, plain 
 
C03AB  Thiazides and potassium in combination 
 
The 5th levels correspond to those in C03AA: 
 
C03AA01 - bendroflumethiazide 
C03AB01 - bendroflumethiazide and potassium 
 
C03AH  Thiazides, combinations with psycholeptics and/or analgesics  
 
C03AX  Thiazides, combinations with other drugs 
 
 
C03B  LOW-CEILING DIURETICS, EXCL. THIAZIDES 
 
This group comprises all low-ceiling diuretics not classified in C03A. 
 
Combinations with potassium-sparing agents, see C03EA. 
 
C03BA  Sulfonamides, plain 
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C03BB  Sulfonamides and potassium in combination 
  
The 5th levels correspond to those in C03BA, see example in C03AB. 
 
C03BC  Mercurial diuretics 
 
C03BD  Xanthine derivatives 
 
Includes e.g. theobromine.  See also R03DA - Xanthines. 
 
C03BK  Sulfonamides, combinations with other drugs 
 
Includes e.g. combination with psycholeptics. 
 
C03BX  Other low-ceiling diuretics 
 
All low-ceiling diuretics which cannot be classified in the preceding 
groups are classified here. 
 
 
C03C  HIGH-CEILING DIURETICS 
 
This group comprises high-ceiling diuretics (loop-diuretics) e.g. 
furosemide. 
 
Combinations with potassium-sparing agents, see C03EB. 
 
C03CA  Sulfonamides, plain 
 
C03CB  Sulfonamides and potassium in combination 
 
The 5th levels correspond to those in C03CA.  See example in C03AB. 
 
C03CC  Aryloxyacetic acid derivatives 
 
C03CD  Pyrazolone derivatives 
 
C03CX Other high-ceiling diuretics 
 
All high-ceiling diuretics which cannot be classified in the preceding 
groups are classified here. 
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C03D  POTASSIUM-SPARING AGENTS 
 
C03DA  Aldosterone antagonists 
 
C03DB  Other potassium-sparing agents 
 
 
C03E  DIURETICS AND POTASSIUM-SPARING AGENTS IN COM-
BINATION 
 
Fixed DDDs are assigned for combinations in this group.   
E.g. 1 tablet regardless of strengths is the DDD assigned for 
hydrochlorothiazide and amiloride in combinations.  See comments to 
C02L also. 
 
C03EA  Low-ceiling diuretics and potassium-sparing agents 
 
C03EB  High-ceiling diuretics and potassium-sparing agents 
 
 
C03X OTHER DIURETICS 
 
C03XA Vasopressin antagonists 
 
 
C04  PERIPHERAL VASODILATORS 
 
C04A PERIPHERAL VASODILATORS 
 
This group comprises plain and combined preparations used in the 
treatment of cerebrovascular or peripheral circulatory disorders. 
 
Combinations with Antihypertensives, see C02 - Antihypertensives. 
 
Combinations with vasodilators used in cardiac diseases, see C01DA. 
 
The DDDs are based on the doses used for the treatment of cerebral 
and peripheral vascular disorders.  
 
C04AA  2-amino-1-phenylethanol derivatives 
 
C04AB  Imidazoline derivatives 
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C04AC  Nicotinic acid and derivatives 
 
Includes low strength preparations (e.g. nicotinic acid tablets 50 mg).  
Nicotinic acid preparations in high strength (e.g. nicotinic acid tablets 
500 mg) is used as a cholesterol reducer and is classified in C10AD. 
 
C04AD  Purine derivatives 
 
Combinations with nicotinic acid and derivatives are allowed at each 
5th level. 
 
C04AE  Ergot alkaloids 
 
Includes combinations with other peripheral vasodilators. 
 
Combinations with calcium channel blockers are classified in  
C08CA. 
 
Combinations of cinnarizine and dihydroergcristine are classified in 
N07CA52. 
 
See also G02AB and N02CA. 
 
C04AF  Enzymes 
 
C04AX  Other peripheral vasodilators 
 
Betahistine, cinnarizine and flunarizine are classified as antivertigo 
preparations in N07CA. 
 
Papaverine preparations, see A03AD and G04BE. 
 
 
C05  VASOPROTECTIVES 
 
No DDDs are established in this group, since most of the drugs in this 
group are for topical use. 
 
 
C05A  AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL 
FISSURES FOR TOPICAL USE 
 
This group comprises agents for local use, such as suppositories, 
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ointments etc.  Preparations used for treatment of perineal trauma are 
classified here. 
 
C05AA  Corticosteroids 
 
All antihemorrhoidal products, which contain corticosteroids, are 
classified in this group, including both plain products and combinations 
with antiinfectives, local anesthetics etc.  At each 5th plain level, 
combinations may occur. 
 
C05AB  Antibiotics 
 
All antihemorrhoidal products which contain antibiotics, excl. 
combinations with corticosteroids, are classified in this group.  At each 
5th level combinations may occur. 
 
C05AD  Local anesthetics 
 
All antihemorrhoidal products which contain anesthetics, excl. 
combinations with corticosteroids and/or antibiotics, are classified in 
this group.  At each 5th plain level, combinations may occur. 
 
See also D04AB - Anesthetics for topical use and N01B - Local 
anesthetics. 
 
C05AE Muscle relaxants 
 
Topical products containing glyceryl trinitrate or isosorbide dinitrate 
are classified in this group. 
 
C05AX  Other agents for treatment of hemorrhoids and anal fissures for topical 
use 
 
Agents which cannot be classified in the preceding groups are classified 
in this group, e.g. bismuth/zinc oxide-preparations.  
 
 
C05B  ANTIVARICOSE THERAPY 
 
This group comprises all products for treatment of varices, i.v. infusion 
induced thrombophlebitis etc. 
 
Zinc bandages, see D09A - Medicated dressings. 
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C05BA  Heparins or heparinoids for topical use 
 
Heparin in combination with e.g. dexpanthenol and allantoin is 
classified in C05BA53. 
 
Heparin in combination with diclofenac for topical use is classified in 
M02AA15. 
 
Heparinoids in combination with calcium dobesilate are classified in 
C05BX - Other sclerosing agents. 
 
C05BB  Sclerosing agents for local injection 
 
C05BX  Other sclerosing agents 
 
Combinations of calcium dobesilate and heparinoids are classified here. 
 
 
C05C  CAPILLARY STABILIZING AGENTS 
 
C05CA  Bioflavonoids 
 
Rutoside is classified in this group. 
Oxerutines are classified in C05CA54. 
 
Combinations with other capillary stabilizing agents are classified at 
separate 5th levels using the corresponding 50-series. 
 
C05CX  Other capillary stabilizing agents 
 
Lysine aescinate is classified in C05CX03. 
 
 
C07  BETA BLOCKING AGENTS 
 
C07A  BETA BLOCKING AGENTS 
 
All plain beta blocking agents are classified in this group. Combination 
packages containing two different products (e.g. sotalol tablets and 
aspirin tablets in a combination package) are also classified in this 
group. 
 
Labetalol, and carvedilol are classified in C07AG - Alpha- and beta 
blocking agents.  
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Beta blocking agents in combination with ACE inhibitors are classified 
in C09BX - ACE inhibitors, other combinations. 
 
Beta blocking agents in combination with angiotensin II antagonists are 
classified in C09DX - Angiotensin II antagonists, other combinations. 
 
The DDDs are based on the treatment of mild-moderate hypertension.  
 
The DDDs for oral and parenteral formulations are equal, even if the 
parenteral preparations are used for the initial treatment of 
arrhythmias.  Exception: practolol. 
 
C07AA  Beta blocking agents, non-selective 
 
All plain non-selective beta blocking agents are classified in this group. 
Combined packages containing sotalol tablets and aspirin tablets are 
classified in C07AA57. 
 
C07AB  Beta blocking agents, selective 
 
All plain selective beta blocking agents are classified in this group. 
 
The s-enantiomer and the racemate of atenolol are classified at separate 
5th levels. 
 
Different DDDs have been assigned for the two stereoisomeric forms 
of atenolol due to different potency.  
 
C07AG Alpha and beta blocking agents 
 
 
C07B  BETA BLOCKING AGENTS AND THIAZIDES 
 
This group comprises combinations of beta blocking agents and 
thiazides.  Different thiazides may occur at each 5th level. 
 
Combinations of beta blocking agents, thiazides and other agents are 
classified at separate 5th levels using the 50-series. 
 
See comments to C02L concerning the principles for assignment of 
DDDs for the combined preparations. 
 
C07BA  Beta blocking agents, non-selective, and thiazides  
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C07BB  Beta blocking agents, selective, and thiazides 
 
C07BG Alpha and beta blocking agents and thiazides 
 
 
C07C  BETA BLOCKING AGENTS AND OTHER DIURETICS 
 
This group comprises combinations of beta blocking agents and 
diuretics excl. thiazides.  Different diuretics except thiazides, may occur 
at each 5th level. 
 
Combinations with other agents in addition, are classified at separate 
5th levels using the 50-series. 
 
See comments to C02L concerning the principles for assignment of 
DDDs for combined preparations. 
 
C07CA  Beta blocking agents, non-selective, and other diuretics  
 
C07CB  Beta blocking agents, selective, and other diuretics  
 
C07CG Alpha and beta blocking agents and other diuretics 
 
 
C07D BETA BLOCKING AGENTS, THIAZIDES AND OTHER 
DIURETICS 
 
This group comprises combinations of beta blocking agents, thiazides 
and other diuretics.  Different thiazides and diuretics may occur at each 
5th level. 
Combinations with other agents in addition, are classified at separate 
5th levels using the 50-series. 
 
See comments to C02L concerning the principles for assignment of 
DDDs for combined preparations. 
 
C07DA  Beta blocking agents, non-selective, thiazides and other diuretics  
 
C07DB  Beta blocking agents, selective, thiazides and other diuretics  
 
 
  
 118 
C07E  BETA BLOCKING AGENTS AND VASODILATORS 
 
This group comprises beta blocking agents and vasodilators (excl. 
calcium channel blockers) in combination. 
 
Combinations with calcium channel blockers are classified in C07F. 
 
See comments to C02L concerning the principles for assignment of 
DDDs for combined preparations. 
 
C07EA  Beta blocking agents, non-selective, and vasodilators 
 
C07EB  Beta blocking agents, selective, and vasodilators 
 
 
C07F BETA BLOCKING AGENTS, OTHER COMBINATIONS 
 
Beta blocking agents in combination with ACE inhibitors are classified 
in C09BX - ACE inhibitors, other combinations. 
 
Beta blocking agents in combination with angiotensin II antagonists are 
classified in C09DX - Angiotensin II antagonists, other combinations. 
 
See comments to C02L concerning the principles for assignment of 
DDDs for combined preparations. 
 
C07FB  Beta blocking agents and calcium channel blockers 
 
C07FX Beta blocking agents, other combinations 
 
Combinations of propranolol and hydralazine or dihydralazine are 
classified in C07FX01. 
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C08 CALCIUM CHANNEL BLOCKERS 
 
The calcium channel blockers are classified according to selectivity of 
calcium channel activity and direct cardiac effects.  The ATC 4th levels 
are subdivided according to chemical structure. 
 
Combinations with ergot alkaloids (C04AE) are classified in this group 
by using the 50-series. 
 
Combinations with diuretics are classified in C08G. 
 
Combinations with ACE inhibitors are classified in C09BB. 
 
Combinations with beta blocking agents are classified in C07FB. 
 
Combinations with statins are classified in C10BX. 
 
The DDDs for calcium channel blockers are based on the treatment of 
mild-moderate hypertension, although some are used for other 
indications (e.g. angina pectoris).  
 
The DDDs for oral and parenteral preparations are equal and are based 
on the oral dose, since oral preparations represent the major fraction of 
the total consumption. 
 
 
C08C SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY 
VASCULAR EFFECTS 
 
C08CA Dihydropyridine derivatives 
 
Preparations containing nifedipine in combination with ergot alkaloids 
are classified in C08CA55. 
Combinations with diuretics are classified in C08G. 
 
Amlodipine in combination with atorvastatin is classified in C10BX03. 
 
C08CX Other selective calcium channel blockers with mainly vascular effects 
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C08D SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT 
CARDIAC EFFECTS 
 
C08DA Phenylalkylamine derivatives 
 
Combinations containing verapamil and quinidine are classified in 
C08DA51. 
 
C08DB Benzothiazepine derivatives 
 
 
C08E NON-SELECTIVE CALCIUM CHANNEL BLOCKERS 
 
C08EA Phenylalkylamine derivatives 
 
C08EX Other non-selective calcium channel blockers 
 
 
C08G CALCIUM CHANNEL BLOCKERS AND DIURETICS 
 
C08GA Calcium channel blockers and diuretics 
 
 
C09 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM 
 
The DDDs are based on the treatment of mild-moderate hypertension. 
 
See comments to C02L concerning the principles for assignment of 
DDDs for combined preparations. 
 
 
C09A ACE INHIBITORS, PLAIN 
 
All plain ACE inhibitors are classified in this group.  No separate ATC 
codes are assigned for the esters of the ACE inhibitors (e.g. enalaprilat, 
quinaprilat). 
 
Combinations with diuretics, see C09BA - ACE inhibitors and 
diuretics. 
 
Combinations with calcium channel blockers, see C09BB - ACE 
inhibitors and calcium channel blockers. 
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Combinations with beta blocking agents, see C09BX - ACE inhibitors, 
other combinations. 
 
C09AA ACE inhibitors, plain 
 
 
C09B ACE INHIBITORS, COMBINATIONS 
 
Combinations of ACE inhibitors, statins and acetylsalicylic acid are 
classified in C10BX. 
 
C09BA ACE inhibitors and diuretics 
 
C09BB  ACE inhibitors and calcium channel blockers 
 
Combinations with statins are classified in C10BX. 
 
C09BX ACE inhibitors, other combinations 
 
Combinations with beta blocking agents are classified in this group.  
 
 
C09C ANGIOTENSIN II ANTAGONISTS, PLAIN 
 
C09CA Angiotensin II antagonists, plain 
 
 
C09D ANGIOTENSIN II ANTAGONISTS, COMBINATIONS 
 
Combinations with statins are classified in C10BX. 
 
C09DA Angiotensin II antagonists and diuretics 
 
C09DB Angiotensin II antagonists and calcium channel blockers 
 
Combinations with hydrochlorothiazide are classified in C09DX. 
 
C09DX Angiotensin II antagonists, other combinations 
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C09X OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN 
SYSTEM 
 
C09XA Renin-inhibitors 
 
Fixed combinations of aliskiren and valsartan are classified in C09DX. 
 
 
C10 LIPID MODIFYING AGENTS 
 
The DDDs are based on the treatment of hypercholesterolemia. 
 
 
C10A  LIPID MODIFYING AGENTS, PLAIN 
 
Pantethine, which is also used in the treatment of hyperlipidemi, is 
classified as a vitamin in A11HA. 
 
C10AA  HMG CoA reductase inhibitors  
 
This group comprises agents which act as competitive inhibitors of 3-
hydroxy-3-methylglutaryl coenzyme A reductase (HMG CoA 
reductase).  
Atorvastatin in combination with amlodipine is classified in C10BX03. 
 
C10AB  Fibrates  
 
Clofibrate and analogues are classified here.  
 
The DDD for fenofibrate is based on the micronised formulation. 
 
C10AC  Bile acid sequestrants 
 
This group comprises substances (such as colestyramine and colestipol) 
which reduces the cholesterol level by increasing the excretion of bile 
acid.  
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C10AD  Nicotinic acid and derivatives 
 
This group comprises high strength preparations (e.g. nicotinic acid tab 
500 mg) used as cholesterol reducers.  Nicotinic acid or derivatives in 
low strength preparations (e.g. nicotinic acid tab 50 mg) are classified 
in C04A - Peripheral vasodilators.  
 
Combinations of nicotinic acid and laropiprant are classified in 
C10AD52. 
 
C10AX  Other lipid modifying agents 
 
This group comprises all cholesterol and triglyceride reducers, which 
cannot be classified in the preceding groups.  
 
Sulodexide is classified in B01AB. 
 
The DDD for evolocumab is based on dosing every second week. 
 
 
C10B LIPID MODIFYING AGENTS, COMBINATIONS 
 
Fixed combinations of blood glucose-lowering drugs and lipid 
modifying agents are classified in A10B. 
 
For fixed combinations in C10B the DDD is based on dosing 
frequency only. This implies that 1 UD (1 tablet) is the DDD for 
all products given once daily and the DDD for products given 
twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 
tablets) respectively. 
 
 
C10BA HMG CoA reductase inhibitors in combination with other lipid 
modifying agents 
 
C10BX HMG CoA reductase inhibitors, other combinations 
 
Combinations with e.g. ACE inhibitors, angiotensin II antagonists, 
calcium channel blockers or diuretics are classified in C10BX. 
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D   DERMATOLOGICALS  
 
D01  ANTIFUNGALS FOR DERMATOLOGICAL USE 
A Antifungals for topical use 
B Antifungals for systemic use 
 
D02  EMOLLIENTS AND PROTECTIVES 
A Emollients and protectives 
B Protectives against UV-radiation  
 
D03 PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS 
A Cicatrizants 
B Enzymes 
 
D04 ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. 
A Antipruritics, incl. antihistamines, anesthetics, etc. 
 
D05  ANTIPSORIATICS  
A Antipsoriatics for topical use 
B Antipsoriatics for systemic use 
 
D06 ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR 
DERMATOLOGICAL USE  
A Antibiotics for topical use 
B Chemotherapeutics for topical use 
C Antibiotics and chemotherapeutics, combinations 
 
D07  CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS 
A Corticosteroids, plain 
B Corticosteroids, combinations with antiseptics 
C Corticosteroids, combinations with antibiotics 
X Corticosteroids, other combinations 
 
D08  ANTISEPTICS AND DISINFECTANTS 
A Antiseptics and disinfectants 
 
D09  MEDICATED DRESSINGS 
A Medicated dressings 
 126 
D10  ANTI-ACNE PREPARATIONS 
A Anti-acne preparations for topical use 
B Anti-acne preparations for systemic use 
 
D11  OTHER DERMATOLOGICAL PREPARATIONS  
A Other dermatological preparations 
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D  DERMATOLOGICALS 
 
 
Most of the drugs in this group are preparations for topical use.  Some 
few preparations for systemic use with clear dermatological 
applications, e.g. griseofulvin (antimycotic), retinoids (for treatment of 
acne) and psoralens and retinoids (for treatment of psoriasis) are 
classified in this group. 
 
Only oral preparations in ATC group D are given DDDs.  Most 
products in this group are for topical use, and no DDDs are assigned 
because the amount given per day can vary very much according to the 
intensity and distribution of the disease.  Consumption figures for 
these dermatological preparations can be expressed in grams of 
preparations regardless of strength. 
 
 
D01  ANTIFUNGALS FOR DERMATOLOGICAL USE 
 
This group comprises preparations for topical and systemic treatment of 
dermatological mycoses.  Preparations with systemic antimycotic 
effect, see also J02A - Antimycotics for systemic use. 
 
Topical preparations used especially in gynecological infections are 
classified in G01A - Antiinfectives and antiseptics, excl. combinations 
with corticosteroids or G01B - Antiinfectives/antiseptics in combination 
with corticosteroids.  Preparations for local treatment of fungal 
infections in the mouth, see A01AB - Antiinfectives and antiseptics for 
local oral treatment. 
 
 
D01A  ANTIFUNGALS FOR TOPICAL USE 
 
Combined preparations are classified in this group if mycosis is the 
main indication. 
 
D01AA Antibiotics 
 
Preparations used in the treatment of bacterial dermatological 
infections, see D06A - Antibiotics for topical use. 
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D01AC  Imidazole and triazole derivatives 
 
Shampoos containing imidazoles are classified here.  Topical 
metronidazole is mainly used in rosacea and is classified in D06BX - 
Other chemotherapeutics.   
 
Combinations with corticosteroids are classified in D01AC20. All other 
combinations are classified by using the 50-series e.g. miconazole and 
zinc. 
 
Combinations of clotrimazole, gentamicin and corticosteroids are 
classified in D07C. 
 
D01AE  Other antifungals for topical use 
 
See also D08AH - Quinoline derivatives  
 
Combined preparations containing salicylic acid, which are used as 
antifungals (e.g. dusting powders), are classified in this group in 
D01AE20.  See also D02AF - Salicylic acid preparations. 
 
Derivatives of undecylenic acid are classified in D01AE04. 
 
 
D01B  ANTIFUNGALS FOR SYSTEMIC USE 
 
This group comprises preparations used in the systemic treatment of 
dermatological mycoses.  See also J02A - Antimycotics for systemic 
use. 
 
D01BA  Antifungals for systemic use 
 
The DDDs for griseofulvin and terbinafine are based on the treatment 
of dermatophyte infections in skin, hair or nails. 
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D02  EMOLLIENTS AND PROTECTIVES 
 
D02A  EMOLLIENTS AND PROTECTIVES 
 
This group comprises all types of emollients and protectives with no 
specific therapeutic effect or use, and also preparations for use in 
wounds, which are not classified in D09 - Medicated dressings. 
 
Some similar products are classified in D03A - Cicatrizants, e.g. cod-
liver oil ointments. 
 
D02AA  Silicone products 
 
D02AB  Zinc products 
 
D02AC  Soft paraffin and fat products 
 
Some similar products with a higher water content (creams) are 
classified in D02AX - Other emollients and protectives.  Soft paraffin 
dressings, see D09AX. 
 
D02AD  Liquid plasters 
 
Liquid plasters are classified in this group whereas non-medicated 
adhesive plasters, surgical tapes etc. are classified in V07AA. 
 
D02AE  Carbamide products 
 
D02AF  Salicylic acid preparations 
 
Preparations containing salicylic acid used for the treatment of mycosis 
are classified in D01AE - Other antifungals for topical use. 
 
Salicylic acid in combination with corticosteroids, see D07X. 
 
Medicated shampoos containing salicylic acid are classified in 
D11AC30 - others. 
 
Topical products for joint and muscular pain containing combinations 
with salicylic acid are classified in M02AC. 
 
All other preparations containing salicylic acid, including anti-acne 
preparations, should be classified in this group. 
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D02AX  Other emollients and protectives 
 
Soft paraffin and fat products with high water content (creams) are 
classified in this group.  See also D02AC - Soft paraffin and fat 
products. 
 
Weak boric acid vaseline is classified here. 
Other boric acid products are classified in D08AD. 
 
 
D02B  PROTECTIVES AGAINST UV-RADIATION 
 
This group comprises special protectives against UV-radiation. 
 
D02BA  Protectives against UV-radiation for topical use 
 
Derivatives may by included in each plain 5th level. 
 
D02BB  Protectives against UV-radiation for systemic use 
 
The DDD of betacarotene is based on the treatment of patients with 
erythropoietic protoporphyria. 
 
 
D03  PREPARATIONS FOR TREATMENT OF WOUNDS AND 
ULCERS 
 
Topical preparations used in the treatment of wounds and ulcers, e.g. 
leg ulcers, are classified in this group.  Protective ointments are 
classified in D02A - Emollients and protectives. 
 
See also  
D06 - Antibiotic and chemotherapeutics for dermatological use. 
D08 - Antiseptics and disinfectants. 
D09 - Medicated dressings. 
 
 
D03A  CICATRIZANTS 
 
Topical vitamin preparations etc. are classified in this group if they 
cannot be classified in other groups. 
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D03AA Cod-liver oil ointments 
 
Includes cod-liver (vitamin A) ointments in combination with 
chlorhexidine. 
 
D03AX  Other cicatrizants 
 
Includes e.g. dextranomer powders with or without antiseptics.  See 
also D09A - Medicated dressings.   
 
Medicated dressings containing hyaluronic acid are classified here.  
 
Topical products containing glyceryl trinitrate or isosorbide dinitrate 
used for treatment of anal fissures are classified in C05AE. 
 
 
D03B  ENZYMES 
 
Proteolytic enzymes for topical treatment of ulcers are classified here. 
 
D03BA  Proteolytic enzymes 
 
 
D04 ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. 
 
D04A ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. 
 
This group comprises antipruritics for topical use in the treatment of 
pruritus, minor burns, insect stings, herpes zoster etc. 
 
See also D07 - Corticosteroids, dermatological preparations. 
 
D04AA  Antihistamines for topical use 
 
At each 5th level, antiseptics, siccants etc. may occur in combination 
with the antihistamines.  Combinations with corticosteroids, see  
D07 - Corticosteroids, dermatological preparations. 
 
Combinations with anesthetics are classified in D04AB. 
 
Combinations of diphenhydramine and diethyltoluamid are classified at 
the plain level for diphenhydramine in D04AA. 
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D04AB  Anesthetics for topical use 
 
At each 5th plain level, antiseptics, siccants etc. may occur in 
combination with the anesthetics.  Combinations with corticosteroids, 
see D07 - Corticosteroids, dermatological preparations. 
 
Combinations with antihistamines are classified in D04AB at the 
corresponding plain 5th level. 
 
See also C05A - Agents for treatment of hemorrhoids and anal fissures 
for topical use, and N01B - Anesthetics, local. 
 
D04AX  Other antipruritics 
 
This group comprises ointments, creams, liniments etc. containing e.g. 
camphora, menthol, calamine.  Crotamiton is classified here. When 
classifying products in this group, alternative groups should be 
considered, e.g.:  
 
D02 - Emollients and protectives 
D08  -  Antiseptics and disinfectants 
M02  -  Topical products for joint and muscular pain 
 
 
D05  ANTIPSORIATICS 
 
D05A  ANTIPSORIATICS FOR TOPICAL USE 
 
This group comprises products for topical use mainly for the treatment 
of psoriasis.  Corticosteroids for topical use are classified in D07 - 
Corticosteroids, dermatological preparations. 
 
D05AA  Tars 
 
All tar preparations for dermatological use are classified in this group, 
except for combinations with corticosteroids. 
 
D05AC  Antracen derivatives 
 
D05AD  Psoralens for topical use 
 
  
 133 
D05AX  Other antipsoriatics for topical use 
 
Corticosteroids in combination with vitamin D analogues indicated only 
for the treatment of psoriasis are classified in D05AX. 
 
 
D05B  ANTIPSORIATICS FOR SYSTEMIC USE 
 
This group comprises drugs for systemic use against psoriasis.  
Antineoplastic agents, sometimes used in severe psoriasis, are classified 
in group L - Antineoplastic and immunomodulating agents. 
 
D05BA  Psoralens for systemic use 
 
The DDDs for psoralens for systemic use are based on the combined 
treatment with drug and UV-A irradiation. 
 
D05BB  Retinoids for treatment of psoriasis 
 
Retinoids for the treatment of acne are classified in D10BA. 
 
Alitretinoin used for hand eczema is classified in D11A. 
 
D05BX Other antipsoriatics for systemic use 
 
Alefacept and efalizumab are classified in L04AA. 
 
 
D06  ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR 
DERMATOLOGICAL USE  
 
This group comprises products for topical use in skin infections etc. 
 
 
D06A  ANTIBIOTICS FOR TOPICAL USE 
 
This group comprises antibiotics for dermatological use, except  
 
Antibiotics with antimycotic properties - D01A 
Combinations with chemotherapeutics - D06C 
Combinations with corticosteroids - D07C 
Antiinfectives for treatment of acne - D10AF 
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D06AA  Tetracycline and derivatives 
 
Combined preparations, which contain oxytetracycline and other 
antibiotics, are classified in D06AA03 - oxytetracycline. 
 
D06AX  Other antibiotics for topical use 
 
Combined preparations which contain neomycin and other antibiotics 
(e.g. bacitracin) are classified in D06AX04 - neomycin.   
 
 Combined preparations containing bacitracin and chlorhexidine are 
classified in D06AX05 - bacitracin. 
 
 
D06B  CHEMOTHERAPEUTICS FOR TOPICAL USE 
 
This group includes chemotherapeutics for dermatological use, except:  
 
Combinations with antibiotics - D06C 
 
Combinations with corticosteroids - D07C 
 
D06BA  Sulfonamides 
 
D06BB  Antivirals 
 
This group includes both direct acting antivirals and other agents for 
viral diseases. 
 
Mucoadhesive formulations of aciclovir are classified in J05AB01. 
 
Podophyllin preparations are classified at the 5th level for 
podophyllotoxin. 
 
D06BX  Other chemotherapeutics 
 
This group comprises chemotherapeutics used in different skin 
disorders, which cannot be classified in the preceding groups, e.g. 
metronidazole for the treatment of rosacea. 
 
D06C  ANTIBIOTICS AND CHEMOTHERAPEUTICS, COMBINATIONS 
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D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS 
 
As a main rule, all topical corticosteroid preparations should be 
classified in this group.  There are, however, some few exceptions: 
 
Combinations of corticosteroids and antiinfectives for gynaecological 
use, see G01B. 
 
Corticosteroids for local oral treatment, see A01AC. 
 
Corticosteroids in combination with antifungals are classified in D01A.  
 
Anti-acne preparations, see D10A. 
 
Antihemorrhoidals with corticosteroids, see C05AA. 
 
Corticosteroids for ophthalmological or otological use, see S - Sensory 
organs. 
 
 
D07A  CORTICOSTEROIDS, PLAIN 
 
The group is subdivided according to clinical potency of the steroids as 
such.  Additional agents meant to enhance the penetration and increase 
the potency of the product do not influence the classification, neither do 
the strength of the preparations or the vehicle. 
 
D07AA  Corticosteroids, weak (group I) 
 
D07AB  Corticosteroids, moderately potent (group II) 
 
D07AC  Corticosteroids, potent (group III) 
 
D07AD  Corticosteroids, very potent (group IV) 
 
 
D07B  CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS 
 
This group comprises combined corticosteroid/antiseptic preparations 
for dermatological use. 
 
Antifungal preparations with corticosteroids are classified in D01A - 
Antifungals for topical use.  Corticosteroids, antiseptics and salicylic 
acid in combination are classified in D07X.  
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The group is subdivided according to clinical potency, see D07A.  
Exceptions, see D07.  At each 5th level various antiseptics may occur. 
 
D07BA  Corticosteroids, weak, combinations with antiseptics 
 
D07BB  Corticosteroids, moderately potent, combinations with antiseptics  
 
D07BC  Corticosteroids, potent, combinations with antiseptics 
 
D07BD  Corticosteroids, very potent, combinations with antiseptics  
 
 
D07C  CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS 
 
This group comprises combined corticosteroid/antibiotic preparations 
for dermatological use.  The group is subdivided according to clinical 
potency, see D07A.  Exceptions, see D07. 
 
At each 5th level various antibiotics may occur. 
 
D07CA  Corticosteroids, weak, combinations with antibiotics 
 
D07CB  Corticosteroids, moderately potent, combinations with antibiotics  
 
D07CC  Corticosteroids, potent, combinations with antibiotics 
 
Combinations of beclomethasone, gentamycin and clotrimazole are 
classified here. 
 
D07CD  Corticosteroids, very potent, combinations with antibiotics  
 
 
D07X  CORTICOSTEROIDS, OTHER COMBINATIONS 
 
This group comprises most other combined corticosteroid preparations 
for dermatological use, e.g. combinations with coal tar, carbamide and 
salicylic acid.  Salicylic acid is regarded as a keratolytic agent.  
Preparations with salicylic acid and antiseptics are classified in this 
group, as salicylic acid is regarded as being more important than the 
antiseptics for the therapeutic use of these products (psoriasis, 
seborrhea). 
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The group is subdivided according to clinical potency, see D07A.   
Exceptions, see D07. 
 
Corticosteroids in combination with antifungals are classified in D01A. 
 
D07XA  Corticosteroids, weak, other combinations 
 
D07XB  Corticosteroids, moderately potent, other combinations 
 
D07XC  Corticosteroids, potent, other combinations 
 
D07XD  Corticosteroids, very potent, other combinations 
 
 
D08  ANTISEPTICS AND DISINFECTANTS 
 
D08A ANTISEPTICS AND DISINFECTANTS 
 
This group comprises all dermatological antiinfective preparations, 
which are not classified in any of the following groups:  
 
D01 - Antifungals for dermatological use 
D03A - Cicatrizants 
D06 - Antibiotics and chemotherapeutics for dermatological use  
D07B -  Corticosteroids, combinations with antiseptics  
D07X -  Corticosteroids, other combinations 
D09A -  Medicated dressings 
D10A -  Anti-acne preparations for topical use 
D11AC -  Medicated shampoos 
P03A -  Ectoparasiticides, incl. scabicides 
 
 Antiviral agents, see D06BB. 
 
Non-therapeutic auxiliary products, such as exploration creams and 
lubricants, are classified in V07AY.  Lubricants, which contain anti-
septics, are, however, classified in this group. 
 
The group is subdivided according to chemical structure. 
 
 At each 5th plain level combinations with alcohols are allowed. 
 
D08AA  Acridine derivatives 
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D08AB  Aluminium agents 
 
Combinations with quarternary ammonium compounds are classified in 
D08AJ. 
 
D08AC  Biguanides and amidines 
 
D08AD  Boric acid products 
 
Weak boric acid vaseline is classified in D02AX. 
 
D08AE  Phenol and derivatives 
 
Each 5th level also allows combinations with alcohol. 
 
D08AF  Nitrofuran derivatives 
 
D08AG  Iodine products 
 
See also D03AX and D09AA.  Cadexomer iodine is classified in 
D03AX.  Medicated dressings containing iodine are classified in 
D09AA. 
 
D08AH  Quinoline derivatives 
 
Chloroquinaldol and clioquinol are classified in this group and not in 
D01 - Antifungals for dermatological use. 
 
Chloroquinaldol and clioquinol for systemic use are classified in 
P01AA - Hydroxyquinoline derivatives 
 
D08AJ  Quaternary ammonium compounds 
 
Combinations with aluminium agents are classified here. 
 
D08AK  Mercurial products 
 
Combined products, which also contain silver compounds, are 
classified in this group. 
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D08AL  Silver compounds 
 
Combined products, which also contain mercury compounds, see 
D08AK. 
 
D08AX  Other antiseptics and disinfectants 
 
 
D09  MEDICATED DRESSINGS 
 
D09A  MEDICATED DRESSINGS 
 
This group comprises medicated dressings, ointment dressings etc.  
Liquid wound protectives are classified in D02AD - Liquid plasters. 
Local hemostatics, e.g. gauze, tampons etc. are classified in B02BC - 
Local hemostatics.  Medicated dressings containing hyaluronic acid are 
classified in D03AX - Other cicatrizants. 
 
D09AA  Medicated dressings with antiinfectives 
 
See also D03AX and D08AG.  Products containing cadexomer iodine 
are classified in D03AX. 
 
D09AB  Zinc bandages 
 
Zinc bandages with or without supplements are classified in this group. 
 
D09AX  Soft paraffin dressings 
 
Dressings with antiinfectives, see D09AA. 
 
Dressings with scarlet red are classified in this group. 
 
 
D10  ANTI-ACNE PREPARATIONS 
 
The DDDs are based on the treatment of severe acne. 
 
 
D10A  ANTI-ACNE PREPARATIONS FOR TOPICAL USE 
 
This group comprises all topical preparations used specifically in the 
treatment of acne, incl. preparations with antibiotics, corticosteroids etc. 
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D10AA  Corticosteroids, combinations for treatment of acne 
 
Only combined corticosteroid preparations specifically used in the 
treatment of acne are classified in this group.  Other dermatological 
corticosteroid preparations are classified in D07 - Corticosteroids, 
dermatological preparations. 
 
 Combinations with retinoids are classified in D10AD. 
 
D10AB  Preparations containing sulfur 
 
Preparations, which contain sulfur in addition to a sulfur derivative, 
should be classified at the 5th level of the derivative. 
 
The products may contain other active ingredients such as resorcinol. 
 
D10AD  Retinoids for topical use in acne 
 
All retinoids for topical use  are classified in D10AD. 
 
D10AE  Peroxides 
 
 Combinations with antiinfectives are classified in D10AF. 
 
D10AF  Antiinfectives for treatment of acne 
 
This group comprises antibiotics for topical use with acne as the main 
indication. 
Other topical antiinfectives are classified in D06 - Antibiotics and 
chemotherapeutics for dermatological use. 
 
Combinations with retinoids are classified in D10AD. 
 
D10AX  Other anti-acne preparations for topical use 
 
 
D10B  ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE 
 
This group comprises drugs for systemic use in the treatment of acne. 
Antibiotics, such as tetracyclines and erythromycin, which are also used 
for the treatment of acne, are classified in group J. 
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Combinations of e.g. estrogen and antiandrogen, used for the treatment 
of acne, are classified in group G03 - Sex hormones and modulators of 
the genital system. 
 
D10BA  Retinoids for treatment of acne 
 
Retinoids used in severe psoriasis are classified in D05BB, whereas 
alitretinoin used for hand eczema is classified in D11A. 
 
D10BX Other anti-acne preparations for systemic use 
 
Ichtasol preparations for systemic use in treatment of acne are classified 
in this group. 
 
 
D11  OTHER DERMATOLOGICAL PREPARATIONS 
 
D11A  OTHER DERMATOLOGICAL PREPARATIONS 
 
This group comprises various dermatological preparations, which 
cannot be classified in the preceding groups. 
 
Insect repellents are classified in P03B - Insecticides and repellents. 
 
D11AA  Antihidrotics 
 
D11AC  Medicated shampoos 
 
Shampoos containing imidazoles are classified in D01AC. 
 
Shampoos containing coal tar are classified in D05AA. 
 
D11AE  Androgens for topical use 
 
D11AF  Wart and anti-corn preparations 
 
Preparations such as keratolytics for the treatment of common warts and 
cornified lesions are classified in this group. 
 
Podophyllotoxin/podophyllin e.g. for the treatment of genital warts, is 
classified in D06BB. 
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D11AH Agents for dermatitis, excluding corticosteroids 
 
This group includes agents used for atopic dermatitis or eczema. 
 
Corticosteroides, see D07. 
 
D11AX  Other dermatologicals 
 
This group comprises products, which cannot be classified in the 
preceding groups.  E.g. minoxidil for the treatment of male pattern 
baldness is classified here. 
Lithium succinate in combination with other substances, e. g. zinc 
sulphate is classified in D11AX04 - lithium succinate. 
 
Diclofenac formulated as a 3% hyaluronic acid gel used in treatment of 
actinic keratoses is classified here. 
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G   GENITO URINARY SYSTEM AND SEX HORMONES 
 
G01  GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS 
A Antiinfectives and antiseptics, excl. combinations with cortico-
steroids  
B Antiinfectives/antiseptics in combination with corticosteroids  
 
G02  OTHER GYNECOLOGICALS 
A Uterotonics 
B Contraceptives for topical use 
C Other gynecologicals 
 
G03 SEX HORMONES AND MODULATORS OF THE GENITAL 
SYSTEM  
A Hormonal contraceptives for systemic use 
B Androgens 
C Estrogens  
D Progestogens  
E Androgens and female sex hormones in combination  
F Progestogens and estrogens in combination 
G Gonadotropins and other ovulation stimulants 
H Antiandrogens 
X Other sex hormones and modulators of the genital system  
 
G04  UROLOGICALS 
B Urologicals 
C Drugs used in benign prostatic hypertrophy 
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G GENITO URINARY SYSTEM AND SEX HORMONES 
 
G01  GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS 
 
This group comprises gynecological antiinfectives and antiseptics 
mainly for local use.  See also:  
 
J  - Antiinfectives for systemic use 
D06 - Antibiotics and chemotherapeutics for dermatological use  
P01AB - Nitroimidazole derivatives 
 
The DDDs are based on the treatment of vaginal infections. 
 
 
G01A ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS 
WITH CORTICOSTEROIDS  
 
This group comprises preparations, mainly for local use.   
 
Combinations with corticosteroids, see G01B.  
 
Antivirals for topical use, including gynecological use, such as 
podophyllotoxin, are classified in D06 - Antibiotics and 
chemotherapeutics for dermatological use.  
 
G01AA  Antibiotics 
 
 Nystatin in combination with nifuratel is classified in G01AA51. 
 
G01AB  Arsenic compounds 
 
G01AC  Quinoline derivatives 
 
G01AD  Organic acids 
 
G01AE  Sulfonamides  
 
Combinations of different sulfonamides are given the code G01AE10.  
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G01AF  Imidazole derivatives 
 
Imidazole derivatives (e.g. metronidazole and ornidazole) in 
formulations for vaginal administration are classified in this group.  
Parenteral formulations are classified in J01XD, as they are mainly used 
in anaerobic infections.  Imidazole derivatives in oral (including tablets 
used for the treatment of gynecological infections only) and rectal 
dosage forms are classified in P01AB.  Metronidazole for topical use in 
skin disorders is classified in D06BX - Other chemotherapeutics. 
 
G01AG  Triazole derivatives 
 
Fluconazole tablets in single dose packages, only for gynecological 
infections, are classified together with other packages for systemic use 
in J02A - Antimycotics for systemic use.  
 
G01AX  Other antiinfectives and antiseptics  
 
 Nifuratel in combination with nystatin is classified in G01AA51. 
 
 
G01B  ANTIINFECTIVES/ANTISEPTICS IN COMBINATION WITH 
CORTICOSTEROIDS  
 
All antiinfectives/antiseptics for gynecological use, which contain 
corticosteroids, are classified in this group.  
 
G01BA  Antibiotics and corticosteroids 
 
G01BC  Quinoline derivatives and corticosteroids 
 
G01BD Antiseptics and corticosteroids 
 
G01BE  Sulfonamides and corticosteroids 
 
G01BF  Imidazole derivatives and corticosteroids 
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G02  OTHER GYNECOLOGICALS 
 
Analgesics used in dysmenorrhea, see N02B - Other analgesics and 
antipyretics and M01A - Antiinflammatory and antirheumatic products, 
non-steroids.  
 
 
G02A  UTEROTONICS 
 
Plain preparations of oxytocin and analogues are classified in H01B - 
Posterior pituitary lobe hormones.  
 
G02AB  Ergot alkaloids 
 
This group comprises ergot alkaloids, e.g. methylergometrine, used for 
stimulation of uterine contractions.  Other ergot alkaloids are classified 
in C04A - Peripheral vasodilators, and in N02C - Anti-migraine 
preparations.  
 
The DDDs are based on use in delivery. 
 
G02AC  Ergot alkaloids and oxytocin incl. analogues, in combination  
 
G02AD  Prostaglandins 
 
G02AX  Other uterotonics 
 
This group comprises uterotonics, which cannot be classified in the 
preceding groups. 
 
 
G02B  CONTRACEPTIVES FOR TOPICAL USE 
 
Contraceptives for systemic use, see G03A. 
 
G02BA  Intrauterine contraceptives  
 
IUDs (intrauterine devices) are classified in this group. IUDs containing 
progestogens are also classified in this group. 
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G02BB  Intravaginal contraceptives 
 
Pessaries, vaginal foams etc. are classified in this group.  
 
Intravaginal devices containing hormones are also classified in this 
group. 
 
The DDDs for combined devices containing estrogen and progestogen 
are based on use in menstrual cycles of 28 days.  Thus the DDD is 
0.0357 UD (1 UD = 1 device). 
 
 
G02C  OTHER GYNECOLOGICALS 
 
G02CA  Sympathomimetics, labour repressants 
 
This group includes sympathomimetics used to repress labour.  Similar 
adrenergic drugs, which are mainly used in the treatment of asthma, are 
classified in R03C.  
 
Fenoterol infusion only intended for repressing preterm labour is 
classified in this group, while other systemic formulations of fenoterol 
are classified in R03CC04. 
 
The DDDs are based on use as labour repressants. 
 
G02CB  Prolactine inhibitors 
 
Cabergoline and bromocriptine low dose tablets are classified in this 
group.  Cabergoline and bromocriptine tablets in higher strengths are 
classified in N04 - Anti-Parkinson drugs.  
 
Lisuride tablets in high strength (0.2 mg) are classified in this group, 
while low strength tablets (25 mcg) are classified in N02C -
Antimigraine preparations. 
 
The DDDs are based on use as lactation inhibitors.  The DDD for 
parenteral depot formulations of bromocriptine is equal to the DDD for 
oral administration, based on the assumption that the single dose 
parenteral treatment equals 14 days of oral treatment. 
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G02CC Antiinflammatory products for vaginal administration 
 
This group comprises e.g. non-steroidal antiinflammatory drugs for 
vaginal administration. 
 
G02CX Other gynecologicals 
 
 
G03  SEX HORMONES AND MODULATORS OF THE GENITAL 
SYSTEM 
 
Other hormones, see H - Systemic hormonal preparations, excl. sex 
hormones and insulins.  
 
Sex hormones used only in the treatment of cancer (often selected 
strengths) are classified in L - Antineoplastic and immunomodulating 
agents.  
 
The DDDs of many of the hormone preparations may vary 
considerably with the route of administration due to substantial 
differences in bioavailability.  The DDDs of depot preparations are 
calculated as the dose divided by the dosing interval. 
 
 
 
 
G03A  HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE 
 
This group comprises hormonal preparations, which are used as 
contraceptives.  Similar hormonal preparations, which are used for the 
treatment of e.g. menopausal symptoms and menstrual irregularities, are 
classified in G03F.  
 
Combinations of cyproterone and estrogen also used as contraceptives 
are, however, classified in G03HB. 
 
Intravaginal and intrauterine devices containing hormones are classified 
in G02B. 
 
Transdermal patches for contraception are classified here. 
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The DDDs are based on use as contraceptives. 
 
The DDDs of combined preparations of estrogen and progestogen and 
plain progestogen products are based on use in menstrual cycles of 28 
days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle 
package, respectively. The same principle is used for transdermal 
patches. 
 
For the 24 tablets cycle packages the DDD is based on continuous use 
for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 
UD. 
 
The DDDs for preparations only used in postcoital contraception are 
based on the course dose. 
 
G03AA  Progestogens and estrogens, fixed combinations 
 
This group comprises preparations, which contain fixed combinations 
of progestogen and estrogens.  
 
The preparations are classified at 5th levels according to the 
progestogen.  
 
Products containing mestranol (a prodrug of ethinylestradiol) are 
classified together with ethinylestradiol. 
 
G03AB  Progestogens and estrogens, sequential preparations 
 
This group comprises preparations with varying contents of 
progestogens and estrogens adjusted to the normal hormonal cycle.  A 
package which is intended for one cycle, may contain e.g. three types of 
tablets, each designed to cover a special part of the menstrual period.  
Cycle packages may contain some tablets with progestogen only.  
 
5th levels are built up as in G03AA. 
 
G03AC  Progestogens 
 
This group includes hormonal contraceptives, which contain 
progestogens only. 
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G03AD Emergency contraceptives  
 
Levonorgestrel products (packages) indicated only for emergency 
contraception are classified in G03AD01. 
 
 
G03B  ANDROGENS 
 
Anabolic steroids, see A14A.  Norethandrolone, which has both 
anabolic and androgenic effects, is classified in A14A since the 
anabolic effect is considered to be the most important effect. 
 
This group comprises male sex hormones.  Combined preparations are 
included in this group, except combinations with female sex hormones, 
which are classified in G03E - Androgens and female sex hormones in 
combination.  
 
The group is subdivided according to chemical structure.  
 
The DDDs are based on use in substitution therapy in male hypo-
gonadism.  The DDDs for patches (e.g. testosterone) are given in 
amount delivered. 
 
G03BA  3-oxoandrosten (4) derivatives 
 
The DDD for parenteral and oral testosterone is expressed as declared 
amount of ester. The DDD for TD and SL route of administration is 
expressed as declared amount of testosterone. 
 
G03BB  5-androstanon (3) derivatives 
 
 
G03C  ESTROGENS 
 
This group comprises estrogens and combinations, except combinations 
with  
 
-  androgens, see G03E 
-  progestogens, see G03F 
-  antiandrogens, see G03HB 
 
Hormonal contraceptives, see G03A. 
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Estrogens used only in neoplastic diseases, see L - Antineoplastic and 
immunomodulating agents. 
 
The DDDs are based on systemic use in postmenopausal estrogen 
substitution therapy and in the treatment of premenstrual ailments.  
However, for some preparations for vaginal administration the DDDs 
are based on local treatment. 
 
The DDDs for transdermal preparations are based on the amount of 
active ingredient delivered per 24 hours and the number of days each 
patch is used. 
 
G03CA  Natural and semisynthetic estrogens, plain 
 
This group comprises preparations, which contain one or more natural 
or semisynthetic estrogen.  Estradiol/polyestradiol are classified at the 
same 5th level.  The same applies to estriol/polyestriol.  Combinations 
of estradiol and estriol are classified in G03CA53. 
 
Combinations with other drugs, see G03CC. 
 
Estropipate is classified in G03CA07 - estrone. 
 
The DDD for nasal administration of estradiol is based on daily 
treatment. 
 
G03CB  Synthetic estrogens, plain 
 
This group comprises preparations, which contain synthetic estrogens 
only.  
 
Combinations with other drugs, see G03CC. 
 
G03CC  Estrogens, combinations with other drugs 
 
This group includes combined preparations with natural, semisynthetic 
or synthetic estrogens and other drugs.  
 
G03CX Other estrogens 
 
Tibolone is classified in this group even though the chemical structure 
is different from the other estrogens.  
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G03D  PROGESTOGENS 
 
This group comprises progestogens and combinations, except 
combinations with  
 
-  androgens, see G03E 
-  estrogens, see G03F 
 
Hormonal contraceptives, see G03A 
 
IUDs (intrauterine dervices) with progestogens, see G02BA. 
 
Progestogens only used in neoplastic diseases, see L - Antineoplastic 
and immunomodulating agents.  
 
The group is subdivided according to chemical structure.  
 
The DDDs are based on gynecological indications, for instance corpus 
luteum insufficiency and endometriosis. 
 
G03DA  Pregnen (4) derivatives 
 
G03DB  Pregnadien derivatives 
 
G03DC  Estren derivatives 
 
Tibolone is classified in G03CX. 
 
 
G03E  ANDROGENS AND FEMALE SEX HORMONES IN 
COMBINATION 
 
This group comprises preparations with androgen and estrogen and/or 
progestogen.  The preparations are classified at 5th levels according to 
the androgen.  
 
The DDDs are based on the treatment of climacterical ailments. 
 
G03EA  Androgens and estrogens 
 
G03EB  Androgen, progestogen and estrogen in combination 
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G03EK  Androgens and female sex hormones in combination with other drugs  
 
This group comprises preparations, which in addition to the hormones 
also contain other drugs.  
 
 
G03F  PROGESTOGENS AND ESTROGENS IN COMBINATION 
 
This group comprises combined preparations used in the treatment of 
menopausal symptoms, menstrual irregularities etc.  
 
Hormonal contraceptives, see G03A. 
 
The DDDs for combined preparations of estrogens and progestogens 
are based on use in postmenopausal substitution therapy in cycles of 
28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle 
packages, respectively. 
 
G03FA  Progestogens and estrogens, fixed combinations 
 
This group comprises preparations, which contain combinations of 
progestogens and estrogens.  Sequential preparations are classified in 
G03FB.  Combination packages with separate tablets containing 
progestogens and estrogens intended to be taken together are also 
classified in this group.  The preparations are classified at 5th levels 
according to the progestogen.  At each 5th level various estrogens may 
occur.  
 
Combinations of progestogens and estrogens used as contraceptives are 
classified in G03A.  
 
G03FB  Progestogens and estrogens, sequential preparations 
 
This group comprises preparations with varying contents of 
progestogens and estrogens adjusted to the normal hormonal cycle.  A 
package which is intended for one cycle, may contain e.g. three types of 
tablets, each designed to cover a special part of the menstrual period.  
Cycle packages may contain some tablets with progestogens only.  
Combination packages with separate tablets containing progestogens 
and estrogens intended to be taken together and in sequence are also 
classified in this group. 
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5th levels are built up as in G03FA. 
 
Hormonal contraceptives, sequential preparations, see G03AB. 
 
 
G03G  GONADOTROPINS AND OTHER OVULATION STIMULANTS 
 
The DDDs are based on the initial treatment of anovulation. 
 
G03GA  Gonadotropins 
 
This group comprises both naturally occurring gonad-stimulating 
hormones and synthetic ovulation stimulants.  
 
G03GA02 comprises products of human origin (e.g. menotrophin) 
while G03GA30 comprises combinations of recombinant hormones 
(e.g. follitropin alfa and lutropin alfa). 
 
G03GB  Ovulation stimulants, synthetic  
 
 
G03H  ANTIANDROGENS 
 
G03HA  Antiandrogens, plain 
 
Finasteride used for treatment of benign prostatic hypertrophy is 
classified in G04CB. 
 
The DDDs are based on the treatment of hypersexualism. 
 
G03HB  Antiandrogens and estrogens 
 
This group comprises all combinations of cyproterone and estrogen 
regardless of indication. 
 
The DDDs are based on the treatment of hirsutism or prophylaxis of 
postmenopausal osteoporosis. 
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G03X  OTHER SEX HORMONES AND MODULATORS OF THE 
GENITAL SYSTEM  
 
This group comprises drugs modifying the genital functions, which 
cannot be classified in the preceding groups.  
Tibolone is classified in G03DC. 
 
G03XA  Antigonadotropins and similar agents 
 
The DDDs of danazol and gestrinone are based on the treatment of 
endometriosis. 
 
G03XB Progesterone receptor modulators 
 
 Mifepristone indicated for Cushings’s syndrome is also classified in this 
group. 
 
The combination package of mifepristone tablet and misoprostol 
vaginal tablets is classified in G03XB51. 
 
The DDD for mifepristone (G03XB01) and for the combination 
package of mifepristone tablet and misoprostol vaginal tablets 
(G03XB51) is based on the use in termination of pregnancy.   
The DDD for the combination package is given as amount of 
mifepristone. 
 
G03XC Selective estrogen receptor modulators 
 
 
G04  UROLOGICALS 
 
Antiseptic and antiinfective preparations for systemic use specifically 
used in urinary tract infections, see J01.  
 
Antiinfectives for systemic use, see group J.  
 
Gynecological antiinfectives and antiseptics, see G01.  
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G04B  UROLOGICALS 
 
This group comprises urological preparations other than antiseptics and 
antiinfectives.  
 
G04BA  Acidifiers 
 
G04BC  Urinary concrement solvents 
 
This group comprises agents, which dissolve urinary concrements, e.g. 
citrates.  
 
G04BD  Drugs for urinary frequency and incontinence 
 
This group comprises antispasmodics specifically used in the urogenital 
tractus.  
 
Gastrointestinal antispasmodics, see A03.  
 
Trospium in combination with analgesics are classified in A03DA. 
 
The DDD for oral administered emeperonium is higher than the DDD 
for parenteral administered formulations, due to low oral 
bioavailability. 
 
G04BE Drugs used in erectile dysfunction 
 
Alprostadil intracavernosal injection for treatment of erectil dysfunction 
is classified here, while formulations used to maintain the patency of 
the ductus arteriosis in neonates are classified in C01EA01.   
Combinations of papaverine and phentolamine for intracavernous 
administration are classified under G04BE30 - combinations. 
Combinations of phentolamine and aviptadil (polypeptide) are 
classified under G04BE30 - combinations. 
 
Phosphodisesterase inhibitors also indicated for pulmonary arterial 
hypertension (PAH) are classified in this group. Other agents used for 
treatment of PAH are classified in C02KX or in B01AC. 
 
The DDDs are based on single treatment of erectile dysfunction.  
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G04BX  Other urologicals 
 
This group comprises urologicals which cannot be classified in the 
preceding groups.  
 
Phenazopyridine, plain products, are classified here, while 
phenazopyridine in combination with sulfonamides is classified 
according to the sulfonamide in J01EB20, J01EC20 or J01ED20. 
 
Local anesthetic formulations for treatment of premature ejaculation are 
classified in N01B. 
 
The DDD of phenazopyridine is based on analgesic treatment of 
conditions such as cystitis, prostatitis and urethritis.  The DDD for 
phenylsalicylate is based on the prophylaxis of urinary tract infections.  
The other DDDs are based on the prophylaxis of urinary concrements. 
 
 
G04C DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY 
 
G04CA Alpha-adrenoreceptor antagonists 
 
Alfuzosin and terazosin used in the management of urinary obstruction 
caused by benign prostatic hypertrophy, are classified here, while other 
alpha-adrenoreceptor blocking agents used both in the management of 
urinary obstruction and hypertension (e.g. doxazosin) are classified in 
C02CA.  
 
G04CB Testosterone-5-alpha reductase inhibitors 
 
Combinations/combination packages with alpha-adrenoreceptor 
antagonists are classified in G04CA. 
 
G04CX Other drugs used in benign prostatic hypertrophy 
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H  SYSTEMIC HORMONAL PREPARATIONS, EXCL. 
SEX HORMONES AND INSULINS 
 
H01  PITUITARY AND HYPOTHALAMIC HORMONES AND 
ANALOGUES 
A Anterior pituitary lobe hormones and analogues 
B Posterior pituitary lobe hormones 
C Hypothalamic hormones 
 
H02  CORTICOSTEROIDS FOR SYSTEMIC USE 
A Corticosteroids for systemic use, plain 
B Corticosteroids for systemic use, combinations  
C Antiadrenal preparations 
 
H03  THYROID THERAPY 
A Thyroid preparations 
B Antithyroid preparations 
C Iodine therapy 
 
H04  PANCREATIC HORMONES 
A Glycogenolytic hormones 
 
H05  CALCIUM HOMEOSTASIS 
A Parathyroid hormones and analogues 
B Anti-parathyroid agents 
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H  SYSTEMIC HORMONAL PREPARATIONS, EXCL. 
SEX HORMONES AND INSULINS 
 
This group comprises all hormonal preparations for systemic use, 
except:  
 
- Insulins, see A10. 
- Anabolic steroids, see A14. 
- Catecholamines, see C01C and R03C. 
- Sex hormones, see G03. 
- Sex hormones used in treatment of neoplastic diseases, see L02. 
- Metreleptin used for treatment of complications of leptin deficiency in 
patients with generalised lipodystrophy is classified in A16AA. 
 
The DDDs are generally based on the treatment or diagnosis of 
endocrine disorders. 
 
 
H01  PITUITARY AND HYPOTHALAMIC HORMONES AND 
ANALOGUES 
 
H01A  ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES 
 
This group comprises anterior pituitary lobe hormones; extracts, 
purified natural hormones and synthetic analogues. 
 
Somatropin antagonists are classified in H01AX. 
 
H01AA  ACTH 
 
This group comprises ACTH and synthetic analogues. 
 
The DDD of corticotrophin is based on therapy, whereas that of 
tetracosactide is based on use as a diagnostic agent. 
 
H01AB  Thyrotropin 
 
Biological thyrotropin is also classified in H01AB01. Thyrotropin 
products approved for diagnostic purposes only are classified in 
V04CJ. 
 
The DDD for biological thyrotropin classified in H01AB01 is 5 U. 
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H01AC  Somatropin and somatropin agonists 
 
Mecasermin (insulin like growth factor) is classified in this group since 
it is used on the same indications as somatropin and somatrem. High 
strength preparations of sermorelin are classified here. 
Low strength preparations used as diagnostic agents for pituitary 
function are classified in V04CD. 
 
Tesamorelin used in the treatment of HIV patients with lipodystrophy is 
classified in this group. 
 
 
The DDDs are based on the treatment of growth retardation in children 
with a body weight of 25 kg. 
 
H01AX Other anterior pituitary lobe hormones and analogues 
 
 Somatropin antagonists are classified here. 
 
 
H01B  POSTERIOR PITUITARY LOBE HORMONES 
 
This group comprises posterior pituitary lobe hormones; extracts, 
purified natural hormones and synthetic analogues. 
 
H01BA  Vasopressin and analogues 
 
The DDDs are based on the treatment of diabetes insipidus. 
 
The DDD for terlipressin is based on treatment of bleeding 
oesophageal varices. 
 
H01BB  Oxytocin and analogues 
 
Oxytocin and analogues in combination with ergot alkaloids are 
classified in G02A - Uterotonics  
 
The DDDs are based on use in delivery. 
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H01C HYPOTHALAMIC HORMONES 
 
This group comprises hypothalamic hormones; extracts, purified natural 
hormones and synthetic analogues. 
 
Hypothalamic hormones used as diagnostic agents for pituitary function 
are classified in V04CD. 
 
H01CA  Gonadotropin-releasing hormones 
 
Buserelin, goserelin, histrelin, leuprorelin, and triptorelin are classified 
in L02AE Gonadotropin releasing hormone analogues. 
 
Gonadorelin used as diagnostic agent is classified in V04CM. 
 
The DDD of nafarelin is based on the treatment of endometriosis.  No 
other DDDs have been assigned, due to the highly variable dosages 
used. 
 
H01CB  Somatostatin and analogues 
 
Somatostatin, octreotide and lanreotide, which are also used in cancer, 
are classified in this group. 
 
The DDDs of octreotide and lanreotide are based on the treatment of 
acromegaly. 
 
H01CC Anti-gonadotropin-releasing hormones 
 
 
H02  CORTICOSTEROIDS FOR SYSTEMIC USE 
 
As a main rule, systemic corticosteroids should be classified in this 
group.  There is, however, one exception:  M01BA - Antiinflam-
matory/antirheumatic agents in combination with corticosteroids. 
 
Corticosteroids for local oral treatment, see A01AC. 
 
Enemas and rectal foams for local treatment of e.g. ulcerative colitis, 
see A07E. 
 
Corticosteroids for topical use, see D07. 
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Combined corticosteroid preparations for local treatment of acne, see 
D10AA. 
 
Corticosteroids in combination with antiinfectives/antiseptics for local 
treatment of gynecological infections, see G01B. 
 
Corticosteroids for nasal use, see R01AD. 
Corticosteroids for inhalation, see R03BA. 
 
Corticosteroids, eye/ear preparations, see S. 
 
 
H02A  CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN 
 
Only plain preparations are classified in this group.  The group also 
includes corticosteroid preparations for local injection. 
 
H02AA  Mineralocorticoids 
 
The DDDs are based on substitution therapy in Addison's disease. 
 
H02AB  Glucocorticoids 
 
Oral formulations used solely in local treatment are classified in 
A07EA. 
 
Depot preparations may have different DDDs, compared to other 
formulations, due to different indications.  
 
 
H02B  CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS 
 
This group comprises all combined preparations, e.g. combinations with 
local anesthetics.   
 
No DDDs have been assigned. 
 
H02BX  Corticosteroids for systemic use, combinations 
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H02C  ANTIADRENAL PREPARATIONS 
 
H02CA Anticorticosteroids 
 
Trilostane used in Cushing's syndrome is classified in this group. 
 
Mifeprostone used in Cushing’s syndrome is classified in G03XB. 
 
Metyrapone used in Cushing’s syndrome is classified in V04CD. 
 
Ketoconazole used in Cushing´s syndrome is classified in J02AB. 
 
The DDD of trilostan is based on the treatment of Cushing's syndrome. 
 
 
H03  THYROID THERAPY 
 
H03A  THYROID PREPARATIONS 
 
This group comprises thyroid extracts and synthetic analogues used in 
the treatment of hypothyrosis. 
 
The DDDs are based on the treatment of hypothyrosis. 
 
H03AA  Thyroid hormones 
 
This group comprises natural and synthetic thyroid hormones. 
Combinations of levothyroxine and liothyronine are classified at a 
separate 5th level: H03AA03. 
 
Liothyronine hydrochloride is classified in H03AA02. 
 
 
H03B  ANTITHYROID PREPARATIONS 
 
This group comprises preparations used in the treatment of 
hyperthyrosis. 
 
The DDDs are based on the treatment of hyperthyrosis. 
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H03BA  Thiouracils 
 
H03BB  Sulfur-containing imidazole derivatives 
 
H03BC  Perchlorates 
 
H03BX  Other antithyroid preparations 
 
 
H03C  IODINE THERAPY 
 
This group comprises iodine preparations for systemic use. 
 
H03CA  Iodine therapy 
 
The DDDs are based on systemic therapy in thyroid disease. The DDD 
is given in amount of iodide. 
 
 
H04  PANCREATIC HORMONES 
 
H04A  GLYCOGENOLYTIC HORMONES 
 
H04AA  Glycogenolytic hormones 
 
The pancreas glycogenolytic hormone glucagon is classified in this 
group. 
 
Diazoxide, which is also used for treatment of hypoglycemia, is 
classified in C02DA01 and V03AH01. 
 
Insulins are classified in A10A. 
 
The DDD of glucagon is based on single dose treatment of 
hypoglycemia. 
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H05  CALCIUM HOMEOSTASIS 
 
Drugs acting on calcium homeostasis are classified in this group. 
 
Vitamin-D preparations, see A11CC. 
 
 
H05A  PARATHYROID HORMONES AND ANALOGUES 
 
H05AA  Parathyroid hormones and analogues 
 
Extracts from parathyroid glands are classified in this group. 
 
 
H05B  ANTI-PARATHYROID AGENTS 
 
H05BA  Calcitonin preparations 
 
Calcitonin, natural and synthetic, is classified in this group.  Other 
drugs for treatment of hypercalcemia, see M05B. 
 
The DDDs of the calcitonins are based on the treatment of Paget's 
disease.  
 
H05BX Other anti-parathyroid agents 
 
Paricalcitol and doxercalciferol indicated for the prevention and 
treatment of secondary hyperparathyroidism are classified here.  
 
Modified-release oral formulations of calcifediol indicated for the 
treatment of hyperparathyroidism are classified in A11CC06. 
 
The DDD for cinacalcet is based on the treatment of secondary 
hyperparathyroidism. 
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J   ANTIINFECTIVES FOR SYSTEMIC USE 
 
J01  ANTIBACTERIALS FOR SYSTEMIC USE 
A  Tetracyclines 
B  Amphenicols 
C  Beta-lactam antibacterials, penicillins 
D  Other beta-lactam antibacterials 
E Sulfonamides and trimethoprim 
F  Macrolides, lincosamides and streptogramins 
G  Aminoglycoside antibacterials 
M Quinolone antibacterials 
R Combinations of antibacterials 
X Other antibacterials 
 
J02  ANTIMYCOTICS FOR SYSTEMIC USE 
A  Antimycotics for systemic use 
 
J04  ANTIMYCOBACTERIALS 
A  Drugs for treatment of tuberculosis 
B Drugs for treatment of lepra 
 
J05  ANTIVIRALS FOR SYSTEMIC USE 
A  Direct acting antivirals 
 
J06  IMMUNE SERA AND IMMUNOGLOBULINS 
A  Immune sera 
B  Immunoglobulins 
 
J07  VACCINES 
A  Bacterial vaccines 
B Viral vaccines 
C Bacterial and viral vaccines, combined 
X Other vaccines 
 168 
J ANTIINFECTIVES FOR SYSTEMIC USE 
 
Antiinfectives are also classified in the following groups: 
 
A01AB Antiinfectives and antiseptics for local oral treatment 
A02BD Combinations for eradication of Helicobacter pylori 
A07A Intestinal antiinfectives 
D01 Antifungals for dermatological use 
D06 Antibiotics and chemotherapeutics for dermatological use 
D07C Corticosteroids, combinations with antibiotics 
D09AA Ointment dressings with antiinfectives 
D10AF Antiinfectives for treatment of acne 
G01 Gynecological antiinfectives and antiseptics 
P  Antiparasitic products, insecticides and repellents 
R02AB Antibiotics 
R05X Other cold preparations 
S01/ 
S02/ 
S03 Eye and ear preparations with antiinfectives 
 
Even systemically administered antibacterials and antimycotics may be 
classified in other groups if their target is exclusively local, e.g. the 
skin - D01 - Antifungals for dermatological use 
 
Inhaled antiinfectives are classified in J. 
 
The DDDs for the antiinfectives are as a main rule based on the use in 
infections of moderate severity.  However, some antiinfectives are 
only used in severe infections and their DDDs are assigned 
accordingly.  The DDDs assigned are based on daily treatment.  The 
duration of the treatment periods is not taken into consideration.  For 
antiinfectives given in a high initially starting dose followed by a 
lower daily "maintenance" dose, the DDDs are based on the 
"maintenance" dose if the total duration of the treat-ment course is 
more than one week.  If, however, the treatment course is 7 days or 
less, the DDDs are assigned according to the average daily dose i.e. 
the total course dose divided by the number of treatment days (e.g 
azithromycin). 
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J01 ANTIBACTERIALS FOR SYSTEMIC USE 
 
This group comprises antibacterials for systemic use, except anti-
mycobacterials, which are classified in J04.  The antibacterials are 
classified according to their mode of action and chemistry. 
 
Combinations of two or more systemic antibacterials from different 
third levels are classified in J01R, except combinations of sulfonamides 
and trimethoprim, which are classified at a separate 4th level, J01EE. 
 
Combinations of antibacterials and tuberculostatics are classified in 
J04AM. 
 
Combinations of antibacterials with other drugs, including local 
anesthetics or vitamins, are classified at separate 5th levels in the 
respective antibacterial group by using the 50-series.  Common cold 
preparations containing minimal amounts of antibacterials are classified 
in R05X. 
 
Inhaled antiinfectives are classified here based on the fact that 
preparations for inhalation can not be separated from preparations for 
injection. 
 
 
 
J01A TETRACYCLINES 
 
J01AA Tetracyclines 
 
This group comprises tetracycline antibacterials inhibiting the bacterial 
protein synthesis through binding to the 30-S part of ribosomes. 
 
The tetracyclines have different DDDs due to kinetic differences.  The 
use of tetracyclines in long-term, low dose treatment of acne is not 
taken into account in the assignment of DDDs. 
 
 
J01B AMPHENICOLS 
 
J01BA Amphenicols 
 
This group comprises amphenicol antibacterials inhibiting the bacterial 
protein synthesis. 
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Thiamphenicol acetylcysteinate glycinate for inhalation is classified in 
J01BA52. 
 
 
J01C BETA-LACTAM ANTIBACTERIALS, PENICILLINS 
 
This group comprises penicillin beta-lactam antibacterials, inhibiting 
the bacterial cell wall synthesis.  Combinations of penicillins from 
different 4th levels, including beta-lactamase inhibitors, are classified in 
J01CR. 
 
J01CA Penicillins with extended spectrum 
 
This group comprises penicillins with enhanced activity against gram 
negative rods, e.g. ampicillin and similar antibiotics. 
 
The esters, for instance pivampicillin and pivmecillinam, have a higher 
bioavailability and thus a lower DDD than the corresponding non-ester 
compounds. 
 
The DDDs for some of the compounds, for instance carbenicillin, 
piperacillin, ticarcillin and sulbenicillin, are based on the dosages used 
for narrow indications, i.e. life threatening infections. 
 
J01CE Beta-lactamase sensitive penicillins 
 
Benzylpenicillin and phenoxymethylpenicillin have different DDDs 
due to differences in indications, route of administration and 
bioavailability.  The DDDs for the combination of benzylpenicillin and 
procaine penicillin is based on the treatment of syphilis, see list of 
DDDs for combination products, www.whocc.no.  
 
J01CF Beta-lactamase resistant penicillins 
 
J01CG Beta-lactamase inhibitors 
 
The DDD for sulbactam is based on its use together with ampicillin, 
usually in a dose ratio of 1:2 respectively. 
 
J01CR Combinations of penicillins, incl. beta-lactamase inhibitors 
 
This group comprises combinations of penicillins and/or beta-lactamase 
inhibitors.  Combinations containing one penicillin and enzyme 
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inhibitor are classified at different 5th levels according to the penicillin.  
Combinations of two or more penicillins with or without enzyme 
inhibitor are classified at a separate 5th level, J01CR50.  Sultamicillin, a 
prodrug for sulbactam and ampicillin, is given a separate 5th level code: 
J01CR04. 
 
The DDD for sultamicillin, a prodrug for sulbactam and ampicillin, is 
lower than the corresponding DDD for the ordinary combination due 
to higher bioavailability. 
 
 
J01D OTHER BETA-LACTAM ANTIBACTERIALS 
 
This group comprises beta-lactam antibacterials, other than penicillins. 
 
The cephalosporins are classified into subgroups according to 
generations.  The reference applied when defining generations is 
“Principles and Practice of Infectious Diseases” by Mandell, Douglas 
and Benett, sixth edition, 2005.  For the definitions used in this 
textbook, see under J01DB, J01DC, J01DD and J01DE. 
 
Combinations with beta-lactamase inhibitors are classified by using the 
50-series. 
 
The cephalosporins are used in highly variable dosages for different 
indications, which should be reflected in the assigned DDDs.  The 
indications for use of the cephalosporins (i.e. the severity of the 
infections) vary rather extensively from one country to another.  The 
assigned DDDs are placed in the upper area of the dose range for 
moderate to severe infections.  
 
J01DB First-generation cephalosporins 
 
The first generation compounds have relatively narrow spectrum of 
activity focused primarily on the gram-positive cocci. 
 
J01DC Second-generation cephalosporins 
 
The second generation cephalosporins have a variable activity against 
gram-positive cocci but have increased activity against gram-negative 
bacteria.  The cephamycin group is included in the second-generation 
cephalosporins. 
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J01DD Third-generation cephalosporins 
 
The third generation cephalosporins have a marked activity against 
gram-negative bacteria. Limited activity against gram-positive cocci, 
particularly methicillin susceptible S. aureus, might occur. 
 
J01DE Fourth-generation cephalosporins 
 
The fourth generation cephalosporins have activity against gram-
positive cocci and a broad array of gram-negative bacteria, including P. 
aeruginosa and many of the Enterobacteriaceae with inducible 
chromosomal -lactamases. 
 
J01DF Monobactams 
 
Arginin and lysine salts of aztreonam are classified in J01DF01; thus 
aztreonam for inhalation is classified together with systemic 
formulations. 
 
J01DH Carbapenems 
 
J01DI Other cephalosporins and penems 
 
 
J01E SULFONAMIDES AND TRIMETHOPRIM 
 
This group comprises systemic sulfonamide and trimethoprim 
preparations.  Combinations of sulfonamide and trimethoprim are 
classified in J01EE.  Preparations containing two or more sulfonamides 
are classified within the different 4th levels, using the 5th level code 20.  
 
In such combinations, the half-life of the most long-acting sulfonamide 
determines the classification.  Sulfonamides in combinations with other 
antibacterials (excl. trimethoprim) are classified in J01R.  Dapsone is 
classified in J04 - Antimycobacterials. See also A07A - Intestinal 
antiinfectives. 
 
Preparations, which in addition contain a urine acidifier, such as 
vitamin C, calcium- or ammonium chloride, are classified at the plain 
5th levels. 
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The DDDs for the sulfonamides are related to the duration of effect, 
i.e. usually the long-acting sulfonamides will have lower DDDs than 
the short-acting. 
 
J01EA Trimethoprim and derivatives 
 
The DDDs are based on the treatment of acute urinary-tract infections. 
 
J01EB Short-acting sulfonamides 
 
This group comprises sulfonamides with a biological half-life not 
exceeding approx. 7 hours. 
 
J01EC Intermediate-acting sulfonamides 
 
This group comprises sulfonamides with a biological half-life of 
approx. 11-12 hours. 
 
J01ED Long-acting sulfonamides 
 
This group comprises sulfonamides with a biological half-life of 
approx. 35 hours or more. 
 
J01EE Combinations of sulfonamides and trimethoprim, incl. derivatives 
 
When establishing DDDs for combination products, both components 
are taken into consideration, see list of DDDs for combination 
products, www.whocc.no. 
 
 
J01F MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS 
 
This group comprises macrolide, lincosamide and streptogramin 
antibacterials inhibiting bacterial protein synthesis through binding to 
the 50-S part of the ribosomes. 
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J01FA Macrolides 
 
Erythromycin ethylsuccinate tablets have been assigned a higher DDD 
than other preparations of erythromycin due to a lower bioavailability.  
This DDD is mainly based on the dose recommendations. 
 
The oral DDD for azithromycin is based on a 5-day regimen. 
 
J01FF Lincosamides 
 
Orally and parenterally administered clindamycin have different 
DDDs due to different indications, i.e. the intestinal and systemic 
infections, respectively. 
 
J01FG Streptogramins 
 
The streptogramin components dalfopristin/quinupristin are 
semisynthetic derivatives of pristinamycin.  The two components have 
synergistic antibacterial effect and are always used together.  
Quinupristin/dalfopristin are therefore classified at the ATC plain level 
J01FG02. 
 
 
J01G AMINOGLYCOSIDE ANTIBACTERIALS 
 
This group comprises aminoglycoside antibacterials disturbing the 
bacterial protein synthesis through binding to the 30-S part of the 
ribosomes. 
 
J01GA Streptomycins 
 
Streptomycins in combination with antimycobacterials are classified in 
J04AM. 
 
J01GB Other aminoglycosides 
 
 Tobramycin for inhalation is classified together with systemic 
formulations in J01GB01. 
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The DDDs for the aminoglycosides are based on use in severe 
infections. 
 
 
J01M QUINOLONE ANTIBACTERIALS 
 
This group comprises quinolone antibacterials, inhibiting the bacterial 
DNA-gyrase.   
 
J01MA Fluoroquinolones 
 
Flumequine is classified in J01MB. 
 
The DDDs for the fluoroquinolones are mainly based on the treatment 
of respiratory tract infections. 
The DDDs for pefloxacin, enoxacin and norfloxacin are based on the 
treatment of complicated urinary tract infections. 
 
J01MB Other quinolones  
 
Preparations, which in addition contain a urine acidifier, such as 
vitamin C, calcium- or ammonium chloride, are classified at the plain 
5th levels. 
 
The DDDs are generally based on the treatment of acute urinary tract 
infections.  The DDD for rosoxacin is based on single dose treatment 
of gonorrhoea. 
 
 
J01R COMBINATIONS OF ANTIBACTERIALS 
 
This group comprises combinations of two or more antibacterials for 
systemic use from different ATC 3rd levels. 
 
The detailed classification of antibacterial combinations in J01RA is 
based on the general concern with the use of antibacterials worldwide 
and the need for drug monitoring, incl. mapping of the use with 
resistance patterns. 
 
J01RA Combinations of antibacterials 
 
Combinations of urinary antiseptics and antiinfectives are classified in 
J01RA02. 
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J01X OTHER ANTIBACTERIALS 
 
This group comprises antibacterials with various modes of action not 
classified in the preceding groups. 
 
J01XA Glycopeptide antibacterials 
 
This group comprises glycopeptide antibacterials, inhibiting the cell 
wall synthesis of gram positive bacteria.  Teicoplanin and intravenous 
preparations of vancomycin are classified in this group.  Oral 
formulations containing vancomycin are classified in A07A. 
 
J01XB Polymyxins 
 
This group comprises polymyxin antibacterials acting on the bacterial 
cytoplasm membrane.  Oral formulations containing colistin are 
classified in A07A. 
 
J01XC Steroid antibacterials 
 
This group comprises steroid antibacterials, inhibiting the binding of 
bacterial transfer-RNA and the 50-S part of the ribosomes.   
 
J01XD Imidazole derivatives 
 
This group comprises imidazole antibacterials acting through active 
metabolites in anaerobic bacteria.  Only formulations for parenteral use 
of e.g. metronidazole are classified in this group.  Oral formulations and 
suppositories of imidazole derivatives are classified in P01 - 
Antiprotozoals.  Pessaries are classified in G01 - Gynecological 
antiinfectives and antiseptics. 
 
The DDDs for the parenteral imidazole formulations are based on the 
treatment of anaerobic bacteria infections. 
 
J01XE Nitrofuran derivatives 
 
Preparations, which in addition contain a urine acidifier, such as 
vitamin C, calcium- or ammonium chloride, are classified at the plain 
5th levels. 
 
Nitrofurantoin in combination with phenazopyridine is classified in 
J01XE51.  
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The DDDs are generally based on the treatment of acute urinary tract 
infections. 
 
J01XX Other antibacterials 
 
Preparations, which in addition contain a urine acidifier, such as 
vitamin C, calcium- or ammonium chloride, are classified at the plain 
5th levels. 
 
The parenteral DDD for fosfomycin is based on the use of a single 
prophylactic dose in connection with surgery, whilst the oral DDD is 
based on treatment of uncomplicated lower urinary tract infections 
given as a single dose of fosfomycin trometamol. 
 
The DDD for spectinomycin is based on the use of a single dose for 
treatment of uncomplicated gonorrhea. 
 
The DDD for methenamine is based on prophylaxis of urinary tract 
infections.  The DDDs for mandelic acid and nitroxoline are based on 
the treatment of acute urinary tract infections. 
 
 
J02 ANTIMYCOTICS FOR SYSTEMIC USE 
 
J02A ANTIMYCOTICS FOR SYSTEMIC USE 
 
This group does not include antimycotics specifically for dermato-
logical use even if they are administered systemically (see D01B). 
 
Antimycotics - see also: 
 
A01AB  Antiinfectives and antiseptics for local oral treatment 
A07A  Intestinal antiinfectives 
D01 Antifungals for dermatological use 
G01 Gynecological antiinfectives and antiseptics 
 
Fumagillin used in the treatment of intestinal microsporidiosis is 
classified in P01AX. 
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J02AA Antibiotics 
 
The DDD for amphotericin B is based on the conventional 
formulation.  Dosages of other formulations (e.g. liposomal) of 
amphotericin B may vary considerably.  This should be taken into 
consideration when comparing drug use. 
 
J02AB Imidazole derivatives 
 
Ketaconazole used in patients with Cushing´s syndrome is also 
classified in this group. 
 
J02AC Triazole derivatives 
 
All oral and parenteral formulations of fluconazole are classified here.  
Vaginal formulations of triazole derivatives, see G01AG. 
 
J02AX Other antimycotics for systemic use 
 
 
J04 ANTIMYCOBACTERIALS 
 
This group comprises drugs mainly used for the treatment of tuber-
culosis or lepra.  However, streptomycins are classified in J01G - 
Aminoglycoside antibacterials.  Streptomycin in combination with 
antimycobacterials are classified in J04AM. 
 
 
J04A DRUGS FOR TREATMENT OF TUBERCULOSIS 
 
The DDDs are based on combination therapy in the treatment of 
tuberculosis. DDDs for combination products see www.whocc.no. 
 
J04AA Aminosalicylic acid and derivatives 
 
J04AB Antibiotics 
 
This group comprises antibiotics specifically used in tuberculosis, 
except streptomycin - see comment under J04AM.  Other antibiotics, 
see J01 -Antibacterials for systemic use. 
 
The DDD for rifapentine is based on the first 6 months treatment 
period, including both the initial phase and the continuous phase. 
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J04AC Hydrazides 
 
Combinations of isoniazid and rifampicin or other tuberculostatics are 
classified in J04AM. 
 
J04AD Thiocarbamide derivatives 
 
J04AK Other drugs for treatment of tuberculosis 
 
J04AM Combinations of drugs for treatment of tuberculosis 
 
Combinations of drugs classified in J04AA - J04AK are classified in 
this group (e. g. isoniazid + rifampicin).  Combinations of 
antimycobacterials and streptomycin are classified in this group while 
plain streptomycin is classified in J01GA - Streptomycins. 
 
 
J04B DRUGS FOR TREATMENT OF LEPRA 
 
J04BA Drugs for treatment of lepra 
 
Thalidomide, which is also used for treatment of lepra, is classified in 
L04AX. 
 
 
J05 ANTIVIRALS FOR SYSTEMIC USE 
 
This group comprises specific antiviral agents, excl. vaccines.   
 
Antivirals for dermatological use, see D06BB. 
Antivirals for ophthalmological use, see S01A - Antiinfectives. 
 
Amantadine, which is also used as an antiviral agent, is classified in 
N04BB. 
 
 
J05A DIRECT ACTING ANTIVIRALS 
 
This group comprises agents acting directly on the virus. 
 
J05AA Thiosemicarbazones 
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J05AB Nucleosides and nucleotides excl. reverse transcriptase inhibitors 
 
Ribavirin is classified in J05AP. 
 
The combinations of ribavirin and peginterferon alfa-2a or 
peginterferon alfa-2b are classified in L03AB. 
 
 
The DDDs for aciclovir, valaciclovir and famciclovir are based on the 
treatment of herpes zoster infections. 
 
The DDD for ribavirin is based on the treatment of respiratory syncytial 
viral (RSV) infections in neonates and infants. 
 
The DDD for ganciclovir is based on the treatment of cytomegalovirus 
infections in immunosuppressed patients.  
 
The DDD for cidofovir is based on the treatment of CMV-retinitis in 
AIDS patients. 
 
J05AC Cyclic amines 
 
Amantadine is classified in N04 - Anti-Parkinson drugs. 
 
J05AD Phosphonic acid derivatives 
 
The DDD for foscarnet is based on the treatment of CMV-retinitis in 
AIDS patients. 
 
J05AE Protease inhibitors 
 
The DDDs are based on combination therapy in HIV infections. 
 
The DDDs for atazanavir and fosamprenavir are based on combination 
therapy with ritonavir as a pharmacokinetic enhancer. 
 
The DDD for saquinavir is based on the dose recommendations for 
hard capsules. 
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J05AF Nucleoside and nucleotide reverse transcriptase inhibitors 
 
The DDDs are based on combination therapy in HIV infections. 
 
The DDD for tenofovir disoproxil is 245 mg and is equivalent to 300 
mg tenofovir disoproxil fumarat. 
 
The DDDs for entecavir and telbivudine are based on monotherapy in 
the treatment of chronic hepatitis B virus infections. 
 
J05AG Non-nucleoside reverse transcriptase inhibitors 
 
The DDDs are based on combination therapy in HIV infections. 
 
J05AH Neuraminidase inhibitors 
 
All neuraminidase inhibitors are classified here, regardless of 
formulation. 
 
The DDD of oseltamivir is based on the treatment of influenza. 
 
J05AP Antivirals for treatment of HCV infections 
 
This group includes both single substances and combinations. 
 
J05AR Antivirals for treatment of HIV infections, combinations 
  
Combinations with pharmacokinetic enhancers are classified in this 
group, regardless of their antiviral effect. Plain products with cobicistat 
are classified in V03AX. 
 
See list of DDDs for combination products, www.whocc.no.  
 
J05AX Other antivirals 
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J06 IMMUNE SERA AND IMMUNOGLOBULINS 
 
No DDDs have been assigned, except for nebacumab in J06BC01. 
 
 
J06A IMMUNE SERA 
 
J06AA Immune sera 
 
This group comprises specific antisera. 
J06B IMMUNOGLOBULINS 
 
This group comprises normal human immunoglobulins and specific 
immunoglobulins. 
 
J06BA Immunoglobulins, normal human 
 
Products containing immunoglobulin and hyaluronidase are classified 
in J06BA01. 
 
J06BB Specific immunoglobulins 
 
Combinations with vaccines are classified in J07. 
 
J06BC Other immunoglobulins 
 
 
J07 VACCINES 
 
The vaccines are divided in bacterial, viral and combinations of 
bacterial and viral at separate ATC 3rd levels.  Subdivision at the 4th 
level is made mainly according to indication, while subdivision at the 
5th level is mainly related to the manufacturing process.  Combinations 
of vaccines within the same 3rd level are given separate 5th levels using 
the 50-series.  5th levels may contain adjuvans. 
 
See comments under the 4th levels. 
 
No DDDs have been assigned. 
 
 
  
 183 
J07A BACTERIAL VACCINES 
 
J07AC Anthrax vaccines 
 
J07AD Brucellosis vaccines 
 
J07AE Cholera vaccines 
 
Combinations with typhoid vaccine are classified in this group. 
 
J07AF Diphtheria vaccines 
 
Different strengths of the diphtheria vaccines are classified at the same 
5th level.  Combinations with tetanus vaccine are classified in J07AM.  
Combinations with both tetanus and pertussis are classified in J07AJ. 
 
Combinations with hemophilus influenza and tetanus vaccines are 
classified in J07AG. 
 
Combinatins with poliomyelitis and/or rubella are classified in J07CA. 
  
J07AG Hemophilus influenzae B vaccines 
 
Combinations with diphtheria and tetanus vaccines are classified here. 
 
Combinations with pertussis and toxoids are classified here. 
Combinations with poliomyelitis are classified in J07CA. 
 
J07AH Meningococcal vaccines 
 
Meningococcal vaccines are classified at separate 5th levels according 
to the number of serotypes of neisseria meningitis contained in the 
vaccine. Monovalent vaccines obtained from group A are classified at a 
separate 5th level, while other monovalent vaccines are classified 
together. 
 
Products containing oligosaccharides instead of polysaccharides may be 
included at each 5th level. 
 
J07AJ Pertussis vaccines 
 
Combinations with tetanus and/or diphtheria vaccine are classified in 
this group. 
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Combinations with hemophilus influenzae B are classified in J07AG. 
 
Combinations with polimyelitis are classified in J07CA. 
 
J07AK Plague vaccines 
 
J07AL Pneumococcal vaccines 
 
J07AM Tetanus vaccines 
 
Combinations with tetanus immunoglobulin are classified in this group. 
Combinations with diphtheria and/or typhoid vaccines are classified in 
J07AM51.   
 
Combinations with diphtheria and pertussis vaccines are classified in 
J07AJ. 
 
Combinations with hemophilus influenza and diphteria vaccines are 
classified in J07AG. 
 
Combinations with poliomyelitis and/or rubella are classified in J07CA. 
 
J07AN Tuberculosis vaccines 
 
J07AP Typhoid vaccines 
 
Combinations with tetanus vaccine, also when including diphtheria 
vaccine, are classified in J07AM. 
 
J07AR Typhus (exanthematicus) vaccines 
 
J07AX Other bacterial vaccines 
 
This group comprises bacterial vaccines, which cannot be classified in 
the preceding groups, e.g. Q fever vaccine. 
 
 
J07B VIRAL VACCINES 
 
J07BA Encephalitis vaccines 
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J07BB Influenza vaccines 
 
Split virus vaccine is classified in J07BB02 together with surface 
antigen. 
 
J07BC Hepatitis vaccines 
 
Recombinant and plasma derived hepatitis vaccines are classified at the 
same 5th level. 
 
Therapeutic vaccines for chronic hepatitis B are classified in J07BC01. 
 
J07BD Measles vaccines 
 
Combinations with mumps and/or rubella are classified in this group. 
 
J07BE Mumps vaccines 
 
Combinations with measles vaccine, with or without rubella, are 
classified in J07BD.  Combinations with rubella vaccine are classified 
in J07BJ. 
 
J07BF Poliomyelitis vaccines 
 
Poliomyelitis vaccines are classified according to the number of virus 
types included and according to administration form, i.e. oral or 
parenteral. 
 
Combinations with diphteria/tetanus/pertussis and/or Hemophilus 
influenzae B are classified in J07CA. 
 
J07BG Rabies vaccines 
 
J07BH Rota virus diarrhea vaccines 
 
J07BJ Rubella vaccines 
 
Combinations with mumps vaccine are classified in this group. 
Combinations with measles vaccine, with or without mumps vaccine, 
are classified in J07BD.   
 
Combinations with diphteria and tetanus are classified in J07CA. 
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J07BK Varicella zoster vaccines 
 
J07BL Yellow fever vaccines 
 
J07BM Papillomavirus vaccines 
 
J07BX Other viral vaccines 
 
 
J07C BACTERIAL AND VIRAL VACCINES, COMBINED 
 
J07CA Bacterial and viral vaccines, combined 
 
Combinations including bacterial and viral vaccines are classified at 
separate 5th levels.  No specific system for subdivision is established. 
 
 
J07X OTHER VACCINES 
 
No 4th levels are assigned in this group. 
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L ANTINEOPLASTIC AND IMMUNOMODULATING 
AGENTS 
 
L01  ANTINEOPLASTIC AGENTS 
A Alkylating agents 
B Antimetabolites 
C Plant alkaloids and other natural products 
D Cytotoxic antibiotics and related substances 
X Other antineoplastic agents 
 
L02  ENDOCRINE THERAPY 
A Hormones and related agents 
B Hormone antagonists and related agents 
 
L03  IMMUNOSTIMULANTS 
A Immunostimulants 
 
L04 IMMUNOSUPPRESSANTS 
A Immunosuppressants 
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L  ANTINEOPLASTIC AND IMMUNOMODULATING 
AGENTS 
 
This group comprises preparations used in the treatment of malignant 
neoplastic diseases, and immunomodulating agents.   
 
Corticosteroids for systemic use, see H02. 
 
 
L01  ANTINEOPLASTIC AGENTS 
 
Combination products are classified in L01XY - Combinations of 
antineoplastic agents. 
 
Detoxifying agents used in connection with high dose treatment of 
antineoplastic agents are classified in V03AF (e.g. calcium folinate). 
 
Radium-223 dichloride used in the treatment of cancer is classified in 
V10XX. 
 
No DDDs have been established because of highly individualised use 
and wide dosage ranges.  The doses used vary substantially because of 
various types and severity of neoplastic diseases, and also because of 
the extensive use of combination therapy. 
 
The consumption of the antineoplastic agents is in some countries 
measured in grams.  This is recommended as a method to be used 
internationally for these particular agents. 
 
 
L01A  ALKYLATING AGENTS 
 
L01AA  Nitrogen mustard analogues 
 
L01AB  Alkyl sulfonates 
 
L01AC  Ethylene imines 
 
L01AD  Nitrosoureas 
 
L01AG  Epoxides 
 
L01AX  Other alkylating agents 
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L01B  ANTIMETABOLITES 
 
L01BA  Folic acid analogues 
 
Trimetrexate is classified in P01AX - Other agents against amoebiasis 
and other protozoal agents. 
 
Oral formulations and pre-filled syringe/pen of methotrexate for use in 
non-cancer indications are classified in L04AX03. 
 
L01BB  Purine analogues 
 
Parenteral formulations of cladribine used in cancer are classified in this 
group, while oral formulations for multiple sclerosis are classified in 
L04AA. 
 
L01BC  Pyrimidine analogues  
 
Fluorouracil for systemic and local treatment is classified here. 
 
 
L01C  PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS 
 
L01CA  Vinca alkaloids and analogues 
 
Synthetic analogues are also classified in this group. 
 
L01CB  Podophyllotoxin derivatives 
 
Antivirals for topical use, e.g. podophyllotoxin, see D06BB - Antivirals. 
 
L01CC  Colchicine derivatives  
 
Colchicine is classified in M04AC01. 
 
L01CD Taxanes 
 
 L01CD01- paclitaxel includes solvent based paclitaxel and paclitaxel 
albumin. 
 
L01CX Other plant alkaloids and natural products 
 
 
  
 190 
L01D  CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES 
 
L01DA  Actinomycines 
 
L01DB  Anthracyclines and related substances 
 
L01DC  Other cytotoxic antibiotics 
 
 
L01X  OTHER ANTINEOPLASTIC AGENTS 
 
This group comprises antineoplastic preparations which cannot be 
classified in the preceding groups. 
 
L01XA Platinum compounds 
 
L01XB  Methylhydrazines 
 
L01XC Monoclonal antibodies 
 
Monoclonal antibodies indicated only for the treatment of cancer are 
classified in L01XC. 
 
Anecortave, indicated for the treatment of exudative age-related 
macular degeneration, is classified in S01XA - Other 
ophthalmologicals. 
 
Dinutuximab and dinutuximab beta are classified at the same 5th level.. 
 
L01XD Sensitizers used in photodynamic/radiation therapy 
 
L01XE Protein kinase inhibitors 
 
L01XX  Other antineoplastic agents  
 
Also antineoplastic agents for dermatological use are classified here. 
 
All asparaginases regardless of origins are classified in L01XX02. 
 
The 50-serie codes are used for single substances due to lack of 
numbers. 
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L01XY  Combinations of antineoplastic agents 
 
All combinations of antineoplastic agents in L01 - Antineoplastic 
agents are classified in this group. 
 
 
L02  ENDOCRINE THERAPY 
 
Estrogens and progestogens used specifically in the treatment of 
neoplastic diseases are classified in this group.  This means that some 
strengths may be classified in this group, while remaining strengths are 
classified in G03 - Sex hormones and modulators of the genital system.  
 
The DDDs are based on the treatment of cancer (breast-, endometrial, 
and prostatic). 
 
 
L02A  HORMONES AND RELATED AGENTS 
 
Antigrowth hormones like somatostatin and octreotide, which are also 
used in the treatment of neoplastic diseases, are classified in H01CB. 
 
L02AA  Estrogens 
 
Polyestradiol and combined products, which contain polyestradiol and 
local anestethics, are classified at the plain level L02AA02 - 
polyestradiol phosphate. 
 
L02AB  Progestogens 
 
L02AE  Gonadotropin releasing hormone analogues 
 
 See also H01CA - Gonadotropin releasing hormones. 
 
The DDD of 60 mcg for leuprorelin implant is based on 5 mg 
implant/90 days. 
 
The depot DDD for triptorelin is based on treatment of prostatic cancer 
while the other DDD of 0.1 mg is based on the dose in one syringe 
used in women undergoing controlled ovarian hyperstimulation. 
 
L02AX  Other hormones 
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L02B  HORMONE ANTAGONISTS AND RELATED AGENTS 
 
L02BA  Anti-estrogens 
 
L02BB  Anti-androgens 
 
L02BG  Aromatase inhibitors 
 
L02BX Other hormone antagonists and related agents 
 
 
L03  IMMUNOSTIMULANTS 
 
Immunosuppressants, see L04A. 
 
 
L03A  IMMUNOSTIMULANTS 
 
Levamisole, which also affects the immune response, is classified in 
P02CE. 
 
L03AA  Colony stimulating factors 
 
The DDDs for pegfilgrastim (L03AA13) and lipegfilgrastim 
(L03AA14) are based on the declared amount of filgrastim and on the 
use of one single dose per cycle of chemotherapy. The DDDs for the 
other G-CSFs are based on daily dosing for six subsequent days. 
 
L03AB Interferons 
 
Peginterferon alfa-2b in combination with ribavirin and peginterferon 
alfa-2a in combination with ribavirin are classified in L03AB60 and 
L03AB61, respectively. 
 
The DDD for interferon alfa is based on the treatment of chronic active 
hepatitis B, whilst the DDD for interferon beta is based on the 
treatment of multiple sclerosis. 
 
The DDDs of interferon beta-1a is based on i.m. administration. 
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L03AC Interleukins 
 
The DDD for aldesleukin is based on the use of 5 vials (6.5 mg) per 
treatment cycle of 33 days. 
 
L03AX Other immunostimulants 
 
The DDD for tasonermin is based on single dose treatment. 
 
The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the 
total dose devided by days of first treatment cycle (42 days). 
 
 
L04 IMMUNOSUPPRESSANTS 
 
Immunosuppressants are defined as agents that completely or partly 
suppress one or more factors in the immunosystem. 
 
 
L04A IMMUNOSUPPRESSANTS 
 
This group comprises immunosuppressants excl. corticosteroids. 
 
The DDDs are  based on prophylaxis of allograft transplant rejection if 
this is an approved indication.   
 
 
 
 
L04AA Selective immunosuppressants 
 
Antilymphocyte immunoglobulin from horse serum is classified in 
L04AA03. 
 
Antithymocyte immunoglobulin from rabbit serum is classified in 
L04AA04. 
 
Oral formulations of cladribine used in multiple sclerosis are classified 
in this group, while parenteral formulations for cancer are classified in 
L01BB. 
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The DDD for muromonam-CD3 is based on combination therapy in 
acute allograft rejection. 
 
The DDDs for leflunomide, abatacept and tofacitinib are based on the 
treatment of rheumatoid arthritis. 
 
The DDDs for natalizumab, fingolimod, teriflunomide and 
alemtuzumab are based on the treatment of multiple sclerosis.  
 
The DDD for efalizumab is based on the treatment of psoriasis. 
 
L04AB Tumor necrosis factor alpha (TNF-α) inhibitors 
 
The DDDs for etanercept, infliximab and adalimumab are based on the 
treatment of rheumatoid arthritis. 
 
The DDD for cerolizumab pegol is based on the treatment of Crohn’s 
Disease. 
 
L04AC Interleukin inhibitors 
 
Interleukin inhibitors used in asthma are classified in R03DX. 
 
Dupilumab is classified in D11AH. 
 
The DDDs for anakinra and tocilizumab are based on the treatment of 
rheumatoid arthritis. 
 
The DDD for daclizumab is based on the treatment of multiple 
sclerosis. 
 
The DDDs for ustekinumab and ixekizumab are based on the treatment 
of psoriasis. 
 
L04AD Calcineurin inhibitors 
 
L04AX Other immunosuppressants 
 
Oral formulations and prefilled syringe/pen of methotrexate are 
classified in this group. Parenteral formulations used in cancer are 
classified in L01BA01. 
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The DDD for pomalidomide is based on the starting dose. 
 
The DDD for thalidomide is based on the treatment of lepra. 
 
The DDD for lenalidomide is based on the treatment of 
myelodysplastic syndromes. 
 
The DDD for pomalidomide is based on the starting dose in the 
treatment of multiple myeloma. 
 
The DDDs for methotrexate are based on the treatment of rheumatoid 
arthritis. 
 
 
 197 
M   MUSCULO-SKELETAL SYSTEM 
 
M01  ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS 
 A Antiinflammatory and antirheumatic products, non-steroids  
 B Antiinflammatory/antirheumatic agents in combination  
 C Specific antirheumatic agents  
 
M02  TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN 
 A Topical products for joint and muscular pain 
 
M03  MUSCLE RELAXANTS 
 A Muscle relaxants, peripherally acting agents  
 B Muscle relaxants, centrally acting agents  
 C Muscle relaxants, directly acting agents  
 
M04  ANTIGOUT PREPARATIONS 
 A Antigout preparations 
 
M05 DRUGS FOR TREATMENT OF BONE DISEASES 
 B Drugs affecting bone structure and mineralization 
 
M09  OTHER DRUGS FOR DISORDERS OF THE MUSCULO-
SKELETAL SYSTEM  
 A Other drugs for disorders of the musculo-skeletal system 
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M  MUSCULO-SKELETAL SYSTEM 
 
M01  ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS 
 
M01A  ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, 
NON-STEROIDS  
 
This group comprises antiinflammatory and antirheumatic preparations 
for systemic use. 
 
The substances in this group have a broad range of indications, 
however, they should be kept together in M01A. 
 
NSAIDs in combination with paracetamol are classified in N02BE. 
 
Corticosteroids, see H02 - Corticosteroids for systemic use. 
 
Disease Modifying Antirheumatic Drugs (DMARDs) see: 
A07EC - Aminosalicylic acid and similar agents 
L01BA - Folic acid analogues 
L04AA - Selective immunosuppressants 
L04AX - Other immunosuppressants 
M01C - Specific antirheumatic agents 
P01BA - Aminoquinolines 
 
All preparations containing salicylic acid and derivatives are classified 
in N02BA - Salicylic acid and derivatives, as it is difficult to 
differentiate between use of salicylates in rheumatic conditions and 
other therapeutic uses. 
 
Exception:  Salicylates in combination with corticosteroids are 
classified in M01B. 
 
Combinations of antiinflammatory/antirheumatic agents (e.g. 
corticosteroids) are classified in M01B. 
 
Combinations with muscle relaxants are classified in M03B. 
 
Combinations with antibacterials are classified in J01. 
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Antiinflammatory or antirheumatic agents in combination with opioids 
are classified in N02AJ - Opioids in combination with non-opioid 
analgesics.  Other combinations are classified at separate 5th levels 
using the corresponding 50-series.  
 
Combined cold preparations with therapeutic levels of antiinflammatory 
agents are classified in this group at separate 5th levels by using the 50-
series. 
 
Combinations with drugs classified in A02B (e.g. esomeprazole) are 
classified in M01A using the 50-series. 
 
The DDDs are based on the treatment of rheumatoid arthritis, except 
for the coxibs (M01AH). 
 
M01AA  Butylpyrazolidines 
 
M01AB  Acetic acid derivatives and related substances 
 
M01AC  Oxicams 
 
Piroxicam and piroxicam-beta-cyclodextrin are given the same ATC 5th 
level code M01AC01. 
 
The DDD for meloxicam is based on the treatment of osteoarthritis. 
 
M01AE  Propionic acid derivatives  
 
All plain ibuprofen preparations are classified in this group, even if they 
are only intended for use as pain relief. 
 
Combinations of ibuprofen and paracetamol are classified in N02BE51. 
 
Ketoprofen lysine is classified at the same ATC 5th level as ketoprofen.  
 
Ibuprofen lysine is classified at the same 5th level as ibuprofen. 
 
M01AG Fenamates 
 
Tolfenamic acid, used in the treatment of migraine, is classified here. 
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M01AH Coxibs 
 
Celecoxib used in FAP (familiar adenomatous polyposis) is classified in 
L01XX. 
 
The DDDs for the coxibs are based on the treatment of osteoarthritis. 
 
M01AX  Other antiinflammatory and antirheumatic agents, non-steroids  
 
This group comprises antiinflammatory and antirheumatic drugs which 
cannot be classified in the preceding groups. 
 
The DDD for glucosamine refers to glucosamine sulfate. 
 
 
M01B  ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN 
COMBINATION  
 
M01BA Antiinflammatory/antirheumatic agents in combination with 
corticosteroids  
 
This group comprises antiinflammatory and antirheumatic drugs in 
combination with corticosteroids. 
 
Combinations with salicylic acid derivatives are classified in this group. 
 
The preparations are classified at 5th levels according to the anti-
inflammatory/analgesic component.  At each 5th level, different 
corticosteroids may occur. 
 
M01BX  Other antiinflammatory/antirheumatic agents in combination with other 
drugs 
 
All combinations of different antiinflammatory agents (excl. corti-
costeroids) are classified in this group. 
 
 
M01C  SPECIFIC ANTIRHEUMATIC AGENTS 
 
This group comprises specific antirheumatic preparations.    
 
Penicillamine, which is also used in conditions associated with impaired 
copper metabolism and as an antidot in copper poisoning, is classified 
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in this group regardless of indication. 
 
Other Disease Modifying Antirheumatic Drugs (DMARDs) see: 
 
A07EC - Aminosalicylic acid and similar agents 
L01BA - Folic acid analogues 
L04AA - Selective immunosuppressants 
L04AX - Other immunosuppressants 
P01BA - Aminoquinolines 
 
The DDDs are based on the treatment of rheumatoid arthritis. 
 
M01CA  Quinolines 
 
Chloroquine and hydroxychloroquine are classified as antimalaria 
agents in P01BA. 
 
M01CB  Gold preparations 
 
M01CC  Penicillamine and similar agents 
 
M01CX Other specific antirheumatic agents 
 
 
M02  TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN 
 
M02A  TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN 
 
This group comprises ointments, liniments, plasters, etc. which may 
produce symptomatic relief in joint and muscular pain. 
 
No DDDs have been assigned in this group. 
 
M02AA  Antiinflammatory preparations, non-steroids for topical use  
 
All non-steroidal antiinflammatory derivatives for topical use are 
classified here, regardless of indication.  Exception is a product 
containing diclofenac formulated as a 3% hyaluronic acid gel which is 
used in treatment of actinic keratoses.  This particular formulation is 
classified in D11AX. 
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Combinations of non-steroidal antiinflammatory derivatives and other 
substances for topical use are classified together with plain preparations 
at the different 5th levels. 
 
M02AB Capsaicin and similar agents  
 
Capsaicin products indicated for the symptomatic treatment of 
peripheral neuropathic pain (incl. postherpetic neuralgia) are classified 
in N01BX. 
 
Combined preparations containing nonivamide used as a rubefacient are 
classified in this group on a 4th level. 
 
M02AC  Preparations with salicylic acid derivatives 
 
No separate 5th levels are established in this group. 
Combinations of salicylic acid derivatives and other products are 
classified in this group. 
 
M02AX  Other topical products for joint and muscular pain 
 
This group comprises topical products, which cannot be classified in the 
preceding groups. 
 
Preparations with menthol are generally classified in D04 - 
Antipruritics, incl. antihistamines, anesthetics, etc. 
 
 
M03  MUSCLE RELAXANTS 
 
This group comprises peripherally, centrally and directly acting muscle 
relaxants. 
 
See also G04BD - Drugs for urinary frequency and incontinence. 
 
 
M03A  MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS 
 
This group comprises peripherally acting muscle relaxants such as 
curare alkaloids and suxamethonium. 
 
The drugs in this group are mainly used together with anesthetics. 
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As for other drugs used in general anesthesia (see N01A), no DDDs 
have been established in this group because the doses used vary 
substantially. 
 
M03AA  Curare alkaloids 
 
M03AB  Choline derivatives 
 
M03AC  Other quaternary ammonium compounds 
 
Sugammadex indicated for reversal of neuromuscular blockade induced 
by rocuronium or vecuronium is classified in V03AB - Antidotes. 
 
M03AX Other muscle relaxants, peripherally acting agents 
 
Botulinum toxin used e.g. for treatment of blepharospasm, hemifacial 
spasm and migraine is classified in this group. 
 
 
M03B  MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS 
 
This group comprises centrally acting muscle relaxants.  Combined 
preparations are classified at separate 5th levels using the corresponding 
50-series (comb. Excl. psycholeptics), or the 70-series (comb. With 
psycholeptics):  
 
The group is subdivided according to chemical structure. 
 
Combinations with NSAIDs (M01A) or analgesics (N02B) are 
classified here. 
 
These drugs are used in different conditions associated with pain and 
rigidity in the muscles, joints etc. 
 
DDDs for combination products, see list on the website 
www.whocc.no. 
 
M03BA  Carbamic acid esters 
 
M03BB  Oxazol, thiazine, and triazine derivatives 
 
M03BC  Ethers, chemically close to antihistamines 
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Orphenadrine citrate is classified here.  Preparations containing 
orphenadrine chloride are classified in N04AB.   
 
Combinations with e.g. paracetamol are classified in this group at 
separate 5th levels by using the 50-series. 
 
M03BX  Other centrally acting agents 
 
 
M03C  MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS 
 
This group comprises agents acting directly on the muscles such as 
dantrolene. 
 
M03CA  Dantrolene and derivatives 
 
The DDD of dantrolene is based on the treatment of spasticity after 
spinal injury. 
 
 
M04  ANTIGOUT PREPARATIONS 
 
M04A  ANTIGOUT PREPARATIONS 
 
The group is subdivided according to mode of action. 
 
The DDDs are based on prophylaxis. 
 
M04AA  Preparations inhibiting uric acid production 
 
Combinations of allupurinol and other antigout preparations are 
classified here. 
 
Rasburicase for the treatment of hyperuricemia is classified in V03AF. 
 
M04AB  Preparations increasing uric acid excretion 
 
M04AC  Preparations with no effect on uric acid metabolism 
 
M04AX  Other antigout preparations 
 
This group comprises preparations which cannot be classified in the 
preceding groups. 
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M05 DRUGS FOR TREATMENT OF BONE DISEASES 
 
Drugs used for the treatment of bone diseases, see also: 
 
A11CC - Vitamin D and analogues 
A12A - Calcium 
A12AX - Calcium, combinations with vitamin D and/or other 
drugs 
A12CD - Fluoride 
G03C/G03F -  Estrogens/Progestogens and estrogens in combination 
H05BA - Calcitonins 
 
 
M05B DRUGS AFFECTING BONE STRUCTURE AND 
MINERALIZATION 
 
M05BA Bisphosphonates 
 
This group includes plain preparations.  Combination packages with 
calcium for sequential use are classified in M05BB. 
 
The DDDs for the bisphosphonates are based on the treatment of 
osteoporosis if this is an approved indication. 
 
The DDDs for clodronic acid, pamidronic acid, zoledronic acid, 
parenteral etidronic acid and parenteral ibandronic acid are based on 
tumor induced hypercalcemia. The oral DDD for ibandronic acid is 
based on osteoporosis.  Since the duration of the intravenous treatment 
courses with the bisphosphonates are varying, from 1-5 days, the 
DDDs for these parenteral formulations are assigned according to the 
total course dose.  The DDDs for the oral formulations, which are 
mainly used for maintenance therapy, are assigned according to daily 
dosages.  
 
The DDD for tiludronic acid is based on the treatment of Paget’s 
disease. 
 
M05BB Bisphosphonates, combinations 
 
M05BC Bone morphogenetic proteins 
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M05BX Other drugs affecting bone structure and mineralization 
 
The DDD for denosumab is based on the treatment of osteoporosis. 
 
 
M09  OTHER DRUGS FOR DISORDERS OF THE MUSCULO-
SKELETAL SYSTEM  
 
M09A  OTHER DRUGS FOR DISORDERS OF THE MUSCULO-
SKELETAL SYSTEM  
 
This group comprises preparations used in disorders of the musculo-
skeletal system, which cannot be classified in the preceding groups. 
 
M09AA  Quinine and derivatives 
 
Hydroquinine, which is used in the treatment of nocturnal leg cramps is 
classified in this group. 
 
Quinine is classified as an antimalaria agent in P01BC.  Quinine in 
combination with psycholeptics is classified in M09AA72, since these 
combinations are used for treatment of nocturnal leg cramps. 
Combinations used for cold conditions, containing quinine as an 
antipyretic, are classified in R05X. 
 
M09AB  Enzymes 
 
All enzyme preparations, which are used to treat inflammatory 
conditions in the musculo-skeletal system, are classified in this group. 
 
M09AX Other drugs for disorders of the musculo-skeletal system 
 
Hyaluronic acid injection for intraarticular administration 
(e.g. 2.5 mg/ampoule) used in the treatment of arthritis is classified in 
this group.  Hyaluronic acid injection used during surgical procedures 
on the eye (e.g. 4-20 mg/ampoule) is classified in S01K. 
 
The DDD for hyaluronic acid is based on intraarticular treatment of 
arthritis.  The DDD is assigned according to daily dose even if the 
product is given as weekly injections. 
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N   NERVOUS SYSTEM 
 
N01  ANESTHETICS 
A Anesthetics, general 
B Anesthetics, local 
 
N02  ANALGESICS 
A  Opioids 
B  Other analgesics and antipyretics 
C  Antimigraine preparations 
 
N03  ANTIEPILEPTICS 
A  Antiepileptics 
 
N04  ANTI-PARKINSON DRUGS 
A  Anticholinergic agents 
B  Dopaminergic agents 
 
N05  PSYCHOLEPTICS 
A  Antipsychotics 
B  Anxiolytics 
C  Hypnotics and sedatives 
 
N06  PSYCHOANALEPTICS 
A  Antidepressants 
B  Psychostimulants, agents used for ADHD and nootropics 
C  Psycholeptics and psychoanaleptics in combination 
D Anti-dementia drugs 
 
N07  OTHER NERVOUS SYSTEM DRUGS 
A  Parasympathomimetics 
B Drugs used in addictive disorders 
C Antivertigo preparations 
X  Other nervous system drugs 
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N  NERVOUS SYSTEM 
 
N01  ANESTHETICS 
 
No DDDs have been established in this group because the doses used 
vary substantially. 
 
 
N01A  ANESTHETICS, GENERAL 
 
This group comprises agents which produce general anesthesia, surgical 
analgesia or neuroleptanalgesia.  See also M03A - Peripherally acting 
muscle relaxants. 
 
Benzodiazepine derivatives are classified in N05BA or N05CD. 
 
N01AA Ethers 
 
N01AB  Halogenated hydrocarbons 
 
N01AF  Barbiturates, plain 
 
This group comprises barbiturates used as anesthetics. 
 
Barbiturates used as hypnotics/sedatives and as premedication, see 
N05CA - Barbiturates, plain. 
 
N01AG  Barbiturates in combination with other drugs 
 
Only preparations used as anesthetics are classified in this group.  See 
also N05CB - Barbiturates, combinations. 
 
N01AH  Opioid anesthetics 
 
Opioid anesthetics in combination with other anesthetics are classified 
in this group at separate 5th levels using the corresponding 50-series. 
 
Transdermal, nasal and sublingual formulations of fentanyl are 
classified in N02AB. 
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N01AX Other general anesthetics 
 
This group comprises various plain and combined drugs used to 
produce anesthesia/analgesia, which cannot be classified in the 
preceeding groups. 
 
 
N01B  ANESTHETICS, LOCAL 
 
Local anesthetics in this context mean anesthetics which only affect a 
local area as opposed to general anesthetics affecting the entire body. 
 
Creams, plasters and sprays containing e.g. lidocaine or prilocaine used 
as anesthetics/analgesics or in premature ejaculation are classified in 
N01BB. 
 
Local anesthetics for dermatological use such as treatment of pruritus, 
minor burns and insect stings are classified in D04AB - Anesthetics for 
topical use. 
 
Antihemorrhoidals containing anesthetics, see C05AD - Local 
anesthetics. 
 
Stomatologicals with anesthetics, see A01AD. 
 
Combinations of corticosteroids and anesthetics, see A01AC. 
 
Throat preparations with anesthetics, see R02AD - Anesthetics, local. 
 
Ophthalmological anesthetics, see S01HA. 
 
Combinations with e.g. epinephrine are classified at separate 5th levels 
by using the 50-series. 
 
N01BA  Esters of aminobenzoic acid 
 
Plasters containing lidocaine and tetracaine are classified in N01BB. 
 
Combinations of tetracaine and oxymetazoline for nasal application 
used as local dental anesthetics are classified in N01BA53. 
 
N01BB  Amides 
 
Lidocaine injections used as antiarrhythmics are classified in C01BB. 
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N01BC  Esters of benzoic acid 
 
N01BX  Other local anesthetics 
 
Capsaicin products indicated for the symptomatic treatment of 
peripheral neuropathic pain (incl. postherpetic neuralgia) are classified 
in N01BX. See also M02AB. 
 
 
N02  ANALGESICS 
 
This group comprises general analgesics and antipyretics. 
 
All salicylic acid derivatives except combinations with corticosteroids 
(M01B) or opioids (N02AJ) are classified in N02BA - Salicylic acid 
and derivatives, as it is difficult to differentiate between the use of 
salicylates in rheumatic conditions and other therapeutic uses of 
salicylates. 
 
All plain ibuprofen preparations are classified in M01A, even if they are 
only intended for use as pain relief. 
 
There are a number of combined preparations, which contain analgesics 
and psycholeptics.  These are classified in N02, as pain relief must be 
regarded as the main indication.  Analgesics used for specific 
indications are classified in the respective ATC groups. E.g.:  
 
A03D/ 
A03EA - Antispasmodic/psycholeptics/analgesic combinations 
M01 - Antiinflammatory and antirheumatic products 
M02A - Topical products for joint and muscular pain 
M03 - Muscle relaxants 
 
See comments to these groups. 
 
Lidocaine indicated for postherpetic pain is classified in N01BB. 
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N02A  OPIOIDS 
 
This group comprises strong analgesics of the opiate type and 
analgesics with similar structure or action. 
 
Sufentanil, which is also used as an epidural analgesic or in 
postoperative pain, is classified in N01AH. 
 
Combinations with antispasmodics are classified in N02AG. 
 
The DDDs in this group are based on the treatment of pain. 
 
The DDD for oral morphine is higher than the parenteral DDD 
because of lower bioavailability.  
 
N02AA  Natural opium alkaloids 
 
This group includes natural and semi-synthetic opiates. 
 
All plain morphine preparations are classified in this group. 
 
Opium, see also A07DA - Antipropulsives. 
 
Plain codeine preparations are classified in R05D - Cough 
suppressants, excl. combinations with expectorants, while 
dihydrocodeine is classified in N02AA.  Codeine or dihydrocodeine in 
combination with other analgesics or NSAIDs are classified in N02AJ - 
Opioids in combination with non-opioid analgesics.  
 
Other combinations with e.g. caffeine, antihistamines and 
anticholinergic agents are classified in N02AA. Combinations of 
codeine with psycholeptics are classified in N02AA79. 
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The DDDs are based on approved dose recommendations. 
 
When establishing DDDs for combination products in the 50-series, all 
analgesic components are taken into consideration.   
 
The DDD, expressed in UD, should normally not exceed the approved 
dose recommendations for any of the components. 
See list of DDDs for combination products, www.whocc.no. 
 
N02AB  Phenylpiperidine derivatives 
 
Fentanyl patches are classified in this group whereas parenteral 
formulations are classified in N01AH. 
 
The transdermal DDD for fentanyl is based on the amount delivered 
per 24 hours. 
 
N02AC  Diphenylpropylamine derivatives 
 
Methadone and levacetylmethadol are classified in N07BC - Drugs 
used in opioid dependence. 
 
Dextropropoxyphene in combination with a muscle relaxant is 
classified in M03B. 
 
Different DDDs are assigned for different dextropropoxyphene salts 
based on their different solubility. 
 
N02AD  Benzomorphan derivatives 
 
N02AE  Oripavine derivatives 
 
 High strength formulations (above 0.4 mg) of buprenorphine used in 
opioid dependence are classified in N07BC. 
 
N02AF  Morphinan derivatives 
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N02AG  Opioids in combination with antispasmodics 
 
Preparations are classified at 5th levels according to the analgesic.  At 
each level different antispasmodics may occur. 
 
The DDDs in this group are as far as possible equipotent to the DDD 
for parenteral morphine. 
 
N02AJ Opioids in combination with non-opioid analgesics 
 
Includes combinations with opioids and other non-opioid analgesics 
(e.g. paracetamol, acetylsalicylic acid or NSAIDs). At each 5th level 
other active ingredients such as e.g. caffeine, vitamins and 
antihistamines are allowed.  
 
Various combinations of codeine with other analgesics are included in 
N02AJ09 - codeine and other non-opioid analgesics. For example 
combinations containing three analgesic components (codeine, 
paracetamol and ibuprofen) are classified in N02AJ09.  
 
Various combinations of tramadol with other analgesics are included in 
N02AJ15 - tramadol and other non-opioid analgesics. For example 
combinations containing tramadol and ibuprofen (or ketorolac or 
diclofenac) are classified in N02AJ15.  
 
Combinations of codeine, non-opioid analgesics and psycholeptics are 
classified in N02AA79 - codeine, combinations with psycholeptics.  
Other analgesics may be included in the 70-series codes. 
 
All plain and combination products containing dextropropoxyphen are 
classified in N02AC. 
 
 
The DDDs are based on approved dose recommendations. 
 
When establishing DDDs for combination products all analgesic 
components are taken into consideration. 
 
The DDD, expressed in UD, should normally not exceed the approved 
dose recommendations for any of the components. 
See list of DDDs for combination products, www.whocc.no. 
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N02AX  Other opioids 
 
The group comprises opioids, which cannot be classified in the 
preceding groups. 
 
 
N02B  OTHER ANALGESICS AND ANTIPYRETICS 
 
See general considerations under N02. 
 
Combinations with opioids should be classified in N02AJ - Opioids in 
combination with non-opioid analgesics. Combinations with codeine, 
non-opioid analgesics and psycholeptics are classified in N02AA79. 
  
Combinations with opioids and antispasmodics are classified in 
N02AG  - Opioids in combination with antispasmodics.   
 
Combinations with muscle relaxants are classified in M03B. 
 
Combined preparations which contain more than one analgesic, should 
be classified by using the following ranking:  
 
1.  Phenacetin 
2.  Bucetin 
3.  Dipyrocetyl 
4.  Paracetamol 
5.  Acetylsalicylic acid 
6.  Phenazone 
7.  Salicylamide 
8.  Propyphenazone 
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This means that a product containing paracetamol and phenazone 
should be classified in N02BE51 - paracetamol, combinations excl. 
psycholeptics and not in N02BB51 - phenazone, combinations excl. 
psycholeptics. 
 
Dextropropoxyphene plain, and in combination with other analgesics, is 
classified in N02AC. 
 
Cold preparations with therapeutic levels of analgesics are classified in 
this group at separate 5th levels by using the 50-series. 
 
Preparations are subdivided on 4th levels according to chemical 
structure. 
 
Combinations with ascorbic acid (i.e. 50 mg or more per unit dose) are 
classified at separate 5th levels using the corresponding 50-series. 
Products containing less than 50 mg per unit dose are classified at the 
plain level of the analgesic component. 
 
The DDDs are based on approved dose recommendations. 
 
When establishing DDDs for combination products in the 50-series, all 
analgesic components are taken into consideration. 
The DDD expressed in UD, should normally not exceed the approved 
dose recommendations for any of the components. See list of DDDs 
for combinations products, www.whocc.no.   
 
N02BA  Salicylic acid and derivatives 
 
All salicylic acid derivatives including some commonly regarded as 
non-steroid antiinflammatory drugs, e.g. diflunisal, are classified in this 
group.  See comment under N02 - Analgesics. 
 
Salicylic acid derivatives in combination with corticosteroids are 
classified in M01B.  Acetylsalicylic acid preparations specifically 
intended for use as antithrombotic agents are classified in B01AC. 
 
Lysine acetylsalicylate is classified at the same 5th level as 
acetylsalicylic acid. 
 
Combinations with antiemetics are classified here. 
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The DDDs are based on the treatment of pain and not on use in 
rheumatic diseases.   
 
DDDs for combined preparations, see N02B. 
 
N02BB  Pyrazolones 
 
N02BE  Anilides 
 
Propacetamol, a prodrug of paracetamol is classified at a separate ATC 
5th level in this group. 
 
Benorilate, which is an ester of acetylsalicylic acid and paracetamol, is 
classified in N02BA. 
 
 
Combinations of paracetamol and e.g. ibuprofen are classified in 
N02BE51. 
 
Paracetamol in combination with orphenadrine (citrate) is classified in 
M03BC. 
 
N02BG  Other analgesics and antipyretics 
 
This group comprises analgesics, which cannot be classified in the 
preceding groups. 
 
The DDD for ziconotide is based on intrathecal administration. 
 
DDDs established for products classified in 
N02BG10 cannabinoids are available on the list of DDDs for 
combinations on the website www.whocc.no. 
 
 
N02C  ANTIMIGRAINE PREPARATIONS 
 
This group comprises preparations specifically used in the prophylaxis 
and treatment of migraine.  Analgesics, see N02A and N02B. 
 
Beta blocking agents, see C07. 
 
Antivertigo preparations, see N07. 
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Cyproheptadine, see R06A - Antihistamines for systemic use. 
 
Tolfenamic acid, see M01AG - Fenamates. 
 
Indometacin in combination with prochlorperazine and caffeine is 
classified in M01AB51 - Indometacin, combinations. 
 
Botulinum toxin used in the prophylactic treatment of migraine is 
classified in M03AX01. 
 
N02CA  Ergot alkaloids 
 
Ergot alkaloids for gynecological use, see G02A and G02CB. 
 
See also C04AE - Ergot alkaloids. 
Dihydroergotamine, which is also used in the treatment of hypotension, 
is classified in this group. 
 
Combinations of dihydroergotamine and etilefrine are classified in 
C01CA. 
 
The DDD for ergotamine is based on the treatment of acute migraine 
attacks, whereas the DDDs for dihydroergotamine and methysergide 
are based on prophylaxis. 
 
The DDD for dihydroergotamine nasal spray is based on the treatment 
of acute migraine attacks. 
 
N02CB  Corticosteroid derivatives 
 
The DDDs for corticosteroid derivatives are based on prophylaxis of 
migraine. 
 
N02CC Selective serotonin (5HT1) agonists 
 
The DDDs for the selective serotonin (5HT1) agonists are based on the 
recommended initial dose in acute attacks of migraine.  
 
N02CX  Other antimigraine preparations 
 
This group comprises antimigraine preparations, which cannot be 
classified in the preceding groups. 
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Clonidine low strength tablets (e.g. 25 mcg) are classified here, even if 
the indication also may be “opioid withdrawal symptoms”. 
 
The DDDs for the substances in this group are based on the 
prophylaxis of migraine. 
 
 
N03  ANTIEPILEPTICS 
 
N03A  ANTIEPILEPTICS 
 
This group comprises preparations used in the treatment of epilepsy. 
 
Combined preparations are classified at separate 5th levels using the 
corresponding 50-series. 
 
The group is subdivided according to chemical structure. 
 
The DDDs for the antiepileptics are based on combination therapy. 
 
N03AA  Barbiturates and derivatives 
 
Barbiturates used mainly as hypnotics/sedatives are classified in  
N05C - Hypnotics and sedatives. 
 
Phenobarbital, which is used both as an antiepileptic and as a sedative, 
is classified in this group. 
 
Combinations with phenytoin are classified in N03AB. 
 
N03AB  Hydantoin derivatives 
 
Combinations of phenytoin and barbiturates are classified in this 
group. 
 
N03AC  Oxazolidine derivatives 
 
N03AD  Succinimide derivatives 
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N03AE  Benzodiazepine derivatives 
 
Clonazepam is classified in this group. 
 
All other benzodiazepines are classified as anxiolytics in N05B (e.g. 
diazepam) or hypnotics/sedatives in N05C (e.g. midazolam). 
 
N03AF  Carboxamide derivatives 
 
N03AG  Fatty acid derivatives 
 
N03AX  Other antiepileptics 
 
This group comprises antiepileptics, which cannot be classified in the 
preceding groups. 
 
 
N04  ANTI-PARKINSON DRUGS 
 
This group comprises preparations used in the treatment of Parkinson's 
disease and related conditions, including drug-induced parkinsonism. 
 
The DDDs are based on recommended doses for the long-term 
treatment of symptoms of Parkinson's disease. 
 
No separate DDDs are established for oral depot formulations. 
 
 
N04A  ANTICHOLINERGIC AGENTS 
 
N04AA  Tertiary amines  
 
N04AB  Ethers chemically close to antihistamines 
 
Orphenadrine chloride is classified in this group, while orphenadrine 
citrate is classified in M03BC. 
 
N04AC  Ethers of tropine or tropine derivatives 
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N04B  DOPAMINERGIC AGENTS 
 
N04BA  Dopa and dopa derivatives 
 
Combinations with decarboxylase inhibitors and other dopaminergic 
agents are classified here. 
 
The DDD for the combination of levodopa and decarboxylase 
inhibitor is based on the content of levodopa, see ATC index. 
 
N04BB  Adamantane derivatives 
 
N04BC Dopamine agonists 
 
Bromocriptine used in parkinsonism is classified in this group (e.g. 
tablets of 5 mg and 10 mg).  Low strength bromocriptine tablets (e.g. 
2.5 mg) used as a prolactine inhibitor are classified in G02CB - 
Prolactine inhibitors.   
 
Cabergoline used in parkinsonism is classified in this group (e.g. 
tablets of 1 mg).  Low strength cabergoline tablets (0.5 mg) used as a 
prolactine inhibitor are classified in G02CB. 
 
Lisuride in high strength formulations (e.g. 0.2 mg tablets), which is 
also used in the treatment of Parkinsonism, are classified in G02CB 
while lisuride in low strength formulations (e.g. 25 mcg tablets) are 
classified in N02CA. 
 
N04BD  Monoamine oxidase B inhibitors 
 
N04BX Other dopaminergic agents 
 
This group comprises dopaminergic agents which cannot be classified 
in the preceding groups. 
 
The combination of levodopa, decarboxylase inhibitor and COMT 
inhibitor is classified in N04BA - Dopa and dopa derivatives. 
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N05  PSYCHOLEPTICS 
 
The group is divided into therapeutic subgroups: 
 
N05A -  Antipsychotics 
N05B -  Anxiolytics 
N05C -  Hypnotics and sedatives 
 
 
N05A  ANTIPSYCHOTICS 
 
This group comprises drugs with antipsychotic actions (i.e. 
neuroleptics). 
 
Reserpine is classified in C02 - Antihypertensives. 
 
Antipsychotics in combination with antidepressants are classified in 
N06C - Psycholeptics and psychoanaleptics in combination. 
 
The group is subdivided mainly according to chemical structure. 
 
The DDDs are based on the treatment of psychosis.  The substances in 
this group are sometimes used for other indications in much lower 
doses. 
 
For depot injections, the DDDs are based on the average 
recommended doses divided by the dosing interval. 
 
N05AA  Phenothiazines with aliphatic side-chain 
 
N05AB  Phenothiazines with piperazine structure 
 
N05AC  Phenothiazines with piperidine structure 
 
N05AD  Butyrophenone derivatives 
 
The DDD for parenteral droperidol is based on treatment of post-
operative nausea and vomiting.   
 
N05AE  Indole derivatives 
 
Isoindoles are classified here. 
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N05AF  Thioxanthene derivatives 
 
N05AG  Diphenylbutylpiperidine derivatives 
 
N05AH  Diazepines, oxazepines, thiazepines and oxepines 
 
N05AL  Benzamides 
 
 Levosulpiride used as a propulsive is classified in this group. 
 
N05AN  Lithium 
 
The DDD is based on the prophylaxis of mania or depression. 
 
Antidepressants, see N06A. 
 
N05AX  Other antipsychotics 
 
This group comprises antipsychotics which cannot be classified in the 
preceding groups. 
 
 
N05B  ANXIOLYTICS 
 
This group comprises preparations used in the treatment of neuroses 
and psychosomatic disorders associated with anxiety and tension, e.g. 
benzodiazepines. 
 
See also: 
N05A -  Antipsychotics 
N05C -  Hypnotics and sedatives  
 
Usually the presence of an anxiolytic (or other psycholeptics) in 
combined preparations must be regarded as being of secondary 
importance and the preparations should be classified in the respective 
therapeutic groups (e.g. A03C - Antispasmodics in combination with 
psycholeptics, N02 - Analgesics). 
 
Combined preparations used mainly for the treatment of anxiety are 
classified at separate 5th levels using the corresponding 50-series. 
 
The group is subdivided according to chemical structure. 
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The DDDs are based on the treatment of anxiety. 
 
N05BA  Benzodiazepine derivatives 
 
Benzodiazepines used mainly in the treatment of sleep disturbances are 
classified in N05C - Hypnotics and sedatives. 
 
Clonazepam used in the treatment of epilepsy is classified in N03 - 
Antiepileptics. 
 
The parenteral DDD for chlordiazepoxide is higher than the oral DDD 
due to lower bioavailability for intramuscular injections. 
 
N05BB  Diphenylmethane derivatives 
 
N05BC  Carbamates 
 
N05BD  Dibenzo-bicyclo-octadiene derivatives 
 
N05BE  Azaspirodecanedione derivatives 
 
N05BX  Other anxiolytics 
 
This group comprises anxiolytics which cannot be classified in the 
preceding groups. 
 
 
N05C  HYPNOTICS AND SEDATIVES 
 
This group comprises preparations with mainly sedative or hypnotic 
actions. 
 
Melatonin receptor agonists are also classified in this group. 
 
See also:  
N05A -  Antipsychotics 
N05B -  Anxiolytics 
R06A -  Antihistamines for systemic use 
 
Combined preparations are classified at separate 4th levels, N05CB and 
N05CX. 
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Regarding classification of combined preparations, see comments under 
N05B - Anxiolytics. 
 
Combined preparations with barbiturates are mainly classified in A03 
(mainly antispasmodic effect) or in N02 (mainly analgesic effect). 
Combined preparations with barbiturates which remain in N05C are 
mainly "neurostabilizers". 
 
The group is subdivided according to chemical structure. 
 
 
The DDDs are based on use of the drugs as hypnotics.  
 
The DDD for melatonin is based on dose recommendations in EU for 
the 2 mg depot tablet. 
 
N05CA  Barbiturates, plain 
 
This group comprises barbiturates used for insomnia. 
 
Preparations used as premedication are also classified in this group. 
 
Barbiturates used in general anesthesia are classified in N01A - General 
anesthetics. 
 
Barbiturates used mainly in the treatment of epilepsy, e.g. 
phenobarbital, are classified in N03 - Antiepileptics. 
 
Combined preparations are classified in N05CB, see comment under 
N05C. 
 
N05CB  Barbiturates, combinations 
 
This group comprises combined preparations with mainly sedative 
action.  Combinations with analgesics etc., see comments under N05C - 
Hypnotics and sedatives. 
 
 Tetrabamate is classified here. 
 
N05CC  Aldehydes and derivatives 
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N05CD  Benzodiazepine derivatives 
 
Benzodiazepine derivatives used mainly in sleeping disorders are 
classified in this group. 
 
All midazolam medicinal products are classified here. 
 
See also N05BA. 
 
N05CE  Piperidinedione derivatives 
 
N05CF  Benzodiazepine related drugs 
 
N05CH Melatonin receptor agonists 
 
 
The DDD for melatonin is based on dose recommendations for the 2 
mg depot tablet approved in EU. 
 
N05CM  Other hypnotics and sedatives 
 
This group includes drugs, which cannot be classified in the preceding 
groups. 
 
N05CX  Hypnotics and sedatives in combination, excl. barbiturates  
 
All combination products mainly used in sleeping disorders are 
classified in this group, except combinations with barbiturates, see 
N05CB. 
 
 
  
 226 
N06  PSYCHOANALEPTICS 
 
This group comprises antidepressants, psychostimulants, nootropics 
anti-dementia drugs and combinations with psycholeptics. 
 
Antiobesity preparations are classified in A08 - Antiobesity 
preparations, excl. diet products. 
 
 
N06A  ANTIDEPRESSANTS 
 
This group comprises preparations used in the treatment of endogenous 
and exogenous depressions. 
 
The group is subdivided mainly according to mode of action.  The 
various antidepressants have different modes of action, and the 
classification will not reflect the exact mode of action of the various 
antidepressants.  
 
Lithium, see N05AN - Lithium 
 
Combination with psycholeptics, see N06C. 
 
 
The DDDs are based on treatment of moderately severe depressions. 
 
N06AA  Non-selective monoamine reuptake inhibitors 
 
N06AB  Selective serotonin reuptake inhibitors 
 
N06AF  Monoamine oxidase inhibitors, non-selective 
 
N06AG  Monoamine oxidase A inhibitors 
 
N06AX Other antidepressants 
 
This group includes antidepressants, which cannot be classified in the 
preceding groups. 
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N06B  PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND 
NOOTROPICS 
 
Nootropics are classified in N06BX.  
 
Clonidine and guanfacine also used in ADHD are classified in C02AC. 
 
N06BA  Centrally acting sympathomimetics 
 
Amfetamine is classified in this group, see comment under A08AA - 
Centrally acting antiobesity products. 
 
N06BC  Xanthine derivatives 
 
Caffeine in combination with respiratory stimulants is classified in 
R07AB. 
 
N06BX  Other psychostimulants and nootropics 
 
This group comprises substances regarded as nootropics.  
Psychostimulants, which cannot be classified in the preceding groups, 
are also classified here. 
 
Cyprodenate (deanol cyclohexylpropionate) is classified in N06BX04. 
 
 
The DDD for idebenone is based on treatment of Leber’s hereditary 
optic neuropathy. 
 
 
N06C  PSYCHOLEPTICS AND PSYCHOANALEPTICS IN 
COMBINATION 
 
Combinations of e.g. antidepressants and anxiolytics are classified in 
this group.   
 
N06CA  Antidepressants in combination with psycholeptics 
 
Preparations are classified at 5th levels according to the antidepressant.  
At each level various psycholeptics may occur. 
 
N06CB  Psychostimulants in combination with psycholeptics 
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N06D ANTI-DEMENTIA DRUGS 
 
N06DA Anticholinesterases 
 
N06DX Other anti-dementia drugs 
 
 
N07  OTHER NERVOUS SYSTEM DRUGS 
 
This group comprises other nervous system drugs, which cannot be 
classified in the preceding 2nd levels in ATC group N. 
 
 
N07A  PARASYMPATHOMIMETICS 
 
See also cholinergics used in glaucoma therapy, S01EB. 
 
This group includes various drugs used for different indications.  The 
DDDs are therefore established individually for each ATC 5th level. 
 
N07AA  Anticholinesterases 
 
N07AB  Choline esters 
 
N07AX  Other parasympathomimetics 
 
 
N07B DRUGS USED IN ADDICTIVE DISORDERS 
 
 This group comprises drugs used for maintenance treatment of 
addictive disorders.  Drugs used for detoxification are classified in 
V03A - All other therapeutic products. 
 
N07BA Drugs used in nicotine dependence 
 
Bupropion is classified in N06A - Antidepressants. 
 
The DDD for chewing gum and lozenges is identical. 
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N07BB Drugs used in alcohol dependence 
 
Naltrexone, which is also used in the treatment of opioid dependence, 
see N07BC, is classified in this group. 
 
The DDD for nalmefene is based on the recommended dose on 
treatment days. 
 
N07BC Drugs used in opioid dependence 
 
Low strength formulations of buprenorphine (equal or less than 0.4 mg) 
are classified in N02AE.  Naltrexone is classified in N07BB - Drugs 
used in alcohol dependence. 
 
Combinations of buprenorphine and naloxone are classified here. 
 
Morphine used for treatment of opioid dependence is classified in 
N02AA01. 
 
 
N07C ANTIVERTIGO PREPARATIONS 
 
This group comprises agents mainly used in the treatment of vertigo. 
 
See also:  
A04A - Antiemetics and antinauseants 
C04AX - Other peripheral vasodilators 
N02C -  Antimigraine preparations 
N05A -  Antipsychotics 
R06A -  Antihistamines for systemic use  
 
The DDDs are based on treatment of vestibular symptoms.  
 
N07CA Antivertigo preparations 
 
  
Cinnarizine in combination with diphenhydramine teoclate or 
dihydroergcristine are classified in N07CA52.  
 
The DDD for the N07CA52 refers to cinnarizine and is based on the 
combination of cinnarizine and diphenhydramine teoclate.   
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N07X  OTHER NERVOUS SYSTEM DRUGS 
 
N07XA Gangliosides and ganglioside derivatives 
 
N07XX Other nervous system drugs 
 
This group contains substances, which cannot be classified in the 
preceding groups. 
 
Combinations of metenkefalin and tridecactide is classified in N07XX 
(no ATC 5th level). 
 
Combinations of dextromethorphan and quinidine are classified in 
N07XX59. 
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P  ANTIPARASITIC PRODUCTS, INSECTICIDES AND 
REPELLENTS 
 
P01  ANTIPROTOZOALS 
A Agents against amoebiasis and other protozoal diseases 
B  Antimalarials 
C Agents against leishmaniasis and trypanosomiasis 
 
P02  ANTHELMINTICS 
B  Antitrematodals 
C Antinematodal agents 
D Anticestodals 
 
P03  ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES 
 AND REPELLENTS 
A  Ectoparasiticides, incl. scabicides 
B Insecticides and repellents 
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P  ANTIPARASITIC PRODUCTS, INSECTICIDES AND 
REPELLENTS 
 
The group is subdivided according to types of parasites. 
 
 
P01  ANTIPROTOZOALS 
 
P01A AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL 
DISEASES 
 
This group comprises drugs mainly used for amoeba infections and 
other protozoal diseases such as giardiasis and trichomoniasis. 
 
P01AA Hydroxyquinoline derivatives 
 
All combined preparations containing clioquinol are classified in this 
group.  Formulations of chlorquinaldol and clioquinol for 
dermatological use are classified in D08AH. 
 
No DDDs are established in this group. 
 
P01AB Nitroimidazole derivatives 
 
Nitroimidazole derivatives used for amoebiasis, trichomoniasis and 
giardiasis are classified in this group.  Formulations for vaginal 
administration are classified in G01AF.  Parenteral formulations mainly 
used for treatment of anaerobic bacterial infections are classified in 
J01XD.  Fixed combination packages for eradication of Helicobacter 
pylori are classified in A02BD. 
 
Combinations with antibacterials are classified in J01R. 
 
The DDDs are based on the treatment of amoebiasis, giardiasis and 
trichomoniasis.  The duration of the treatment periods is not taken into 
consideration. 
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P01AC Dichloroacetamide derivatives 
 
This group comprises luminal amoebicides. 
 
The DDDs in this group are based on treatment of luminal amoebiasis. 
 
P01AR Arsenic compounds 
 
This group comprises e.g. glycobiarsol.  Combinations containing 
clioquinol are classified in P01AA. 
 
P01AX Other agents against amoebiasis and other protozoal diseases 
 
This group comprises agents, which cannot be classified in the 
preceding groups.  Combinations with clioquinol are classified in 
P01AA.  
 
 
P01B ANTIMALARIALS 
 
This group comprises drugs mainly used for treatment and prophylaxis 
of malaria. 
 
The DDDs are based on the treatment of malaria, except for proguanil, 
which is used for prophylaxis only.  For some substances the DDDs 
are expressed as amount of base.  These are indicated in the ATC 
index. 
 
P01BA Aminoquinolines 
 
Combinations with clioquinol are classified in P01AA.  Combinations 
with glycobiarsol are classified in P01AR. 
 
The DDDs are based on the average daily dose for the treatment 
period. 
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P01BB Biguanides 
 
The DDD for proguanil is based on the daily dose given for 
prophylaxis of malaria.  The DDD for proguanil, combinations is 
based on treatment of acute malaria, see list of DDDs for combination 
products www.whocc.no. 
 
P01BC Methanolquinolines 
 
Combined preparations with quinine and psycholeptics used for 
treatment of nocturnal cramps are classified in M09AA. 
 
Combined preparations with quinine for symptomatic relief in cold 
conditions are classified in R05X. 
 
Hydroquinine is classified in M09AA. 
 
P01BD Diaminopyrimidines 
 
The DDD for pyrimethamine is based on combination therapy with a 
sulphonamide for the treatment of malaria. 
 
P01BE Artemisinin and derivatives, plain 
 
The parenteral DDD for arthemether is based on monotherapy. 
 
The DDDs for artemisinin derivatives are based on combination 
therapy with other antimalarials. 
 
P01BF Artemisinin and derivatives, combinations 
 
P01BX Other antimalarials 
 
This group comprises agents, which cannot be classified in the 
preceding groups.  Combinations of diphenhydramine and 
diethyltoluamide are classified at the plain level for diphenhydramine in 
D04AA. 
 
The DDD for halofantrine is based on a one-day (12h) treatment. 
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P01C AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS 
 
P01CA Nitroimidazole derivatives 
 
Nitroimidazole derivatives used for trypanosomiasis are classified in 
this group.  Other nitroimidazole derivatives, see P01AB. 
 
The DDD for benznidazole is based on the treatment of 
trypanosomiasis. 
 
P01CB Antimony compounds 
 
The DDDs are expressed as pentavalent antimony (Sb5+) used in the 
treatment of visceral leishmaniasis.   
 
P01CC Nitrofuran derivatives 
 
The DDDs are based on the treatment of trypanosomiasis. 
 
P01CD Arsenic compounds 
 
The DDDs are based on the treatment of trypanosomiasis. 
 
P01CX Other agents against leishmaniasis and trypanosomiasis 
 
This group comprises agents, which cannot be classified in the 
preceding groups. 
 
The DDD for pentamidine isethionate is based on amount given per 
injection.  The DDD for suramin sodium is based on the average daily 
dose for the treatment period. 
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P02 ANTHELMINTICS 
 
The anthelmintics are subdivided according to the main type of worms 
(i.e. trematodes, nematodes and cestodes) causing the infections. 
 
 
P02B ANTITREMATODALS 
 
This group comprises drugs mainly used for trematode infections such 
as e.g. schistosomiasis.  Niclosamide, which is also used in trematode 
infections, is classified in P02DA. 
 
The DDDs are based on the treatment of schistosomiasis. 
 
P02BA Quinoline derivatives and related substances  
 
P02BB Organophosphorous compounds 
 
Metrifonate is administered every second week.  The DDD is the dose 
divided by the dosing interval. 
 
P02BX Other antitrematodal agents 
 
This group comprises agents, which cannot be classified in the 
preceding groups.   
 
 
P02C ANTINEMATODAL AGENTS 
 
This group comprises drugs mainly used for nematode infections. 
 
The DDDs are based on the treatment of different nematode infections 
e.g. ascariasis (roundworm) and hookworm infections. 
 
P02CA Benzimidazole derivatives 
 
P02CB Piperazine and derivatives 
 
E.g. diethylcarbamazine is classified in this group. 
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The DDD for diethylcarbamazine is based on the treatment of 
lymphatic filiariasis. 
 
P02CC Tetrahydropyrimidine derivatives 
 
P02CE Imidazothiazole derivatives 
 
P02CF Avermectines 
 
P02CX Other antinematodals 
 
This group comprises agents, which cannot be classified in the 
preceding groups. 
 
 
P02D ANTICESTODALS 
 
This group comprises drugs mainly used for cestode infections.  
Praziquantel and mebendazole which are also used in cestode 
infections, are classified in P02BA and P02CA respectively. 
 
The DDDs are based on the treatment of cestode (tapeworm) 
infections. 
 
P02DA Salicylic acid derivatives 
 
P02DX Other anticestodals 
 
This group comprises agents, which cannot be classified in the 
preceding groups. 
 
 
P03  ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES 
AND REPELLENTS 
 
No DDDs are assigned in this group.  Substances classified in this 
group are for topical use and the consumption figures for these 
preparations could be expressed in e.g. grams of preparations 
regardless of strength. 
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P03A  ECTOPARASITICIDES, INCL. SCABICIDES 
 
This group comprises preparations used against scabies, lice and other 
ectoparasites. 
 
P03AA  Sulfur containing products 
 
Combinations with e.g. benzyl benzoate are classified in this group. 
 
Combinations with chlorine compounds, see P03AB. 
 
P03AB  Chlorine containing products 
 
Combinations with sulfur compounds are classified in this group. 
 
P03AC  Pyrethrines, incl. synthetic compounds 
 
This group comprises various pyrethrum products, including synthetic 
pyrethrinoids and combinations with e.g. piperonyl butoxide. 
 
Combinations with malathion are classified here. 
 
P03AX  Other ectoparasiticides, incl. scabicides 
 
Crotamiton preparations are classified in D04AX - Other antipruritics. 
 
Combinations of benzyl benzoate and sulfur containing compounds are 
classified in P03AA. 
 
Dimeticone used as antiflatulent is classified in A03AX13 - silicones. 
 
 
P03B  INSECTICIDES AND REPELLENTS 
 
P03BA  Pyrethrines 
 
P03BX Other insecticides and repellents 
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R   RESPIRATORY SYSTEM 
 
R01  NASAL PREPARATIONS 
A Decongestants and other nasal preparations for topical use 
B  Nasal decongestants for systemic use  
 
R02  THROAT PREPARATIONS 
A  Throat preparations 
 
R03  DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES 
A  Adrenergics, inhalants 
B  Other drugs for obstructive airway diseases, inhalants 
C  Adrenergics for systemic use 
D  Other systemic drugs for obstructive airway diseases 
 
R05  COUGH AND COLD PREPARATIONS 
C  Expectorants, excl. combinations with cough suppressants 
D  Cough suppressants, excl. combinations with expectorants 
F  Cough suppressants and expectorants, combinations  
X  Other cold preparations 
 
R06  ANTIHISTAMINES FOR SYSTEMIC USE 
A  Antihistamines for systemic use 
 
R07  OTHER RESPIRATORY SYSTEM PRODUCTS 
A  Other respiratory system products 
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R  RESPIRATORY SYSTEM 
 
Inhaled antiinfectives are classified in ATC group J - Antiinfectives for 
systemic use. 
 
R01  NASAL PREPARATIONS  
 
R01A  DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR 
TOPICAL USE  
 
This group comprises preparations for local treatment in nasal 
congestion (e.g. sympathomimetics) or for prophylaxis and treatment of 
allergic rhinitis (e.g. corticosteroids, cromoglicate preparations).  Most 
of the products are nasal drops, nasal sprays or nasal inhalants. 
 
See also R01B - Nasal decongestants for systemic use, and R06 - 
Antihistamines for systemic use. 
 
The DDDs are based on treatment of both nostrils. 
 
R01AA  Sympathomimetics, plain  
 
Small amounts of antiseptics etc. are allowed at each 5th level. 
 
Combinations with antibiotics, antihistamines, ipatropium bromide etc. 
are classified in R01AB, while combinations with corticosteroids are 
classified in R01AD. 
 
The DDDs are based on the treatment of acute rhinitis. 
 
R01AB  Sympathomimetics, combinations excl. corticosteroids  
 
Combinations with e.g. antibiotics, antihistamines and ipatropium 
bromide are classified in this group. 
 
This group also includes preparations with two or more sympatho-
mimetics.  These combinations are classified in a ranking according to 
the ATC codes, e.g. substances classified in R01AB01 take precedence 
over substances classified in R01AB02 etc. 
 
Combinations of phenylephrine and lerimazoline are classified in 
R01AB01. 
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Combinations of tetracaine and oxymetazoline for nasal application 
used as local dental anesthetics are classified in N01BA. 
 
The DDDs are based on the treatment of rhinitis.  DDDs are given in 
volume (i.e. ml).  Most of the products classified in this group are 
combinations with antihistamines.  So far, all these products are given 
a fixed DDD of 0.8 ml. 
 
R01AC  Antiallergic agents, excl. corticosteroids  
 
Antihistamines, cromoglicate disodium and analogues are classified 
here.  Combinations with corticosteroids are classified in R01AD. 
 
 
The DDD of cromoglicic acid is based on the prophylaxis of rhinitis.  
The DDDs of the antihistamines are based on the maintenance 
treatment of rhinitis. 
 
R01AD  Corticosteroids  
 
Combinations of corticosteroids with antiinfectives, sympathomimetics, 
antihistamines etc. are classified in this group at separate 5th levels by 
using the 50-series. 
 
Fluticasone propionate is classified in R01AD08. 
 
The DDDs are mainly based on the starting dose in the treatment of 
rhinitis. 
 
R01AX  Other nasal preparations  
 
This group comprises antiinfectives, antiseptics, mucolytics etc. which 
cannot be classified in the preceding groups.  
 
ATC level R01AX10 is an old level where rather obsolete nasal 
preparations and sodium chloride nasal products are classified.  The 
level R01AX30 is for nasal combination products which cannot be 
classified in the preceding groups. 
 
Combinations of ipatropium bromide and xylometazoline are classified 
in R01AB. 
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The DDDs are based on the treatment of rhinitis. 
 
 
R01B  NASAL DECONGESTANTS FOR SYSTEMIC USE  
 
This group comprises preparations for systemic use in vasomotoric or 
allergic rhinitis etc., excl. plain antihistamines (see R06). 
 
Combinations with antihistamines are classified in this group. 
 
The DDDs are based on the treatment of rhinitis. 
 
R01BA  Sympathomimetics  
 
 
R02  THROAT PREPARATIONS  
 
R02A  THROAT PREPARATIONS  
 
Throat preparations and mouth preparations are classified in the groups 
R02 and A01 according to assumed main therapeutic use.  Preparations 
used in common minor infections of mouth and throat are classified in 
R02, while preparations used in gingivitis, stomatitis etc. are classified 
in A01 - Stomatological preparations. 
 
Preparations for the treatment of symptoms both in mouth and throat 
are classified in R02 - Throat preparations. 
 
The DDDs are based on the treatment of common minor infections of 
mouth and throat.  For combination products, DDDs are given as fixed 
doses of 6 UD (6 tablets). 
 
R02AA  Antiseptics  
 
See also A01AB - Antiinfectives and antiseptics for local oral treatment.  
At each 5th level combinations with anesthetics are allowed. 
 
The combination dichlorobenzyl alcohol and amyl-m-cresol is classified 
in R02AA03. 
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R02AB  Antibiotics 
 
See also A01AB - Antiinfectives and antiseptics for local oral 
treatment.   
 
Combinations of antibiotics and antiseptics are classified in this group. 
 
At each 5th level combinations with anesthetics and/or steroids are 
allowed. 
 
Antibiotics for systemic use, see J01. 
 
R02AD  Anesthetics, local  
 
This group comprises e.g. throat lozenges containing local anesthetics.  
Dental anesthetics for local application are classified in N01B - 
Anesthetics, local. 
 
Combinations of anesthetics and antiseptics/antibiotics are classified in 
R02AA/R02AB respectively. 
 
R02AX Other throat preparations 
 
Combinations of benzydamine and cetylpyridinium are classified at the 
same 5th level as benydamine. 
 
R03  DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES  
 
R03A  ADRENERGICS, INHALANTS  
 
It is complicated to decide DDDs for the different dosage forms and 
even the different inhalation devices of the same dosage form. It has 
been shown that certain inhalation devices give a better deposition of 
the active ingredient in the lungs.  This gives a better clinical effect, 
and therefore the active ingredients can be used in lower dosages.  It 
has been decided not to take this aspect into consideration when 
assigning DDDs in this group, since the picture is very complex and 
satisfactory comparative documentation is not always available.  
Accordingly, only one DDD is assigned for one dosage form of a 
substance (e.g. powder inhalation). 
 
For some substances, the labelling of the strength of identical 
inhalation products may differ between countries.  In some countries, 
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metered dose (measured as the amount of substance released from the 
inhaler with the mouthpiece removed) is used while in other countries 
delivered dose (measured as the amount of substance released from the 
inhaler with the mouthpiece in place) is used in the labelling.  
Delivered dose will usually be lower than metered dose.  This is 
important to take into considerations when linking DDD information 
to the products in the different countries. 
 
The DDDs for inhalation aerosol and inhalation powder of the same 
substance are in most cases given the same DDD value.  The DDDs 
for inhalation solutions are, however, different from these and much 
higher, partly because less amount of the active ingredient will reach 
the target organ, and partly because this dosage form often is used in 
more severe asthma. 
 
R03AA  Alpha- and beta-adrenoreceptor agonists  
 
The DDDs are based on the treatment of asthma. 
 
R03AB  Non-selective beta-adrenoreceptor agonists  
 
The DDDs are based on the treatment of asthma. 
 
R03AC  Selective beta-2-adrenoreceptor agonists  
 
The DDDs are mainly based on the treatment of asthma.  
 
The DDDs for formoterol and salmeterol inhalation powders are based 
on metered dose, even though products containing these substances 
could be declared as delivered dose. 
 
The DDD for indacaterol is based on the treatment of COPD (Chronic 
Obstructive Pulmonary Disease). 
 
R03AH  Combinations of adrenergics  
 
See comments to R03AK. 
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R03AK  Adrenergics in combination with corticosteroids or other drugs, excl. 
anticholinergics 
 
The DDDs for combination products are based on the maintenance 
treatment of severe asthma or COPD (Chronic Obstructive Pulmonary 
Disease).  The assigned DDDs cannot always be compared with the 
DDDs assigned for plain preparations.  See list of DDDs for 
combination products; www.whocc.no. 
 
R03AL Adrenergics in combination with anticholinergics incl. triple 
combinations with corticosteroids  
 
 
R03B  OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, 
INHALANTS  
 
This group comprises all drugs for obstructive airway diseases for 
inhalation excl. adrenergics (R03A). 
 
See comment under R03A. 
 
R03BA  Glucocorticoids  
 
 Combinations with adrenergics are classified in R03AK. 
 
The combination of ciclosonide and tiotropium bromide is classified in 
R03BB54. 
 
The DDDs are based on the starting dose in moderate to severe 
asthma. 
 
R03BB  Anticholinergics  
 
Combinations with adrenergics are classified in R03AL. 
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The combination of tiotropium bromide and ciclosonide is classified in 
R03BB54. 
 
The DDDs are based on the maintenance treatment of asthma. 
 
The DDDs for tiotropium bromide are based on treatment of COPD 
(Chronic Obstructive Pulmonary Disease). 
 
The DDD for tiotropium bromide inhalation powder is based on 
tiotropium, delivered dose. 
 
The DDD for aclidinium bromide inhalation powder is based on 
aclidinium, delivered dose. 
 
The DDD for glycopyrronium bromide inhalation powder is based on 
glycopyrronium, delivered dose. 
 
R03BC  Antiallergic agents, excl. corticosteroids  
 
The DDDs are based on the prophylaxis of asthma. 
 
DDD for inhalation aerosol and inhalation powder differ in this group, 
due to differences in dosage recommendations for these dosage forms. 
 
R03BX  Other drugs for obstructive airway diseases, inhalants  
 
 
R03C  ADRENERGICS FOR SYSTEMIC USE  
 
This group comprises adrenergics for systemic use indicated for e.g. 
bronchial asthma.  Sympathomimetics used in the treatment of hypo-
tension, see C01CA.  Fenoterol infusion only intended for repression of 
labour is classified in G02CA.  Combinations with xanthines are 
classified in R03DB.  Combinations with other anti-asthmatics are 
classified in R03CK. 
 
R03CA  Alpha- and beta-adrenoreceptor agonists  
 
 Ephedrine injections are classified in C01CA. 
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R03CB  Non-selective beta-adrenoreceptor agonists  
 
Isoprenaline for systemic use is classified in this group only if bronchial 
asthma is the only indication for the preparation, otherwise in C01C - 
Cardiac stimulants excl. cardiac glycosides. 
 
R03CC  Selective beta-2-adrenoreceptor agonists  
 
R03CK  Adrenergics and other drugs for obstructive airway diseases  
 
Combinations of adrenergics and other drugs for obstructive airway 
diseases (excl. xanthines, see R03DB) are classified here. 
 
 
R03D  OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY 
DISEASES  
 
Theophyllines are classified in this group.  Other respiratory stimulants 
are classified in R07AB - Respiratory stimulants. 
Corticosteroids for systemic use, see H02. 
 
Sympathomimetics for systemic treatment of rhinitis, see R01BA. 
 
This group comprises mainly the xanthines.  The DDDs for these 
substances are based on treatment of obstructive lung diseases.  
 
R03DA  Xanthines  
 
A number of preparations containing e.g. theophylline are classified in 
this group even if they do not have asthma as an indication. 
 
Combinations of xanthines and other agents (except adrenergics, see 
R03DB - Xanthines and adrenergics) are classified at separate 5th 
levels using the corresponding 50-series (e.g. mucolytics).   
 
R03DB  Xanthines and adrenergics  
 
All combinations of xanthines and adrenergics are classified in this 
group.  
 
R03DC Leukotriene receptor antagonists 
 
 Combinations with antihistamines (R06A) are classified in this group. 
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R03DX  Other systemic drugs for obstructive airway diseases 
 
This group comprises preparations, which cannot be classified in the 
preceding groups.   
 
Interleukin inhibitors used in asthma are classified in this group. 
 
 
R05  COUGH AND COLD PREPARATIONS  
 
This group comprises a large number of preparations, most of which are 
combined preparations.   
 
Cold preparations containing therapeutic levels of antiinfectives should 
be classified in ATC group J - Antiinfectives for systemic use. 
 
Cold preparations with therapeutic levels of analgesics/anti-
inflammatory agents should be classified in the respective N02/M01 
groups. 
 
Cold preparations with both antiinfectives and analgesics should be 
classified in ATC group J - Antiinfectives for systemic use. 
 
Cold preparations with minimal amounts of antiinfectives or analgesics 
are classified in R05X - Other cold preparations. 
 
See also R01 - Nasal preparations, R02 - Throat preparations, and 
R03D - Other systemic drugs for obstructive airway diseases. 
 
 
Fixed DDDs are assigned for combinations. These DDDs are based on 
an average dose regimen of three times daily, and dosages in the upper 
area of the recommended dose ranges are chosen. The strengths of the 
various components are not taken into consideration. E.g. 6 UD (= 30 
ml) is the fixed DDD for products where the recommended dose is 5-
10 ml. 
 
 
R05C  EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH 
SUPPRESSANTS 
 
This group comprises preparations with expectorants and mucolytics. 
 
Combined preparations are classified at separate 5th levels using the 
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code number 10.  These may also contain bronchodilating agents, 
antihistamines etc.   
Preparations, which contain small amounts of herbal extracts, menthol 
etc., are regarded as plain preparations. 
 
R05CA  Expectorants  
 
All combined products of expectorants are classified in R05CA10. 
 
R05CB  Mucolytics  
 
Mesna in i.v. formulations used for the prophylaxis of urothelial 
toxicity is classified in V03AF.  Mesna used as a mucolytic agent (e.g. 
administered by a nebuliser) is classified here. 
 
All combined products of mucolytics are classified in R05CB10. 
Combinations with xanthines are classified in R03DA. 
 
Combinations with antiinflammatory agents are classified in M01. 
 
For acetylcysteine, the DDD for inhalation solution is higher than for 
the oral formulation, due to differences in the dosages recommended. 
 
 
R05D  COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH 
EXPECTORANTS  
 
Combined preparations are classified at separate 5th levels using the 
code number 20 (R05DA20 and R05DB20).  These may also contain 
bronchodilating agents, antihistamines etc. 
 
Combinations with expectorants, see R05F. 
 
Combinations with xanthines, see R03DA. 
 
Preparations, which contain small amounts of herbal extracts, menthol 
etc., are not regarded as combined preparations. 
 
R05DA  Opium alkaloids and derivatives  
 
Plain codeine, also when used as an analgesic, is classified in this 
group. 
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Plain dihydrocodeine products, also used as cough suppressants, are 
classified in N02AA. 
 
All combined products of opium alkaloids and derivatives, are 
classified in R05DA20. 
 
 Combinations with analgesics are classified in N02. 
 
R05DB  Other cough suppressants  
 
All combined products of other cough suppressants are classified in 
R05DB20. 
 
Levocloperastine is classified together with cloperastine in R05DB21. 
 
 
R05F  COUGH SUPPRESSANTS AND EXPECTORANTS, 
COMBINATIONS 
 
In addition to cough suppressants and expectorants, the preparations 
may contain bronchodilating agents, antihistamines etc.  Combinations, 
which contain respiratory stimulants, e.g. theophylline, should be 
classified in R03DA. 
 
R05FA  Opium derivatives and expectorants  
 
R05FB  Other cough suppressants and expectorants  
 
 
R05X  OTHER COLD PREPARATIONS  
 
This group comprises cold preparations with various ingredients, which 
cannot be classified in the preceding groups.  Combinations with 
therapeutic amounts of various ingredients (e.g. quinine as an 
antipyretic, antihistamines, ascorbic acid and caffeine) are classified in 
this group.  Various remedies for symptomatic relief in cough and cold, 
e.g. inhalants with menthol, camphora, thymol etc. are also classified 
here. 
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R06  ANTIHISTAMINES FOR SYSTEMIC USE  
 
R06A  ANTIHISTAMINES FOR SYSTEMIC USE  
 
This group comprises plain and combined antihistamine preparations 
for systemic use.  Antihistamines used in motion sickness are classified 
in this group.  Other preparations used in motion sickness, see A04 - 
Antiemetics and antinauseants. 
 
See also N07C - Antivertigo preparations. 
 
Combined preparations (incl. combinations with hydroxyzine) are 
classified at separate 5th levels using the corresponding 50-series. 
 
Combinations of antihistamines are classified at a separate 4th level, 
R06AK. 
 
Antihistamines are also included in combined preparations classified in 
other groups:  
 
Combinations with analgesics - N02 
 
Combinations with xanthines - R03DA  
 
 Combinations with leukotriene receptor antagonists - R03DC. 
 
Combinations with expectorants - R05C  
 
Combinations with nasal decongestants for systemic use - R01B  
 
Combinations with cough suppressants - R05D  
 
Allergen extracts, see V01. 
 
The group is subdivided according to chemical structure. 
 
For some of the substances, different dosage forms are given different 
DDDs, due to differences in bioavailability.   
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R06AA  Aminoalkyl ethers  
 
 Combinations with codeine are classified in N02AA. 
 
Combinations of cinnarizine and diphenhydramine teoclate 
(dimenhydrinate) are classified in N07CA - Antivertigo preparations. 
 
Different DDDs are established for the two salts of diphenhydramine 
(ATC code R06AA02): -chloride and -teoclate (dimenhydrinate).   
 
The DDD of doxylamine is based on the treatment of insomnia. 
 
R06AB  Substituted alkylamines  
 
R06AC  Substituted ethylene diamines  
 
R06AD  Phenothiazine derivatives  
 
R06AE  Piperazine derivatives  
 
Cinnarizine and flunarizine are classified in N07C - Antivertigo 
preparations. 
 
R06AK  Combinations of antihistamines  
 
R06AX  Other antihistamines for systemic use  
 
 
R07  OTHER RESPIRATORY SYSTEM PRODUCTS  
 
R07A  OTHER RESPIRATORY SYSTEM PRODUCTS  
 
This group comprises lung surfactants and respiratory stimulants. 
Caffeine is classified in N06B - Psychostimulants, agents used for 
ADHD and nootropics.  See also comments under R07AB - Respiratory 
stimulants. 
 
R07AA Lung surfactants 
 
This group comprises surface-tension lowering agents used in 
respiratory distress syndrome.  Combinations of different lung 
surfactants are classified in R07AA30, e.g. sinapultide in combination 
with other lung surfactants are classified here.  
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The DDDs of colfosceril palmitate and natural phospholipids are based 
on the treatment of respiratory distress syndrome in neonates, and 
correspond to the treatment of children weighing 1.6 kg. 
 
R07AB Respiratory stimulants  
 
Centrally acting respiratory stimulants mainly used for asthma and 
similar respiratory diseases (e.g. theophylline) are classified in R03D. 
Other respiratory stimulants are classified here.  This group includes 
plain and combined preparations. 
 
Combinations with respiratory stimulants and caffeine are classified in 
this group.  Plain caffeine preparations are classified in N06B - 
Psychostimulants, agents used for ADHD and nootropics. 
 
This group includes various drugs used on different indications. The 
DDDs are therefore established individually for each ATC 5th level. 
 
R07AX Other respiratory system products 
 
This group comprises preparations used for respiratory disorders, which 
cannot be classified in the preceding groups. 
 
Nitric oxide is classified here, other medical gases, see V03AN. 
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S   SENSORY ORGANS 
 
S01  OPHTHALMOLOGICALS 
A  Antiinfectives 
B  Antiinflammatory agents 
C  Antiinflammatory agents and antiinfectives in combination  
E  Antiglaucoma preparations and miotics 
F  Mydriatics and cycloplegics 
G  Decongestants and antiallergics 
H  Local anesthetics 
J  Diagnostic agents 
K  Surgical aids 
X  Other ophthalmologicals 
 
S02  OTOLOGICALS 
A  Antiinfectives 
B  Corticosteroids 
C  Corticosteroids and antiinfectives in combination  
D  Other otologicals 
 
S03  OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS 
A  Antiinfectives 
B  Corticosteroids 
C  Corticosteroids and antiinfectives in combination  
D  Other ophthalmological and otological preparations  
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S  SENSORY ORGANS 
 
A formulation approved both for use in the eye/ear is classified in S03, 
while formulations only licensed for use in the eye or the ear are 
classified in S01 and S02, respectively. 
 
 
S01  OPHTHALMOLOGICALS 
 
Most of the drugs in this group are topical  preparations.  Systemic 
preparations with clear ophthalmological indications are also classified 
in this group. 
 
Small amounts of antiseptics in eye preparations do not influence the 
classification, e.g. benzalconium. 
 
See also S03 - Ophthalmological and otological preparations. 
 
DDDs have been assigned for antiglaucoma preparations only. 
 
 
S01A  ANTIINFECTIVES 
 
This group comprises plain and combined antiinfective preparations for 
ophthalmological use. 
 
Combinations with corticosteroids are classified in S01CA - 
Corticosteroids and antiinfectives in combination. 
 
S01AA  Antibiotics 
 
Combinations of different antibiotics (incl. sulfonamides) are classified 
at a separate 5th level:  S01AA30. 
 
Combinations with other drugs (e.g. sympathomimetics) are classified 
at a separate 5th level:  S01AA20. 
 
Combinations with antiinflammatory agents are classified in group 
S01C. 
 
S01AB  Sulfonamides 
 
Combinations with antibiotics are classified in S01AA. 
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S01AD  Antivirals 
 
S01AE Fluoroquinolones 
 
S01AX  Other antiinfectives 
 
This group comprises antiinfective preparations for ophthalmological 
use, which cannot be classified in the preceding groups.  Products 
containing boric acid, also in low strengths, are classified in this group. 
Preparations containing benzalconium as the only active substance are 
classified here, on the 4th level. 
 
 
S01B  ANTIINFLAMMATORY AGENTS 
 
This group comprises all eye preparations with non-steroidal 
antiinflammatory agents and corticosteroids, plain and combinations. 
Combinations with antiinfectives are classified in S01C - 
Antiinflammatory agents and antiinfectives in combination. 
 
S01BA  Corticosteroids, plain 
 
S01BB  Corticosteroids and mydriatics in combination 
 
Combinations, which in addition contain anticholinergics, are classified 
here. 
 
Combinations, which in addition contain antiinfectives, are classified in 
S01CB - Corticosteroids/antiinfectives/mydriatics in combination. 
 
S01BC  Antiinflammatory agents, non-steroids 
 
 
S01C  ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN 
COMBINATION  
 
This group comprises all eye preparations, which contain 
corticosteroids or non-steroidal antiinflammatory agents and 
antiinfectives. Preparations may also contain additional drugs. 
 
S01CA  Corticosteroids and antiinfectives in combination 
 
The preparations are classified according to the corticosteroid.  
Different antiinfectives may occur at each 5th level. 
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S01CB  Corticosteroids/antiinfectives/mydriatics in combination  
 
This group is built up as S01CA. 
 
S01CC Antiinflammatory agents, non-steroids and antiinfectives in 
combination 
 
 
S01E  ANTIGLAUCOMA PREPARATIONS AND MIOTICS 
 
This group comprises preparations for local and systemic treatment of 
glaucoma. 
 
Drugs used for producing miosis are classified in this group, even if the 
main indication is not glaucoma. 
 
The DDDs are based on single dose (or single package) and 
administration frequencies.  A single dose is defined as two eye drops 
(one in each eye) corresponding to 0.1 ml.  For eye drops 
administered once daily the DDD is 0.1 ml, for eye drops administered 
twice daily the DDD is 0.2 ml, etc. For single use packages one dose 
is the volume of one package.  This also applies for combinations.  In 
eye ointments one dose corresponds to about 10 mm (20 mg) per eye 
thus corresponding to 40 mg for both eyes.  
 
S01EA  Sympathomimetics in glaucoma therapy 
 
Preparations containing parasympathomimetics in combination with 
epinephrine, are classified in S01EB. 
 
S01EB  Parasympathomimetics 
 
Combinations with beta blocking agents are classified in S01ED. 
 
The DDD for pilocarpine lamellas has been obtained by dividing two 
lamellas by seven days (the recommended dose is 1 lamella/ 
eye/week). 
 
S01EC  Carbonic anhydrase inhibitors 
 
Carbonic anhydrase inhibitors used for different indications are 
classified in this group. 
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The DDDs are based on the average recommended doses in the 
treatment of chronic glaucoma. 
 
S01ED  Beta blocking agents 
 
Combinations of beta blocking agents and other drugs, e.g. pilocarpine, 
are classified in this group, at separate 5th levels using the 
corresponding 50-series. 
 
S01EE Prostaglandin analogues 
 
 Combinations with beta blocking agents are classified in S01ED. 
 
Bimatoprost indicated for treatment of hypotrichosis of the eyelashes is 
classified here.   
 
S01EX  Other antiglaucoma preparations 
 
 
S01F  MYDRIATICS AND CYCLOPLEGICS 
 
S01FA  Anticholinergics 
 
Combinations with sympathomimetics are classified in this group. 
 
Combinations with corticosteroids are classified in S01BB. 
 
S01FB  Sympathomimetics excl. antiglaucoma preparations 
 
Phenylephrine in high strength is classified in this group, see also 
S01GA. 
 
Sympathomimetics used in glaucoma therapy, see S01EA. 
 
 
S01G  DECONGESTANTS AND ANTIALLERGICS 
 
This group comprises drugs used to treat symptoms of e.g. allergy. 
 
S01GA  Sympathomimetics used as decongestants 
 
This group comprises sympathomimetics used as decongestants, plain 
and in combination.  E.g. low strength phenylephrine in combination 
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with other drugs is classified in this group.  See also S01FB. 
 
S01GX  Other antiallergics 
 
Combinations of cromoglicic acid and antihistamines are classified in 
S01GX51. 
 
 
S01H  LOCAL ANESTHETICS 
 
This group comprises topical drugs used as local anesthetics in the eye. 
 
Local anesthetics for other indications are classified in N01B - 
Anesthetics, local.  Other exceptions, see comments to N01B. 
 
Combinations of local anesthetics and diagnostic agents, e.g. 
fluorescein, are classified in S01J. 
 
S01HA  Local anesthetics 
 
 
S01J  DIAGNOSTIC AGENTS 
 
This group comprises topical drugs used for diagnosing diseases in the 
eye.  Mydriatics and cycloplegics used as diagnostic aids are classified 
in S01F. 
 
Diagnostic agents for systemic use for ophthalmological diagnoses, e.g. 
fluorescein injection, are classified in V04CX - Other diagnostic 
agents. 
 
S01JA  Colouring agents 
 
S01JX  Other ophthalmological diagnostic agents 
 
 
S01K  SURGICAL AIDS 
 
This group comprises drugs used in ophthalmological surgery. 
 
Miotics are classified in S01E - Antiglaucoma preparations and 
miotics. 
 
Mydriatics and cycloplegics are classified in S01F. 
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S01KA Viscoelastic substances 
 
Hyaluronic acid injection used during surgical procedures on the eye 
(e.g. 4-20 mg/ampoule) is classified in this group.  Hyaluronic acid 
injection for intra-articular administration (e.g. 2.5 mg/ampoule) used in 
the treatment of arthritis is classified in M09A - Other drugs for 
disorders of the musculo-skeletal system.   
 
Hypromellose is classified in this group.  Hypromellose used as 
artificial tears is, however, classified in S01XA20. 
 
S01KX  Other surgical aids 
 
Preparations containing e.g. enzymes (chymotrypsin) for use in eye 
surgery, are classified in this group. 
 
Mitomycin used in glaucoma surgery is classified in L01DC03. 
 
 
S01L OCULAR VASCULAR DISORDER AGENTS 
 
S01LA Antineovascularisation agents 
 
 
S01X  OTHER OPHTHALMOLOGICALS 
 
This group comprises topical products, which cannot be classified in the 
preceding groups e.g. artificial tears, products for use with contact 
lenses, drugs against cataract etc. 
All products containing boric acid are classified in S01AX - Other 
antiinfectives. 
 
S01XA  Other ophthalmologicals 
 
Hypromellose is classified in S01XA20, if it is used as artificial tears.  
See also S01KA. 
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S02  OTOLOGICALS 
 
Small amounts of antiseptics in otological preparations do not influence 
the classification, e.g. benzalconium. 
 
See also S03 - Ophthalmological and otological preparations. 
 
No DDDs are assigned in this group. 
 
 
S02A  ANTIINFECTIVES 
 
This group comprises plain and combined antiinfective preparations for 
otological use. 
 
Combined preparations are classified at a separate 5th level - 
S02AA30 - antiinfectives, combinations.  This level includes 
combinations of different antiinfectives and combinations of 
antiinfectives/other substances. 
 
Combinations with corticosteroids are classified in S02C - 
Corticosteroids and antiinfectives in combination. 
 
S02AA  Antiinfectives 
 
Ciprofloxacin, declared as ear drops, is classified here. 
 
 
S02B  CORTICOSTEROIDS 
 
This group comprises all otological preparations with corticosteroids, 
plain and combinations, except combinations with antiinfectives.  These 
are classified in S02C - Corticosteroids and antiinfectives in 
combination. 
 
S02BA  Corticosteroids 
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S02C  CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION 
 
This group comprises all otological preparations, which contain 
corticosteroids and antiinfectives.  Preparations may also contain 
additional drugs. 
 
The preparations are classified at separate 5th levels according to the 
corticosteroid. 
 
S02CA  Corticosteroids and antiinfectives in combination 
 
 
S02D  OTHER OTOLOGICALS 
 
This group comprises ear preparations, which cannot be classified in the 
preceding groups. 
 
S02DA  Analgesics and anesthetics 
 
This group comprises e.g. preparations with analgesics and/or local 
anesthetics. 
 
S02DC  Indifferent preparations 
 
This group comprises e.g. oil-preparations used to remove ear wax. 
 
 
S03  OPHTHALMOLOGICAL AND OTOLOGICAL 
PREPARATIONS 
 
This group comprises preparations which can be used in both eye and 
ear. 
 
Small amounts of antiseptics (e.g. benzalconium) in eye/ear 
preparations do not influence the classification. 
 
No DDDs are assigned in this group. 
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S03A  ANTIINFECTIVES 
 
S03AA  Antiinfectives 
 
This group comprises plain and combined antiinfective preparations for 
use in eye/ear. 
 
Combined preparations are classified at a separate 5th level, S03AA30 - 
antiinfectives, combinations.  This level includes combinations of 
different antiinfectives and combinations of antiinfectives and other 
substances. 
 
Combinations with corticosteroids are classified in S03C - 
Corticosteroids and antiinfectives in combination. 
 
 
S03B  CORTICOSTEROIDS 
 
This group comprises all eye/ear preparations with corticosteroids, plain 
and combinations, except combinations with antiinfectives.  These are 
classified in S03C - Corticosteroids and antiinfectives in combination. 
 
S03BA  Corticosteroids 
 
 
S03C  CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION 
 
This group comprises all eye/ear preparations which contain 
corticosteroids and antiinfectives.  Preparations may also contain 
additional drugs. 
 
The preparations are classified according to the corticosteroid. 
 
S03CA  Corticosteroids and antiinfectives in combination 
 
 
S03D  OTHER OPHTHALMOLOGICAL AND OTOLOGICAL 
PREPARATIONS  
 
This group comprises eye/ear preparations, which cannot be classified 
in the preceding groups. 
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V   VARIOUS 
 
V01  ALLERGENS 
A  Allergens 
 
V03  ALL OTHER THERAPEUTIC PRODUCTS 
A  All other therapeutic products 
 
V04  DIAGNOSTIC AGENTS 
B  Urine tests 
C  Other diagnostic agents 
 
V06  GENERAL NUTRIENTS 
A  Diet formulations for treatment of obesity 
B  Protein supplements 
C  Infant formulas 
D  Other nutrients 
 
V07  ALL OTHER NON-THERAPEUTIC PRODUCTS 
A  All other non-therapeutic products 
 
V08 CONTRAST MEDIA 
A X-ray contrast media, iodinated  
B X-ray contrast media, non-iodinated 
C Magnetic resonance imaging contrast media 
D Ultrasound contrast media 
 
V09 DIAGNOSTIC RADIOPHARMACEUTICALS 
A Central nervous system 
B Skeleton 
C Renal system 
D Hepatic and reticulo endothelial system 
E Respiratory system 
F Thyroid 
G Cardiovascular system 
H Inflammation and infection detection 
I Tumour detection 
X Other diagnostic radiopharmaceuticals 
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V10 THERAPEUTIC RADIOPHARMACEUTICALS 
A Antiinflammatory agents 
B Pain palliation (bone seeking agents) 
X Other therapeutic radiopharmaceuticals 
 
V20 SURGICAL DRESSINGS 
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V  VARIOUS 
 
This group comprises many different types of drugs, and assigning 
DDDs are difficult.  Very few DDDs are assigned in this group. 
 
 
V01  ALLERGENS 
 
V01A  ALLERGENS 
 
V01AA  Allergen extracts 
 
This group comprises preparations mainly used in hyposensitisation. 
Preparations for diagnostic use, e.g. prick and scratch tests, are 
classified in V04CL. 
 
This group is divided according to type of allergen, e.g. grass pollen, 
tree pollen, fungi etc.  Artemisia vulgaris allergens are classified in 
V01AA10 - flowers. 
 
Oral and parenteral pharmaceutical forms are classified in the same 
ATC 5th level. 
 
 
V03  ALL OTHER THERAPEUTIC PRODUCTS 
 
V03A  ALL OTHER THERAPEUTIC PRODUCTS 
 
V03AB  Antidotes 
 
Sugammadex indicated for reversal of neuromuscular blockade induced 
by rocuronium or vecuronium is classified here. 
 
Hydroxocobalamine is also classified in B03BA. 
 
Medicinal charcoal is classified in A07BA. 
 
Atropine is classified in A03BA. 
 
Penicillamine, which is also used in copper poisoning, is classified in 
M01CC. 
 
Silibinin, which is also used in amanita poisoning, is classified in 
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A05BA at the same 5th level as silymarin. 
 
Anticholinesterases, which are used as curare antidotes, are classified in 
N07AA. 
 
Clonidine low strength tablets (e.g. 25 mcg) are classified in N02CX, 
even if the indication also may be “opioid withdrawal symptoms”.  
Both DL-methionine and L-methionine are included in the ATC 5th 
level V03AB26 - methionine. 
 
Naltrexone is classified in N07BB - Drugs used in alcohol dependence. 
 
Combinations of oxycodone and naloxone are classified in N02AA - 
Natural opium alkaloids. 
 
Combinations of buprenorphine and naloxone are classified in N07BC - 
Drugs used in opioid dependence. 
 
 
V03AC  Iron chelating agents 
 
V03AE  Drugs for treatment of hyperkalemia and hyperphosphatemia 
 
Plain calcium products also used in hyperphosphatemia are classified in 
A12AA. 
 
The DDD for lanthanum carbonate is expressed as lanthanum and is 
equivalent to 4.3 g lanthanum carbonate.  
 
The DDD for ferric citrate is based on the recommended dose for 
chronic kidney disease patients not on dialysis. 
 
V03AF  Detoxifying agents for antineoplastic treatment 
 
Mesna in i.v. formulations used for the prophylaxis of urothelial 
toxicity are classified in this group.  Mesna used as a mucolytic agent 
(e.g. administered by a nebuliser) is classified in R05CB. 
 
Rasburicase is classified here, other agents (e.g. febuxostat) for 
treatment of hyperuricaemia, see M04AA. 
 
Glutathione is classified in V03AB - Antidotes. 
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The DDDs for calcium folinate, calcium levofolinate, sodium folinate 
and sodium levofolinate are based on the combined treatment with 
high doses of methotrexate.   
 
The DDD for amifostine is based on the use as an adjunct in 
antineoplastic therapy. 
 
V03AG  Drugs for treatment of hypercalcemia 
 
Sodium cellulose phosphate is classified here. 
See also M05 - Drugs for treatment of bone diseases. 
 
Cinacalcet indicated for secondary hyperparathyroidism is classified in 
H05BX. 
 
V03AH  Drugs for treatment of hypoglycemia 
 
Oral preparations containing diazoxide for treatment of hypoglycemia, 
are classified in this group, while parenteral preparations used for 
treatment of hypertension, are classified in C02DA. 
 
V03AK  Tissue adhesives 
 
Tissue adhesives, e.g. cyanoacrylate based adhesives (not containing 
fibrinogen or other local hemostatics) are classified here. 
 
Fibrin sealants providing hemostasis at the site of application should be 
classified in B02BC. 
 
Human fibrinogen for systemic use is classified in B02BB01. 
 
V03AM  Drugs for embolisation 
 
V03AN Medical gases 
 
Nitric oxide used in respiratory conditions is classified in R07AX. 
 
V03AX  Other therapeutic products 
 
This group comprises agents, which cannot be classified in the 
preceding groups. 
 
V03AZ Nerve depressants  
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V04  DIAGNOSTIC AGENTS 
 
V04B  URINE TESTS 
 
 
V04C  OTHER DIAGNOSTIC AGENTS 
 
V04CA  Tests for diabetes 
 
V04CB  Tests for fat absorption 
 
V04CC  Tests for bile duct patency 
 
Pancreozymin is classified in V04CK. 
 
V04CD  Tests for pituitary function 
 
See also V04CM - Tests for fertility disturbances. 
 
The therapeutic use of metyrapone in the management of Cushing’s 
syndrome is also classified in this group. 
 
V04CE  Tests for liver functional capacity 
 
V04CF  Tuberculosis diagnostics 
 
V04CG  Tests for gastric secretion 
 
V04CH  Tests for renal function and ureteral injuries 
 
V04CJ  Tests for thyreoidea function 
 
 
V04CK  Tests for pancreatic function 
 
 V04CK01 - secretin includes synthetic, pork, and human secretin. 
 
V04CL  Tests for allergic diseases 
 
See also V01. 
 
V04CM  Tests for fertility disturbances 
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V04CX  Other diagnostic agents 
 
No ATC 5th levels are established in this group. The following 
substances are e.g. classified here: 
Folic acid (injection for diagnostic use only to investigate folate status), 
methacholine chloride (bronchial provocation test), mannitol (bronchial 
provocation test), 13C-urea (Helicobacter Pylori test), hexyl 
aminolevulinate hydrochloride (diagnosis of bladder cancer), carbon 
monoxide (lung test gas). 
 
 
V06  GENERAL NUTRIENTS 
 
This group comprises nutrients for oral use, incl. preparations used in 
feeding with stomach tube.  Solutions for parenteral nutrition are 
classified in B05BA. 
 
 
V06A DIET FORMULATIONS FOR TREATMENT OF OBESITY 
 
See also A08 - Antiobesity preparations, excl. diet products. 
 
V06AA Low-energy diets 
 
 
V06B  PROTEIN SUPPLEMENTS 
 
 
V06C  INFANT FORMULAS 
 
This group comprises preparations used in metabolic disorders.  Milk 
substitutes are classified V06DF. 
 
V06CA  Nutrients without phenylalanine 
 
 
V06D  OTHER NUTRIENTS 
 
This group comprises a major part of the general nutrients. 
 
V06DA  Carbohydrates/proteins/minerals/vitamins, combinations 
 
V06DB  Fat/carbohydrates/proteins/minerals/vitamins, combinations  
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V06DC  Carbohydrates 
 
V06DD Amino acids, incl. combinations with polypeptides 
 
V06DE  Amino acids/carbohydrates/minerals/vitamins, combinations  
 
V06DF  Milk substitutes 
 
This group comprises milk substitutes used in milk allergy. 
 
V06DX  Other combinations of nutrients 
 
 
V07  ALL OTHER NON-THERAPEUTIC PRODUCTS 
 
V07A  ALL OTHER NON-THERAPEUTIC PRODUCTS 
 
This group comprises e.g. solvents, diluents and solutions for blood 
transfusion products.  Auxiliary products for performing medical 
examinations, e.g. plain exploration creams and lubricants, are also 
classified in this group. 
 
V07AA  Plasters 
 
Non-medicated adhesive plasters, surgical tapes etc. are classified in 
this group whereas liquid plasters are classified in D02AD. 
 
Medicated dressings are classified in D09. 
 
V07AB  Solvents and diluting agents, incl. irrigating solutions  
 
This group comprises sterile water preparations and solvents for 
diluting or dissolving active substances, e.g. allergen extracts. 
 
Storage solutions for the preservation of organs are also classified here. 
 
V07AC  Blood transfusion, auxiliary products 
 
Citric acid/citrate/dextrose (ACD) solutions and similar products are 
classified in this group. 
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V07AD  Blood tests, auxiliary products 
 
Solutions used as diluents or transport media for blood samples are 
classified in this group. 
 
V07AN Incontinence equipment  
 
V07AR  Sensitivity tests, discs and tablets 
 
E.g. antibiotic discs may be classified in this group. 
 
V07AS  Stomi equipment 
 
V07AT  Cosmetics 
 
V07AV  Technical disinfectants 
 
V07AX  Washing agents etc. 
 
V07AY  Other non-therapeutic auxiliary products 
 
Exploration creams and lubricants are classified in this group.  Creams, 
which contain antiseptics, are classified in D08 - Antiseptics and 
disinfectants. 
 
Preparations used as negative contrast media in double-contrast 
radiography only, containing e.g. bicarbonates or hypromellose, are 
classified in this group. 
 
V07AZ  Chemicals and reagents for analysis 
 
 
V08  CONTRAST MEDIA 
 
This group comprises X-ray, MRI and Ultrasound contrast media.  The 
X-ray contrast media are subdivided into iodinated and non-iodinated 
compounds, and are further classified according to water solubility, 
osmolarity and nephrotropic/hepatotropic properties. High osmolar 
substances correspond mainly to ionic substances, except from ioxaglic 
acid, which is classified together with the non-ionic substances.  MRI 
contrast media are subdivided according to magnetic properties. 
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V08A X-RAY CONTRAST MEDIA, IODINATED  
 
V08AA  Watersoluble, nephrotropic, high osmolar X-ray contrast media 
 
V08AB  Watersoluble, nephrotropic, low osmolar X-ray contrast media 
 
V08AC  Watersoluble, hepatotropic X-ray contrast media 
 
V08AD  Non-watersoluble X-ray contrast media 
 
 
V08B X-RAY CONTRAST MEDIA, NON-IODINATED  
 
V08BA  Barium sulfate containing X-ray contrast media 
 
 
V08C  MAGNETIC RESONANCE IMAGING CONTRAST MEDIA 
 
V08CA Paramagnetic contrast media 
 
V08CB Superparamagnetic contrast media 
 
V08CX Other magnetic resonance imaging contrast media 
 
 
V08D ULTRASOUND CONTRAST MEDIA 
 
V08DA Ultrasound contrast media 
 
The microspheres may contain various ingredients.  E.g. perflutren 
suspension in microspheres of phospholipids is classfied in V08DA04. 
 
 Perflenapent covers structural isomers of dodecafluoropentane i.e. 
perflisopent. 
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V09 DIAGNOSTIC RADIOPHARMACEUTICALS 
 
An expert group consisting of Dik Blok (the Netherlands), Per Oscar 
Bremer (Norway) and Trygve Bringhammar (Sweden) is responsible 
for the ATC classification of radiopharmaceuticals in V09 and V10. 
The group has also prepared the guidelines for classification of these 
products. 
 
Radiopharmaceuticals for diagnostic use are classified in this group, 
while radiopharmaceuticals for therapeutic use are classified in V10. In 
general, the 3rd level are subdivided according to site of action or organ 
system, the 4th level according to radionuclide and the 5th level 
specifies the chemical substance.  The ATC 5th level defines the actual 
form essential in nuclear medicine procedures, which includes 
radionuclide and carrier molecule.  Therefore, products on the market, 
that can often be regarded as intermediate products rather than ready-to-
use radiopharmaceuticals, can be given more than one (5th level) ATC 
code, e.g. Technetium (99mTc) exametazime (V09AA01) and 
technetium (99mTc) exametazime labelled cells (V09HA02). 
ATC codes are not assigned for radionuclide precursors which are used 
only in the radiolabelling of another substance prior to administration. 
 
No DDDs have been assigned for radiopharmaceuticals. 
 
 
V09A  CENTRAL NERVOUS SYSTEM 
 
This group comprises preparations used in CNS investigations in 
diagnostic nuclear medicine. 
 
V09AA Technetium (99mTc) compounds 
 
V09AB Iodine (123I) compounds 
 
V09AX Other central nervous system diagnostic radiopharmaceuticals 
 
 
V09B  SKELETON 
 
This group comprises preparations used in bone imaging. 
Radiopharmaceuticals used for the investigation of bone marrow are 
classified in V09D - Hepatic and reticulo endothelial system. 
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V09BA Technetium (99mTc) compounds 
 
This group comprises various technetium bisphosphonates and 
pyrophosphate. 
 
 
V09C  RENAL SYSTEM 
 
This group comprises preparations used for the visualisation of kidneys 
and urinary tract and preparations for functional studies of the renal 
system. 
 
V09CA Technetium (99mTc) compounds 
 
This group comprises technetium compounds given intravenously. 
Technetium compounds used in aerosols for inhalation are classified in 
V09E - Respiratory system. 
 
Technetium-succimer prepared as 'pentavalent' is classified in V09I - 
Tumour detection. 
 
V09CX Other renal system diagnostic radiopharmaceuticals 
 
 
V09D HEPATIC AND RETICULO ENDOTHELIAL SYSTEM 
 
This group comprises radiopharmaceuticals used for the imaging of 
liver, gall bladder, lymphatic system and bone marrow.  
 
V09DA Technetium (99mTc) compounds 
 
This group contains technetium iminodiacetic acid derivatives for 
cholescintigraphy. 
 
V09DB Technetium (99mTc), particles and colloids 
 
This group contains technetium colloidal and particle containing 
preparations for the scintigraphy of liver, spleen, lymphatic system and 
bone marrow. Also orally administered preparations used for 
gastrointestinal tract imaging (gastric emptying, reflux etc.) are 
classified in this group. 
 
Preparations containing larger particles that are used for lung perfusion 
studies are classified in V09E - Respiratory system.  Denatured labelled 
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erythrocytes for spleen scintigraphy are classified in V09G - 
Cardiovascular system. 
 
V09DX Other hepatic and reticulo endothelial system diagnostic 
radiopharmaceuticals 
 
 
V09E RESPIRATORY SYSTEM 
 
This group comprises radiopharmaceuticals for the lung ventilation and 
lung perfusion studies. 
 
V09EA  Technetium (99mTc), inhalants 
 
Technetium preparations for inhalation are classified in this group.   
Preparations with other indications when given intraveneously are 
classified according to such indications, e.g. technetium-pentetate is 
classified in V09C - Renal system. 
 
V09EB Technetium (99mTc), particles for injection 
 
Preparations containing smaller particles or colloids that are used for 
RES function are classified in V09D - Hepatic and reticulo endothelial 
system. 
 
V09EX Other respiratory system diagnostic radiopharmaceuticals 
 
 
V09F THYROID 
 
This group comprises radiopharmaceuticals used for thyroid imaging. 
Thalliumchloride and technetium-sestamibi used for parathyroid 
imaging are classified in V09G - Cardiovascular system. 
 
V09FX Various thyroid diagnostic radiopharmaceuticals 
 
Technetium-pertechnetate used for the scintigraphy of salivary glands 
and Meckels diverticulum is classified in this group.  Technetium-
pentavalent succimer used in medullary thyroid carcinoma is classified 
in V09I - Tumour detection.  Sodium iodide (131I) in low dose is 
classified here.  Sodium iodide (131I) in high dose for therapy is 
classified in V10X - Other therapeutic radiopharmaceuticals. 
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V09G CARDIOVASCULAR SYSTEM 
 
This group comprises radiopharmaceuticals for myocardial 
scintigraphy, ejection fraction measurements, and vascular disorders. 
 
V09GA Technetium (99mTc) compounds 
 
Labelled cells (erythrocytes) for the investigation of cardiovascular 
function are classified in this group. No subdivision is made for in vitro 
or in vivo labelling. Pertechnetate for thyroid imaging is classified in 
V09F - Thyroid. 
 
V09GB Iodine (125I) compounds 
 
V09GX  Other cardiovascular system diagnostic radiopharmaceuticals 
 
 
V09H  INFLAMMATION AND INFECTION DETECTION 
 
This group comprises agents for the detection of inflammation and 
infection. Labelled blood cells are classified in this group.  Agents that 
are used for the labelling of these cells can also be classified elsewhere, 
e.g. technetium-exametazime is classified in V09A -Central Nervous 
System.  No subdivision is made for the type of labelled cells 
(erythrocytes, granulocytes or autologous etc.). 
 
V09HA Technetium (99mTc) compounds 
 
V09HB Indium (111In) compounds 
 
V09HX Other diagnostic radiopharmaceuticals for inflammation and infection 
detection 
 
 
V09I  TUMOUR DETECTION 
 
This group comprises monoclonal antibodies and other compounds used 
for tumour detection. 
 
V09IA Technetium (99mTc) compounds 
 
V09IB Indium (111In) compounds 
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V09IX Other diagnostic radiopharmaceuticals for tumour detection 
 
Gallium-citrate used for non-specific tumour localisation is classified in 
V09H - Inflammation and infection detection.  Thallium-chloride used 
for tumour detection is classified in V09G - Cardiovascular system.  
Iobenguane (131I) in low dose is classified here while high dose for 
therapy is classified in V10X - Other therapeutic 
radiopharmaceuticals. 
 
 
V09X  OTHER DIAGNOSTIC RADIOPHARMACEUTICALS 
 
This group contains various diagnostic radiopharmaceuticals which 
cannot be classified in the preceding groups. 
 
V09XA Iodine (131I) compounds 
 
V09XX Various diagnostic radiopharmaceuticals 
 
 
V10 THERAPEUTIC RADIOPHARMACEUTICALS 
 
Radiopharmaceuticals for therapeutic use are classified in this group, 
while radiopharmaceuticals for diagnostic use are classified in V09 - 
Diagnostic radiopharmaceuticals.   
 
See comments to V09. 
 
V10A ANTIINFLAMMATORY AGENTS 
 
This group comprises radiopharmaceuticals for the therapy of 
inflammatory processes.  
 
V10AA Yttrium (90Y) compounds 
 
In this group yttrium colloidal preparations used for radiation 
synovectomy are classified. 
 
V10AX Other antiinflammatory therapeutic radiopharmaceuticals 
 
This group comprises non-yttrium particulate radiopharmaceuticals for 
radiation synovectomy and intracavitary instillation. 
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V10B PAIN PALLIATION (BONE SEEKING AGENTS) 
 
This group comprises therapeutic radiopharmaceuticals used for pain 
palliation in bone malignancies. 
 
V10BX Various pain palliation radiopharmaceuticals 
 
 
V10X  OTHER THERAPEUTIC RADIOPHARMACEUTICALS 
 
This group contains various therapeutic radiopharmaceuticals which 
cannot be classified in the preceding groups. 
 
V10XA Iodine (131I) compounds 
 
Sodium iodide (131I) in low dose for diagnostic nuclear medicine is 
classified in V09F - Thyroid. 
 
Iobenguane (131I) in low dose for diagnostic nuclear medicine is 
classified in V09I - Tumour detection. 
 
V10XX Various therapeutic radiopharmaceuticals 
 
 
V20 SURGICAL DRESSINGS 
 
A detailed classification of surgical dressings is prepared and 
maintained by the Ministry of Defence in the UK.   
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List of terms: 
 
AC-system Anatomical Classification developed by the EphMRA (page 21). 
 
ATC classification Anatomical Therapeutic Chemical classification system  
 (page 14). 
 
ATC herbal classification ATC classification for herbal remedies (page 46). 
 
ATCvet classification ATC classification for veterinary products (page 46). 
 
ATC levels The ATC system is divided in 5 different levels.  
 1st level: 14 anatomical groups 
 2nd level: Pharmacological/therapeutic/ subgroup 
 3rd and 4th level: Chemical/pharmacological/therapeutic 
subgroups 
 5th level: Chemical substance (page 14). 
 
Average adult dose The dose used for the main indication which reflects the ATC 
code. When referred to body weight, an adult is considered to be 
a person of 70 kg. The DDDs are as a main rule based on the 
average adult dose (page 23). 
 
BAN British Approved Name (page 15). 
 
5th level codes 20 and 30 5th level codes used for combined preparations containing two 
or more active ingredients belonging to the same 4th level.  (e.g. 
page 19). 
 
5th level codes - 50-series Combination products containing two or more active 
components not belonging to the same 4th level are classified by 
using 50- series. (e.g. page 19). 
 
5th level codes - 70 series Combination products containing psycholeptic drugs, which are 
not classified under N05 or N06 are classified at separate 5th 
levels using the 70-series corresponding to the ATC-
classification of the main component. (e.g. page 19). 
 
Combination products Products containing two or more active ingredients (page 18). 
 
DDD Defined Daily Dose - a technical unit of measurement defined as 
the assumed average maintenance dose per day for a drug used 
for its main indication in adults (page 22). 
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DDDs/1000 inhabitants/day Data presented as such provide a rough estimate of the 
proportion of the population within a defined area treated daily 
with certain drugs (page 34). 
 
DDDs per 100 bed days Applied when in-hospital drug use is considered. E.g. 100 DDD 
per 100 bed days indicates that for instance 20 persons get a 
certain treatment for 5 days (page 34). 
 
DDDs per inhabitant per year Often used for antiinfectives or other drugs normally used in 
short periods. E.g. 5 DDDs/inhabitant/year indicate that every 
inhabitant on average is treated with a 5 days course a year 
(page 34). 
 
DURG Drug Utilization Research Group (page 10). 
 
EphMRA European Pharmaceutical Market Research Association  
 (page 21). 
 
Fixed dose DDDs based on the average use for preparations within a group 
without considering and comparing the strengths of the different 
preparations (page 26). 
 
IMS Intercontinental Medical Statistics. IMS produces marketing 
research statistics for the pharmaceutical industry (page 22). 
 
INN International nonproprietary names. The preferred substance 
name in the ATC-system (page 15). 
 
Intermittent dosing In therapeutic groups e.g. hormones, where many of the 
preparations are administered intermittently, the dose 
administered is divided by the number of days in the treatment 
period to obtain the average daily dose (page 26). 
 
Maintenance dose The dose preferred when establishing the DDD. Some drugs are 
used in different initial doses but this is not reflected in the DDD 
(page 23). 
 
“Other” group 3rd or 4th level, often named X, used for substances not clearly 
belonging to any existing ATC 3rd or 4th level (page 17). 
 
PBIRG Pharmaceutical Business Intelligence and Research Group  
 (page 21). 
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PDD The Prescribed Daily Dose for a substance is determined from 
prescription studies, medical- or pharmacy records and patient 
interviews. The PDD must be related to the diagnosis on which 
the dosage is based (page 30). 
 
Plain product Products containing one active component (page 18) 
 
U Unit, both international as well as others (page 27). 
 
UD The unit dose is used when a DDD for various reasons cannot be 
given in amount of active ingredient (page 27). 
 
USAN United States Adopted Name (page 15). 
 
WHO Collaborating Centre  The centre responsible for the development and  
for Drug Statistics  maintenance of the ATC/DDD system (page 10). 
Methodology  
 
WHO Collaborating Centre  A collaborating centre situated in Uppsala, Sweden,  
for International Drug  which receives spontaneous reports of suspected  
Monitoring adverse reactions from national centres and carries the 
operational responsibilities for WHO´s programme on 
International Monitoring (page 46). 
 
WHO Drug Information Published by WHO 4 times a year to bring issues of primary 
concern to drug regulators and pharmaceutical manufacturers to 
the attention of a wide audience of health professionals and 
policy-makers concerned with the rational use of drugs. 
Publishes the new ATC codes/DDD approved at the working 
group meetings (page 39, 40, 41, 43).  Can be ordered from: 
 Marketing and Dissemination, World Health Organization, 
 1211 Geneva 27, Switzerland,  
 Telephone: +41 22 791 24 76, Fax: +41 22 791 48 57 
 Email: publications@who.int 
 
WHO International Working WHO appointed experts in medicine and statistics  
Group for Drug Statistics  who advise the collaborating centre in the  
Methodology    assignment of ATC/DDD and carries out research into the use of 
these methodologies in drug utilization. The Working Group 
meets two times a year, normally March and October (page 11). 
 
 

